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Abstract 
Diabetes mellitus is one of the most prevalent and significant metabolic diseases impacting 
modern human populations.  The goal of this research is to explore several analytical methods to better 
appreciate how diabetes impacts the skeleton, and to determine if this effect can be recognized in 
postmortem remains.  Anthropologists are tasked with elucidating the relationship between nutrition,         
metabolism, growth, development, and skeletal health.  Diabetes represents a crucial point of interface 
between these factors.  Furthermore, as the percentage of diabetics increases in the general population, so 
will their representation in forensic cases.  This study will provide tools for identifying characteristics of 
diabetes in the postmortem material available to anthropologists.  
Diabetes is a disease process that can alter the function of many tissues and systems.  For these 
reasons, three analytical approaches were conducted including: blood serum protein analysis using 
ELISA, bone mineral density (BMD) scans with a dual-energy x-ray absorptiometry (DXA) scanner, and 
macroscopic osteological analysis.  This study was completed employing a sample of 80 known skeletal 
donations and 20 blood samples from the William M. Bass Donated Skeletal Collection at the University 
of Tennessee, Knoxville.   
Results indicated that pro-inflammatory biomarkers may be quantified in postmortem blood 
samples, and that diabetics showed slightly higher average concentrations of cytokines associated with 
diabetes and lower concentrations of those related to insulin sensitivity.  Bone density analysis revealed 
that diabetics and non-diabetics significantly differ in BMD, but this relationship varies between the 
sexes.  Female diabetics had consistently denser bones in all measured variables of the lower limb, and 
one-third of forearm variables. Results based on male data did not display a similar outcome, with little 
difference observed between male diabetics and non-diabetics.  Analysis of skeletal pathologies identified 
a set of three osteological variables, concentrated in the feet, as having the highest discriminatory 
potential.  An accuracy rate of 83% was achieved in classifying individuals into diabetic versus non-
diabetic categories. 
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CHAPTER 1. INTRODUCTION  
Introduction 
 Diabetes mellitus has a profound effect on the human body and this research will provide an 
anthropological perspective and a means for recognition in postmortem remains.  Type 2 diabetes is a 
metabolic disease that has reached epidemic proportions in the unique biocultural environment afforded 
by the twentieth and twenty-first centuries.  Anthropologists are tasked with understanding the interaction 
between nutrition, growth, development, and skeletal health, as well as identifying pathological 
conditions in human remains.  However, diabetes has not been systematically examined in 
anthropological literature or forensic anthropology case studies.   The current work addresses this deficit 
by examining the clinical complications of diabetes that are observable in postmortem blood and skeletal 
samples, and recording a pattern of pathological traits.  The research question driving this study is: Are 
the human remains of diabetics discernable from those of non-diabetics? 
Diabetes is a disease process with many stages.  An individual represents a single point in the 
pathological progression from good health to critical illness.  Diabetics who expire in the early phases of 
the disease will demonstrate a different suite of characteristics than those in middle or later stages of the 
disease.  Furthermore, diabetes alters the function of many different tissues in the body.  This research 
will identify diabetic characteristics in each stage, and underscore those which may be recognized in 
postmortem remains.  For these reasons, three separate methodological approaches are pursued: enzyme-
linked immunosorbent assay (ELISA), dual-energy x-ray absorptiometry (DXA), and macroscopic 
osteological analysis.  Each technique informs about a different aspect or stage of the disease.  The three 
approaches will be analyzed independently in answering the aforementioned research question. Results 
will be incorporated into suggestions for best practices in forensic anthropology.  
Anthropologists have a wealth of information to add to the dialog concerning diabetes.  
Anthropology offers a significant time depth perspective rarely matched in other fields.  Among many 
pursuits, biological anthropologists seek to understand osseous material, track changes in morphology and 
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function over time, characterize population level and within-groups differences, and often do so without 
the living of living testable subjects.     
This research provides skeletal biologists with insight into how bone is involved in energy 
metabolism.  It also expands the role of the skeleton from a mechanical, structural, and hemopoitic 
system, to one that also influences energy storage and metabolism.  This work may supplement current 
knowledge of how dietary factors are affecting bone growth, development, and deterioration.  Just as 
paleopathologists investigate anomalies and defects in ancient and historical remains, biological 
anthropologists must be prepared to recognize contemporary pathologies in the present population and 
modern forensic cases.  The data collected will allow researchers to better understand how human skeletal 
material is interfacing with the modern environment and provide a foundation for future research 
concerning diabetes and skeletal health. 
Initially, this chapter will introduce diabetes, provide historical background, and explain its 
epidemiology and pathophysiology.  Next, the theory of diabetes as an inflammatory disease will be 
discussed, underscoring the significance of inflammatory proteins circulating in the blood that interact 
with skeletal tissue.  Finally, this chapter will conclude with the research design outlining the project, a 
description of the chapters and analyses conducted, and implications for practice in forensic anthropology  
  
 
Background to Diabetes Mellitus 
Diabetes mellitus, or simply diabetes, is a complex metabolic disorder characterized by 
hyperglycemia, excess glucose in blood.  The disease results from defective insulin secretion, inadequate 
insulin action, or a combination of both factors (American Diabetes Association [ADA] 2011a).  
Metabolic disorders, in which diabetes is the hallmark example, are abnormal chemical processes or 
reactions that disrupt the normal break-down of food into nutrient particles for energy expenditure and 
storage.  Given the steadily rising incidence in the general population, diabetes has been heavily studied 
in clinical research and the medical community. 
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Diabetes has been largely disregarded in anthropology for several pertinent reasons.  First, 
diabetes induces well-known functional alterations in soft tissues, but much less is known concerning 
how diabetes affects the skeleton.  Diabetes is intimately related with obesity, and separating the two 
diseases and their independent contributions to the observed phenotype is methodologically difficult.  
Obtaining an appropriately large sample of modern human skeletal remains, with clinically diagnosed 
diabetes mellitus has also proven a constraint.  Diabetes is generally considered to be a recent disease, 
characterizing modern human groups.  However, evidence for diabetes and diabetic symptoms has been 
recognized throughout recorded history (Karanastasis and Mantzoros 2004).   
 
Brief History of Diabetes 
Though diabetes is certainly more prevalent in today’s culture, description of both type 1 and 2 
diabetes have been documented historically.  In texts dated from 230 BC, Apollonius of Memphis devised 
the term diabetes, meaning “to pass through” in Latin, referring to profuse urine production of afflicted 
individuals (Karanastasis and Mantzoros 2004).  Diabetics suffer from polydipsia (excessive thirst) and 
polyuria (disproportionate urination), symptoms readily recognized even in prescientific eras.  In the 
1500s Phillipus Aureolus Theophrastus Bombast von Hohenheim (known as Paracelus) noted a white 
precipitate formed in the urine of certain polyuric individuals.  He erroneously classified this residue as 
salt accumulating from a kidney malfunction, deducting that excess salt in the body caused the 
unquenchable thirst and relentless urine associated of diabetes (Medvei 1993b).  In reality the precipitate 
is formed by surplus glucose.  The glycemic nature of diabetic bodily fluids was simultaneously observed 
by physicians in India.  They noted that ants and flies were drawn to diabetic’s urine.  This observation 
constituted the first rudimentary test for diabetes, a condition they named madhumeha meaning “honey 
urine” (Karanastasis and Mantzoros 2004). 
Matthew Dobson, a British physiologist working in Liverpool in the 1800s, concluded that the 
sweet essence in diabetic urine was sugar.  Dobson further discovered that this component originated in 
the bloodstream rather than being a kidney byproduct, marking the first time hyperglycemia was 
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conceived as being in the blood.  Dobson’s contemporary, Dr. John Rollo first linked blood sugar with 
food intake and was among the first European physicians to use the term diabetes mellitus, with 
“mellitus” being the Greek work for honey.  Later in 1849 Hermann von Fehling developed the first 
method to measure glucose levels in urine and started the first clinical criteria for diagnosing diabetes 
(Medvei 1993a). 
Anatomist Paul Langerhans identified groups of specialized cells within the pancreas but failed to 
discern their function. Edouard Laguesse completed the work by performing a series of pancreatectomies.  
He found that partial removal of the pancreas failed to produce symptoms of diabetes, while total 
extraction the cell clusters caused diabetic symptoms.  Laguesse recognized the cells as intrinsic in 
development of the disease and named them “islets of Langerhans” after his predecessor (Karanastasis 
and Mantzoros 2004).   
In the early twentieth century, a Toronto research team isolated the hormone product of the islets 
of Langerhans in the pancreas. They initially named it “isletin” but changed the term to insulin (Bliss 
1990).  They extracted and purified the first form of insulin for therapeutic purposes.  The discovery and 
development of insulin earned Macleod, Banting, Collip and Best the Nobel Prize in 1923.  
 
Current Prevalence of Diabetes Mellitus 
The number of individuals suffering from diabetes and obesity has reached epidemic proportions 
globally and within the United States (US).  In 2000, over 171 million people worldwide suffered from 
some form of diabetes, and that number is projected to increase to 366 million by the year 2030 (Wild et 
al. 2004).  Within the US, 18.8 million people are currently diagnosed with some form of diabetes, and 
another 7 million are estimated to be living with the condition undiagnosed.  This accounts for almost 9% 
of the total US population (Centers for Disease Control [CDC] 2011).  Diabetes afflicts different sectors 
of the population disproportionately.  Diabetes is slightly more common in adult men than in women, 
affecting 11.8% versus 10.8% of the US population, respectively (CDC 2011).  However the total number 
of female patients is greater, given the greater numbers of elderly women living in the population relative 
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to men.  Nonetheless, elderly individuals of both sexes, represent the largest group suffering from some 
form of diabetes.  In developing nations, the majority of adults diagnosed with diabetes fall into the 45–60 
year-old age-group.  In more developed nations, the largest group of diabetics is 65 years and older, 
owing to the longer life-expectancy and more advanced healthcare systems available.  In the US, diabetics 
constitutes 27% of all persons over the age of 65 years (CDC 2011). 
Certain US minority groups are predisposed to higher rates of diabetes and run a much high risk 
for developing insulin resistance.  Data are available for some, but not all, minority groups via the 
National Health and Nutrition Examination Survey (NHANES), the Indian Health Services (IHS), and the 
National Patient Information Reporting System (NPIRS) 2007–2009 national survey.  After adjusting for 
age differences, compiled data indicate that 7.1% of all non-Hispanic whites, 8.4% of Asian American, 
12.6% of non-Hispanic blacks, and 11.8% of all Hispanics have been diagnosed with diabetes.  Among 
Hispanics, rates were 7.6% for both Cubans and for Central and South Americans, 13.3% for Mexican 
Americans, and 13.8% for Puerto Ricans.  Compared to non-Hispanic whites, risk of developing diabetes 
is 77% higher for African Americans and 87% higher for Mexican Americans (CDC. NCHS. 2007-2009).  
Explanations for the discrepancy include items such as socioeconomic status, access to healthcare and 
educational resources, cultural norms, and opportunities for physical activity.  Some of these factors will 
be subsequently discussed below. 
This metabolic disorder also afflicts juveniles.  About 215,000 people under age 20 suffer from 
diabetes (CDC 2011).  Type 1 diabetes (discussed below) is the predominant form affecting this age 
group.  Search for Diabetes in Youth is a national study co-sponsored by the CDC and the National 
Institute for Diabetes, Digestive, and Kidney Disease (NIDDK) initiated in 2002.   Search represents the 
largest survey to date studying diabetes in juveniles; incorporating multi-regional data collection sites, 
wide age distribution (0 – 19 years), and including all available ethnic groups (Cavallo 2006).  Recent 
results revealed that for the first time, rates of newly-diagnosed cases were higher for type 2 vs. type 1 in 
children from certain ethnic groups (Native Americans and Asian-Pacific Islanders).  Search II, a follow-
up study, has already commenced to better understand the factors driving this outcome. 
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Forms and Diagnoses of Diabetes 
Multiple forms of diabetes have been identified and may be clinically diagnosed.  The different 
types share a common malfunction in insulin production or function, and may display overlapping 
symptoms in different stages of the disease process.  The present study will selectively focus on type 2 
diabetes, as it is most common in the United States and worldwide adult population, and the only form of 
diabetes documented in the skeletal collection used in this research.  Nonetheless, alternate type of 
diabetes should be noted and described to fully understand the breadth of the disease. 
 Type 1 diabetes was formerly referred to as juvenile-onset diabetes, or insulin-dependent 
diabetes mellitus (IDDM).  Type 1 is instigated when the body’s autoimmune system destroys the 
pancreatic β-cells, which house the islets of Langerhans.   β-cells represent the body’s sole source of 
insulin.  Individuals diagnosed with type 1 diabetes are essentially devoid of insulin and therefore must 
reply on regular daily injections to supplement this vital hormone.  Type 1 represents the minority of 
diabetic cases, accounting for approximately 5% of all diabetic sufferers (World Health Organization 
[WHO] 2006).  This form is most prevalent in children and adolescents below the age of 20, but a portion 
of type 1 diabetics diagnosed with Latent Autoimmune Diabetes of Adults (LADA) actually developed 
the condition in adulthood (ADA 2011a).  In contrast to type 2, type 1 diabetes is not correlated with 
surplus body fat or obesity, nor do type 1 diabetics share the classic characteristics of metabolic 
syndrome.  
Causes of type 1 diabetes appear to be primarily genetic, but some factors such as excess mass 
and obesity may hasten progression or exacerbate the disease presentation.  Results from the Search study 
have identified a “hybrid” version of type 1 and type 2, which they are calling type 1.5. These patients 
demonstrate characteristics and clinical complication of both type 1 and type 2 diabetes.  Type 1.5 
patients exhibit the autoimmune response that renders the pancreas unable to produce any insulin, yet they 
tend to be older at the age of diagnosis (adolescence and young adulthood), and are more likely to be 
obese and carry a higher risk of early cardiovascular disease (Cavallo 2006).  This has provided the 
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impetus for longitudinal study to track the development of this type and identify the most effective 
treatment. 
Type 2, formally termed adult-onset, or non-insulin-dependent diabetes mellitus (NIDDM) is the 
most common in the US and worldwide population, constituting 90-95% of all diagnosed cases (Codario 
2005).  Type 2 diabetes begins as insulin resistance, whereby the body does not properly engage insulin 
action, or there is an inadequate response to insulin secretion (National Institute of Diabetes Digestive and 
Kidney Diseases [NIDDK] 2008).  This leads to insulin de-sensitivity and causes a significant 
accumulation of glucose in the bloodstream, rather than being transported into tissues and cells for energy 
storage and expenditure.  Eventually the pancreatic beta-cells deteriorate, decrease in size, and cease to 
produce insulin.  This denotes the transition from insulin resistance to type 2 diabetes (ADA 2011a).  
Early in this process an individual’s glucose level might fall within the normal range and/or the patient 
may be asymptomatic.  Thus, insulin resistance can be prolonged and complications intensified prior to 
diagnosis. 
Causes of type 2 diabetes are multifactorial and complex.  Diabetes is one of several traits 
characteristic of “metabolic syndrome,” which also includes hypertension, cardiovascular disease, 
elevated LDL cholesterol, etc.  Metabolic syndrome, also referred to as insulin resistant syndrome, is a 
significant risk factor, and is pit stop on the road to developing full type 2 diabetes (Codario 2005).  Type 
2 diabetes is found in high prevalence among minority groups, particularly African Americans, Hispanics, 
Native American, and Pacific Islanders.  The type 2 phenotype (regardless of ethnic background) is 
typically overweight or obese; almost 90% of all diagnosed patients have a BMI above 24.  Body fat 
distribution is equally important, with diabetics tending to carry their weight centrally in the abdominal 
region (CDC 2011).   
Pre-Diabetes, formerly termed “intermediate diabetes” is a condition in which individuals 
consistently demonstrate blood glucose levels above the norm, but do not surpass the threshold for 
diabetic classification.  The National Health and Nutrition Survey (NHANES) 2005–2008 survey 
estimates that in 2010, 79 million people in the United States were pre-diabetics (Centers for Disease 
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Control [CDC] and National Center for Health Statistics [NCHS] 2007-2009).  Individuals with pre-
diabetes run a much higher risk of developing the full diabetic condition.  However, therapeutic studies 
have shown that pre-diabetics who engage in weight-loss program and increase their physical activity can 
prevent or delay the onset of diabetes (ADA 2011b).  The reduction in relative risk ranges from 27% in 
the India Diabetes Prevention Program, to 67% in the Toranomon Diabetes Study, conducted by 
researchers in Japan (Kosaka et al. 2005; Ramachandran et al. 2006). 
Gestational diabetes occurs when women develop chronic hyperglycemia exclusively during 
pregnancy.  New criteria for estimation indicate that gestational diabetes affect 18% of all pregnancies 
(ADA 2011a).  For many of these women, gestational diabetes has severe health consequences after 
delivery. Women who suffered from gestational diabetes have a 35-60% chance of developing type 2 
diabetes postpartum (CDC 2011).  
See Table 1.1, Criteria for diagnosis of type 2 diabetes 
 
 
 
 
 
 
 
 
 
 
Table 1.1. Criteria for diagnosis of type 2 diabetes 
 
Re-printed from the American Diabetes Association Diagnosis and Classification for Diabetes Mellitus 2011 
 
Type 2 diabetes Pre-diabetes 
HbA1C level*  ≥ 6.5% HbA1c level 5.7 – 6.4% 
Fasting plasma glucose ≥ 126 mg/dl ** Fasting plasma glucose 100 – 125 mg/dl 
2-hr plasma glucose ≥ 200 mg/dl, during OGTT*** 2-hr plasma glucose 140 – 199 mg/dl during OGTT 
Patients with classic symptoms of hyperglycemia, 
random plasma glucose ≥ 200 mg/dl 
 
 
*HbA1c- Glycated hemoglobin; test should be standardized to the Diabetes Complications and Control Trial (DCCT) reference 
assay 
**Fasting is defined as no caloric intake for at least 8 hours prior         
***Oral glucose tolerance test; uses a glucose load containing 75g anhydrous glucose dissolved in water 
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Etiology of Diabetes 
 Diabetes is a heterogeneous disorder.  This disease is heterogeneous in the different tissues 
affected, the rate of its progression, and the severity of symptoms.  This may be due, in part, by the 
multiple causative factors.  Type 1 appears to have a strong genetic influence.  Of the juveniles who 
develop type 1, 56% have a first-degree relative also suffering from type 1 (Cavallo 2006).  The risk is 
dramatically elevated in twins; a monozygotic twin runs a 1:3 risk if their counterpart develops diabetes.   
The data for type 1 diabetes are consistent with a polygenic threshold model for the inheritance.  
This involves multiple (poly) genes which additively contribute to the phenotype, and once the influence 
surpasses a threshold the trait or condition is expressed.  As early as 1988, three programs were initiated 
to gather data from families with at least one sibling affected by diabetes.  The Human Biological Data 
Interchange (HBDI) in the United States (n = 331), the British Diabetic Association repository (n = 320), 
and the French labs of Phillip Froguel and Mark Lathrop (n = 150) cooperatively performed genome-wide 
scans on sib pairs using 250 microsatellite markers (Bain et al. 1992; Hashimoto et al. 1994).  These 
efforts revealed several susceptibility loci, the most significant of which resides in a major 
histocompatability complex (MHC) located on chromosome 6 (staining region 6p21) (Shetty et al. 2004).   
Referred to collectively as IDDM1, this area contains class I human leukocyte antigen genes, which 
express B-lymphocytes, macrophages, and activated T-lymphocytes (Concannon et al. 1998; Mein et al. 
1998).  These antigens are responsible for the major pathological feature of type 1 diabetes: leukocyte-
mediated autoimmune destruction of β cells (Todd 1997).  Moreover, IDDM1 is implicated in more than 
42% of familial type 1 diabetes cases (Singal and Blajchma 1973).  Since then, more than 20 genetic loci 
have been implicated in contributing to the developments of type 1 diabetes.  Other additional loci to note 
are IDDM2, which has been linked to the genes controlling insulin, and IDDM4, which is related to 
fibroblast growth factors and low-density lipoprotein (LDL) receptor (Concannon et al. 1998; Mein et al. 
1998). 
Development of type 2 diabetes is generally attributed to the combined actions of both genetic 
and environmental components.  Genes associated with type 2 diabetes, coupled with detrimental 
10 
 
lifestyle, jointly act upon a number of intermediate traits of relevance.  These include pancreatic beta-cell 
actions , insulin receptivity, and adipose tissue distribution.  Each of these factors can individually 
contribute to the type 2 phenotype.  The proportion of genetic influence ranges from 20% (risk for full 
siblings) to 60% (documented risk factor for monozygotic twins) (Shetty et al. 2004).  Multiple 
contributory loci have been identified through genome-wide linkage scans.  As of 2011 more than 40 
genes have been associated with the risk of developing type 2 diabetes.  The locus 2q37.3, named 
NIDDM, has been strongly associated with type 2 diabetes in Mexican American populations, and is 
involved in cleavages and intracellular signaling (Horikawa et al. 2000).  One of the stronger, more 
reproducible associations with type 2 diabetes is found with peroxisome proliferative activated receptor 
gamma (PPARγ), a transcription factor that plays a central role in adipocyte development (Deeb et al. 
1998; Sanoudou and Mantzoros 2004).  PPARγ amino acid substitution has been related to morbidly 
obese BMI and has become an important target for insulin-sensitizing drugs known as thiazolidinediones 
(Yen et al. 1997).  All identified genes acting together still constitute only 10% of the total genetic 
heritability of the disease (Herder and Roden 2011).   
Studies indicate that the environmental factors like diet and physical activity presumably act upon 
a genotype that is predetermined to be more or less susceptible to develop type 2 diabetes (Keller et al. 
2008).  Greater genetic predisposition, coupled with stronger environmental factors, results in a more 
amplified diabetic phenotype.  The major behavioral factors predisposing individuals to both type 2 
diabetes and obesity are inappropriate levels/sources of nutrition and sedentary life-style.  The most 
commonly evoked theory relating there two factors is the “Thrifty Gene” hypothesis. 
 The “Thrifty Gene” hypothesis describes the human metabolic system as being far more inclined 
towards caloric storage rather than expenditure (Neel 1962).  Human groups evolved in environments 
where resource scarcity was a primary selective pressure, so that survival depended upon the ability to 
conserve energy.  However, in a modern environment, resources are plentiful and laden with fats and 
calories.  Simultaneous changes in technology and mechanization require fewer people to engage in 
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physical labor in their occupation or even in their daily routine.  The result: what was probably a former 
metabolic advantage has become detrimental in the contemporary age (Neel et al. 1998).   
Neel’s hypothesis is still heavily debated in many areas of study.  Though multiple research teams 
have undertaken the challenge of investigating genes associated with diabetes, employing genome-wide 
scanning capabilities, no set of irrefutably “thrifty” genes has been identified (Corona et al. 2013).  
Recently, a research team examined over 65 diabetes susceptibility loci, but found no global signal for 
positive selection (Ayub et al. 2014).  When considered individually, fourteen loci demonstrated slight 
population-level differentiation, but protective and risk allele variants were observed at equal frequencies.  
These loci exhibited the same selective power as any fourteen loci chosen at random.  Investigators 
concluded that past positive selection has not been a major driving force in the current prevalence of 
diabetes risk alleles (Ayub et al. 2014).   
Other concepts have been proposed suggesting that genes favoring obesity and diabetes were 
subject to random drift, in the absence of selection.  This alternate hypothesis has been termed the “drifty 
gene hypothesis” (Speakman 2008).   Proponents of drifting critique several aspects of the original 
hypothesis, alleging that mortality rates from famine do not appear high enough to select for thrifty gene, 
and that the majority of individuals in famine do not die from starvation (where obesity would clearly 
benefit), but rather disease.  Furthermore, obesity has a well-known negative impact on reproductive 
performance.  The “drifty gene” hypothesis concludes that past human groups removed major predation 
risks with the advent of social behavior and technology, thus eliminating selective force against the upper 
limit of body mass.  Over the past two million years, genes defining the upper limit have been subject to 
random mutation and drift.  Mutations that adversely affect fat storage and lipid oxidation would 
consequently vary between individuals, having no negative consequences as long as diets remain low in 
fat (Speakman 2008).  Embedded in modern society, where energy is freely available, drifting obesity 
genes emerge in a pattern of susceptibility that has become a modern epidemic.  
The “Thrifty Phenotype” is another hypothesis that focuses on the contribution of the 
developmental environment, particularly that which is experienced in utero (Hales and Barker 1992).  The 
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Thrifty Phenotype suggests that resources available during fetal and early postpartum development shape 
an individual’s metabolism into adulthood.  For example, mothers exposed to famine or malnutrition 
during pregnancy will produce children with a metabolic system attuned to scarcity.  If the external 
environment changes to one of nutritional affluence, pre-programmed low levels of insulin secretion and 
glucose handling will be ineffective (Hales and Barker 2001).  Though the thrifty gene versus phenotype 
theories are often considered contradictory, they are not necessarily mutually exclusive and collectively 
may be reasonable explanations for the rise in metabolic dysregulation. 
The rise in diabetes has paralleled that of obesity levels.  Few risk factor – disease relationships 
are as strong as the association between obesity and diabetes.  Data from the Behavioral Risk Factors 
Surveillance System suggest that for every added kilogram of body weight, the risk for diabetes jumps 
about nine percent (Mokdad et al. 2003).  Obesity introduces a number of complications that serve to 
intensify diabetic risk factors.  One key feature, visceral fat distribution, plays a significant role in the 
etiology of type 2 diabetes.  Visceral adiposity is a condition in which fat cells that have accumulated in 
the mid-section, around the central digestive organs.  Adipocytes located in and around the viscera 
increase the amount of free-fatty acids absorbed by insulin-sensitive tissues not equipped for lipid storage.  
Fatty acids compete with glucose for substrate use, which increases the glucose imbalance in the 
bloodstream.  Furthermore, excess lipids can impair cellular function and lead to tissue death in a process 
known as lipotoxicity (Codario 2005; Unger 1995).   
However, not all obese individuals develop diabetes.  Encouraging studies show pre-diabetics are 
not inevitably destined to suffer from the fully-developed disease.  Several major clinical trials have 
demonstrated efficacy in diet/activity modification in diabetes treatment and remission.  The Diabetes 
Prevention Study conducted in the US tested 3234 diabetic patients with impaired glucose tolerance and 
BMI above 24 (overweight or obese).  Three trials groups were created: individuals administered diabetic 
medication, individuals given a placebo pill, and patients engaged in intensive behavioral change 
including calories restriction and increased exercise.  Relative risk of developing diabetes was reduced by 
58% in the altered life-style group, vs. 31 % risk reduction in the medication group.  These results were 
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replicated in the Finnish Diabetes Prevention Study.  The trial group with a modified life-style 
demonstrated exactly 58% reduction in relative risk.  The Da Qing Diabetes Study conducted in China 
tested the impact of physical exercise versus dietary changes on high-risk patients.  The greatest reduction 
in relative risk was observed in the increased exercise group (46%) over the reduced diet group (31%). 
 
Pathophysiology of Type 2 Diabetes 
The pathogenic process of type 2 diabetes is complex and highly variable, both in rate of 
development and pathological manifestations.  Type 2 diabetes universally begins as deficient insulin 
action resulting from inadequate secretion and diminished tissue response (Kahn et al. 2005).  Insulin is 
synthesized by specialized β-cells in the pancreas, located within the islets of Langerhans.  β-cells 
constitute 65-80% of the cells in the islets and are also in charge of secreting amylin and C-peptide.  
Insulin is a vital hormone responsible for glucose uptake and metabolism.  Insulin receptors exist in all 
tissues, including bone cells.  Glucose uptake by insulin primarily occurs in liver, fat cells, and in skeletal 
muscle.  When receptors fail to recognize or respond to insulin, a state of insulin resistance ensues.  De-
sensitivity to insulin causes glucose metabolism to decrease, resulting in hyperglycemia.  The pancreatic 
islets counteract by producing yet more insulin, working beyond the normal capacity and accelerating 
their functional exhaustion.  Defective responsiveness eventually leads to cessation of insulin production 
due to cell apoptosis (Donath et al. 2009).  At this juncture type 2 diabetics also become dependent on 
external provision of insulin for glucose metabolism, similar to their type 1 counterparts.  
 
Diabetes as an Inflammatory Disease 
Several mechanisms have been suggested to explain the origin of insulin resistance.  This 
includes oxidative stress (Evans et al. 2003), endoplasmic reticulum stress (Hotamisligil 2010; Ozcan et 
al. 2004), lipotoxicity (Unger 1995; Unger et al. 2010) and glucotoxicity (Donath et al. 1999).  All 
processes may be caused by a single source: over-nutrition, which instigates metabolic stress within the 
body (Donath and Shoelson 2011).  The normal physiological response to functional stress involves 
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activation of the immune system and inflammation of the affected area. Inflammation is a complex 
biological response in tissue to harmful stimuli such as pathogens, damaged cells, or irritants foreign and 
innate (Ferrero-Miliani et al. 2007).  Inflammation is a protective function, using a number of cellular 
sensing mechanisms to remove harmful insults and initiate the healing process.  When the stress is acute 
inflammation has positive effect, which results in cell repair, tissue regeneration, and return to 
homeostasis.   
Conversely, when the condition is sustained like obesity and insulin resistance, chronic 
inflammation becomes deleterious and maladaptive (Lago et al. 2007; Pickup and Crook 1998).  The 
acute phase instigates movement of specific molecules to the affected site.  Interleukin proteins and 
macrophages are significant mediators in human autoimmune responses.  Tissues have not evolved to 
sustain prolonged exposure to pro-inflammatory molecules, whose presence is ultimately destructive to 
the affected tissue rather than restorative. 
Inflammation provides a causal link between exogenous factors like obesity and highly correlated 
complications like type 2 diabetes and cardiovascular disease.  As early as the 1950s and 1960s, 
researchers noticed that therapeutic treatments for arthritis and rheumatic fever simultaneously alleviated 
both tissue inflammation and hyperglycemia (Shoelson et al. 2006).  Not until recently have such 
observations been framed in a pathological processes framework.  Numerous studies have identified that 
patients suffering from type 2 diabetes demonstrate a pro-inflammatory response in tissues that is related 
to adiposity and glucose handling (Ehses et al. 2007; Fernandez-Real and Pickup 2012; Kolb and 
Mandrup-Poulsen 2005; Pickup and Crook 1998; Shoelson et al. 2006; Xu et al. 2003). 
High fat diets lead to obesity and lipid accumulation in the adipocytes, which triggers cellular 
stress (Hotamisligil 2006; Newgard and McGarry 1995).   This activates certain metabolic pathways 
inside the adipose cell, such as IKKβ and NF-κB pathways.  The transcription factor NF-κB translocates 
inside the adipocyte nucleus, which causes selective upregulation of pro-inflammatory molecules: 
macrophages and cytokines (Kolb and Mandrup-Poulsen 2005; Weisberg et al. 2003).  Macrophages play 
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an important role digesting cellular debris and pathogens, while stimulating lymphocytes (white blood 
cells) and other immune cells (Fernandez-Real and Pickup 2012; Weisberg et al. 2003).   
Cytokines are cell-signaling proteins that serve as mediators of inflammation and instigators of a 
downstream response.  Complementary cytokine receptors are located throughout the body in multiple 
tissues to produce varied action.  “Adipositis” is the pro-inflammatory response produced in fat cells.  
Studies indicate that this innate immune reaction plays a causal role in diabetes, rather than being a 
consequential factor (Kolb and Mandrup-Poulsen 2005).   
Studies have also discovered inflammation within the pancreatic beta-cell islets of diabetic 
patients (Gepts and Lecompte 1981).  This condition has been termed “insulitis” and may clarify the 
degradation of the beta-cells and reduction in insulin production (Donath et al. 2009).  Insulitis is 
characterized by elevated levels of cytokines in the blood stream, the presence immune cells, fibrosis 
(reparative fiber formation), and β-cell apoptosis (death) (Donath and Shoelson 2011; Ehses et al. 2007; 
Weisberg et al. 2003).  Consensus has not been reached on the precise mechanism producing β-cell death.  
Immune mediators can also directly interfere with insulin phosphorylation and signaling, which 
consequently inhibits cellular response and insulin sensitivity (Kolb and Mandrup-Poulsen 2005).  
Biomarkers of inflammation, like cytokines, can be quantified and may be used to track the progression of 
insulin resistance, to determine the severity of the disease, and likelihood of associated complications 
(Esposito et al. 2003; Spranger et al. 2003b). 
The present study will follow this line of research, investigating cytokines in blood as an indicator 
for inflammatory stress associated with type 2 diabetes.  Furthermore, common comorbidities of diabetes 
will be investigated in skeletal material to determine if symptoms documented in clinical practice may be 
observed postmortem. 
 
Research Design and Methods 
 This research examines the effects of diabetes on the human body.  The condition is a complex 
disease that affects any number of tissues and causes a multitude of secondary ailments. This study will 
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investigate type 2 diabetes in postmortem human remains, given the different biological materials that 
may be available to the forensic anthropologist.   Three major modes of analyses will be investigated:  (1) 
enzyme-linked immunosorbant assay (ELISA) analysis of circulating cytokines in postmortem blood 
samples, (2) bone mineral density (BMD) scanning, and (3) osteological analysis of skeletal pathologies.  
The analyses will identify distinctive characteristics of diabetes in different tissues.  Analytical methods 
are separated into three independent chapters.  Each represents a different modality in which diabetes may 
be interpreted from human remains, and indicates a different stage in the diabetic disease progression.    
 Chapter Two will review the inter-relationship between bone and energy metabolism.  The 
skeleton has recently been re-conceptualized as a major contributor to energy homeostasis.  This is an 
important theoretical foundation elucidating how diabetes disrupts normal bone function.  Chapter Three 
describes comorbidities and pathologies associated with diabetes.  Medical research constitutes the 
majority of literature on the effects of diabetes, and provides a reference for pathologies that may be 
observed postmortem.  Clinical work also substantiates the progression of diabetes, beginning as a blood 
glucose imbalance, progressing to soft tissues malfunction, and terminating in organ failure.  The skeleton 
is one such organ vulnerable to diabetes.   
Chapter Four describes the sample used in this study, sourced from the William M. Bass Skeletal 
Collection, maintained by The University of Tennessee’s Department of Anthropology.  The total 
research sample consists of 80 modern individuals.  This assemblage provides a unique opportunity to 
study remains with known demographics factors and medical history. Sex, age at death, body mass, and 
diabetic status are documented for each individual included in the research.  By utilizing the Bass Skeletal 
Collection, the anthropological sampling issue that has previously prevented investigation of diabetes was 
resolved.  The Collection also includes postmortem blood samples preserved on collection cards, 
providing the means to study multiple tissues affected by diabetes. 
 The next three chapters encompass the methodological investigation of diabetes.  The 
background, methodological techniques employed, the results, and their interpretation will be presented 
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separately within Chapters Five, Six, and Seven.  Each represents a discrete investigation, utilizing 
different postmortem tissues, analytical methods, and statistical tests 
Chapter Five involves the ELISA examination of postmortem blood samples.  The first clinically 
detectable biomarkers of pre- and fully-developed diabetes are elevated levels of blood glucose and 
inflammatory proteins (cytokines).  Inflammation is a significant component in the pathophysiology of 
diabetes.  An ELISA affords the identification and quantification of various proteins circulating in blood 
samples.  ELISA is generally conducted to assess the concentration of pro-inflammatory cytokines for 
patients in the pre-diabetic category and those who demonstrated glucose intolerance in fasting plasma 
glucose tests.  The goal in this portion of the dissertation is to determine is pro-inflammatory cytokines 
are detectable and elevated in postmortem diabetic blood samples 
Preliminary research was conducted at the University of Tennessee Obesity Research Center; data 
for this project was collected with assistance from the UT Department of Nutrition.  While ELISA is not 
an independently diagnostic test for diabetes, results may be used in conjunction with other tests to 
conceive a therapeutic plan.  Prior to this point in time, ELISA analysis had not been performed on 
postmortem sample.  This research marks the first time ELISA has been attempted on blood samples 
collected from deceased individuals.  Preliminary results by this author indicated that proteins are viable 
in postmortem samples and that they exist in levels quantifiable by ELISA.  If soft tissue and blood are 
available, they provide essential information about diabetic status after death. 
 Chapter Six discusses the application bone mineral density (BMD) analysis.  The integral 
relationship between bone and energy homeostasis will be discussed in the following chapter.  BMD data 
is often employed as an indicator of bone quality.  Incidence of non-osteoporotic fractures in diabetic 
patients, particularly those with a 10-15 year history of the disease, suggests that diabetes has a delayed 
negative impact on bone quality.  The goal in this portion of the research is to investigate if altered 
metabolism (diabetes) is affecting bone deposition.    
Collaborating with the University of Tennessee Kinesiology, Recreation, and Sport Science 
Department samples from the Bass Skeletal Collection were scanned using dual energy X-ray 
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absorptiometry (iDEXA).  BMD scans are neither invasive nor destructive to bone, and thus may be used 
as a remote method to estimate how metabolism might be influencing osteoblast/osteoclast function.  To 
develop as complete a perspective as possible, loading-bearing and non-mechanically-significant bones 
were scanned.  If diabetes is affecting bone quality, as evidenced by denser bones, than BMD results 
should be consistent throughout skeletal locations. 
 Chapter Seven describes macroscopic osteological analysis conducted on the research sample.  
Many pathological conditions associated with diabetes potentially leave lasting impression on bone.  For 
example, periodontitis, heel spur development, and periostitis are secondary symptoms of diabetes, and 
all may be observed on preserved skeletal material.  Many such pathologies will be discussed in greater 
detail in Chapter Three to provide sufficient background.  
As diabetes progresses towards end stages, the combined effect of vascular dysfunction and soft 
tissue deterioration often culminates with the exposure and destruction of osteological elements.  An apt 
example is the diabetic ulcer preceding osteomyelitis.  The goal of this analysis was to determine the suite 
of pathologies with the highest correlation with diabetes, so that they may be used to suggest diabetic 
status in a set of remains. 
 And finally, Chapter Eight will review the major findings from the blood protein, bone density, 
and pathological analyses.  Results will be interpreted and synthesized.  Methodological short-comings in 
this study will be discussed and suggestions for future research  and suggestions for future research will 
be proposed. 
 
Implications for Skeletal Biology and Forensic Anthropology 
  Anthropologists are tasked with recognizing and interpreting pathological conditions in human 
remains.  In forensic contexts, knowledge of bone pathology should be described, imaged, and included in 
the biological profile.  This report is estimates the sex, age, ancestry, and stature of a set of unidentified 
human remains, and includes osteological anomalies produced by disease or injury.  If soft tissue is 
available, ELISA analysis for inflammatory proteins may be amended to standard set of laboratory blood 
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tests performed in a medical examiner’s context.   Bone mineral density may inform about expected or 
unusual bone quality.  Given the best suite of osteological characteristics to look for, forensic 
anthropologists may investigate markers of diabetes in a set of remains.  Though diabetic status is 
certainly not an individualizing trait, additional sources of information may aid in the identification of 
unknown remains.   
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CHAPTER 2. BONE AND ENERGY METABOLISM 
 This chapter will introduce the intrinsic relationship between the skeletal system and energy 
metabolism.  This connection is significant because diabetes cannot affect one factor (metabolism) 
without influencing the other (bone).  Certain molecules released and functionally altered by diabetes also 
interact with bone cells.  Furthermore, recent research suggests that bone may affect change in 
metabolism. 
 
Interrelationship of Bone and Energy Metabolism 
 The skeleton is a multi-functional system providing mechanical support, protection, and 
locomotion for vertebrates.  Bone serves vital roles as a structural and metabolic organ.  Current research 
suggests that another utility should be attributed to bone, that of an endocrine organ influencing hormone 
secretion and energy regulation (Confavreux et al. 2009).  In the past two decades numerous observations 
about bone have emerged from an integrative physiology perspective.  These observations indicate that 
the skeleton has a substantial relationship with total energy metabolism, and that both systems may be 
regulated by a common homeostatic feedback loop.   
The first point advocating an inter-relationship stems from the sheer size and nutritional 
requirements imposed by the skeleton. The skeletal system is a considerably large organ that requires a 
significant amount of energy throughout an organism’s lifespan.  Variable nutrient availability has always 
been a challenge for mammals.  Towards this end, species evolved sensitive networks to monitor energy 
expenditure and to communicate metabolic information between the major organs that produce, store, and 
use fuel (Fulzele and Clemens 2012).  Bone expends energy during its initial formation, throughout 
growth and development, and commandeers resources for constant maintenance and reparative processes.  
Energy availability and allocation in the body became a survival function for skeletal vertebrates. 
Likewise, bone possesses many post-developmental features that function under tight regulation.  
This suggests that the skeletal system may be related to other energy systems which are similarly 
controlled (Wei and Ducy 2010).  Bone has the ability to regenerate and repair itself through a remodeling 
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mechanism. The well-choreographed actions of bone remodeling, whereby resorption from osteoclast 
cells is seamlessly followed by osteoblastic restoration, occurs in a balanced manner to maintain bone 
mass at nearly constant levels (Martin et al. 1998).  This level of synchrony implies a homeostatic 
function.  Since most homeostatic operations are centrally controlled, this sugges that bone remodeling 
should also be centrally controlled.   
Furthermore, bone’s ability to repair micro and macro damage is another meticulously organized, 
multi-cellular process.  Preservation of bone quality is an essential survival function, common throughout 
vertebrate physiology.   Perpetual maintenance is another tightly regulated and ancient development 
shared by this evolutionary branch. 
 Additional evidence of the skeleton-energy relationship is derived from the bone and fat cells.  
Both osteoblasts and adipocytes  originate from common pre-cursor cells called mesenchymal stem cells 
(MSCs, also: Marrow Stromal Cells, and Multipotent Mesenchymal Marrow Skeletal Stem Cells) 
(Rickard et al. 1996).  During development these cells are capable of differentiating into a number of cell 
types including: osteoblasts, adipocytes, and chondrocytes.  Osteoclasts do not fall into this category.  
They are derived from hemopoietic cells in a separate cell-line, the monocyte-macrophage lineage.  
Research has shown a multiplicity of transcription factors and intracellular signaling pathways control the 
developmental fate of the MSC (Abdallah and Kassem 2012).  An inverse relationship has been observed 
between the amounts of bone versus fat cells in the bone marrow microenvironment.  The suspected cause 
is preferential differentiation into one cell-type at the expense of the other (Gimble et al. 2006).  A 
number of studies have demonstrated that many of the factors promoting adipocyte differentiation 
simultaneously inhibit osteoblast formation, and vice versa (Gimble et al. 2006; Neumann et al. 2007; 
Takeda et al. 2003). This intricate relationship also implies a central control for fat and bone cells at their 
genesis. 
Interpreted collectively, the biological ramifications of these observations signify that regulation 
of bone structure and energy metabolism is intimately connected.  Bone plays an important role in the 
energy feedback loop common to many vertebrates and this function likely evolved with the advent of 
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bone remodeling (Confavreux et al. 2009).  To better elucidate the relationship between bone and 
metabolism, two interrelated lines of inquiry have emerged: How do organs responsible for energy 
storage and expenditure affect bone cells?  And, how do bone cells in turn influence energetic systems?  
 
 
The Effect of Adipose Tissue and Glucose-Handling Molecules on Bone  
Adipose cells were previously considered an inert tissue, primarily utilized for energy storage.  
However, the discovery of adipocyte-derived hormones forced researchers to modify their concept of the 
role of adipose tissue (Zhang et al. 1994).  The adipocyte’s ability to secrete proteins, called adipokines, 
changed the concept of fat cells into a dynamic endocrine tissue, capable of producing and secreting 
molecules that assist in glucose homeostasis (Shetty et al. 2006).  Some of these circulating molecules, 
such as leptin and adiponectin, simultaneously have an influential relationship with bone cells.  The first 
aspect of the bone-energy homeostatic loop is how peripherally secreted molecules affect bone. 
   
Leptin 
The first adipokine discovered and the best-understood is leptin.  Leptin was initially detected in 
1994 by endocrinologists cloning the obesity (ob) gene (Zhang et al. 1994).  Leptin is a 16kDa hormone 
protein which relays information about satiety to the brain.  Leptin acts as a lipostat: as the amount of 
available fat stored in adipocytes changes, leptin is released or withheld into the blood stream and it 
signals the brain about nutrition sufficiency.  During periods of resource scarcity leptin levels are low, 
indicating to the brain that more food need be acquired.  Alternatively, leptin levels rise in response to 
over-feeding and increases in the number of adipocytes cells.  Circulating leptin concentrations are 
consistently elevated in clinically diagnosed type 2 diabetics (Auwerx and Staels 1998).  The diabetic 
group appears to be resistant or insensitive to leptin.  The leptin signal that should  normally indicate 
excess energy accumulation in the body is not being transmitted and/or it is not properly received 
(Karsenty 2006).   
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Leptin probably first appeared in vertebrate evolutionary biology along with the ability to 
remodel bone.  Leptin primarily functions as a signal of energy storage or deficit.  Nonetheless, it is 
logical that leptin would be created at a time when these when energy and bone regulation first co-existed 
(Wei and Ducy 2010).  Thus, it appears that leptin may have a very close relationship with bone. 
Advances in genetic testing and transgenic models, whereby specific genes can be “silenced” or 
“knocked-out” in murine subjects, have granted scientists the ability to identify the actions of certain 
secretory molecules like leptin.  Such knock-out models revealed that leptin has a complex, and 
sometimes conflicting effect on bone properties.  Ob/ob mice have had their leptin gene inactivated; 
alternatively db/db mice lack functional leptin receptors.  Leptin-deficient mice are clinically obese, 
demonstrate insulin resistance, compromised glucose handling, and have significantly higher bones mass 
when compared to the wild-type littermates.  Higher bone mass was specifically observed as a two-fold 
increase in trabecular bone in both long bones and vertebrae (Ducy et al. 2000).  Leptin-receptor deficient 
mice display a virtually identical phenotype (Ducy et al. 2000).  Histomorphometric analysis showed that 
results were due to a massive increase in bone formation parameters, far exceeding the slight 
augmentation in resorptive action. 
The de facto assumption is that the ob/ob mice demonstrate increased bone properties due to the 
amplified mechanical loading conferred by their obesity.  This is a critical hypothesis which necessitated 
testing.  Consequently another sample of transgenic mice was created: mice lacking both leptin and 
adipocytes (“fat-free mice”).  These mice demonstrated the same high bone mass phenotype as the 
original set, yet lacked obesity or increased loading stress.  These results indicate that leptin plays a role 
in bone metabolism in the absence of mechanical forces  (Ducy et al. 2000).  Furthermore, transgenic 
samples producing surplus leptin (l/l mice, “gain-of-leptin-function”), demonstrate normal appetite and 
body weight, but relatively lower bone mass (Shi et al. 2008).  Bone accrual is the only phenotypic 
feature altered in the presence of extra leptin.  This further confirms that regulation of bone mass is a 
significant function of leptin (Wei and Ducy 2010).  
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The next stage in leptin research was to clarify how leptin signals from adipocytes are transmitted 
to bone cells.  Leptin possesses a number of receptors throughout the body, but the most significant 
pathways in terms of bone function are the central neuronal relay and the peripheral pathway.   
Central control of bone mass employs neuronal mediation through the brain (Takeda et al. 2002).  
A large concentration of leptin receptors is located on the ventromedial and the arcuate hypothalamic 
nuclei (VMH and ARC, respectively).  The VMH has proven more influential in skeletal research.  Leptin 
binding on the VMH activates the sympathetic nervous system (SNS), increasing the sympathetic tone.  
The SNS accordingly sends signals to osteoblasts via the beta-2 adrenergic receptor (β2Ar).  This is the 
only sympathetic receptor located on osteoblasts and thus the only target for a leptin central pathway 
(Elefteriou et al. 2005).  
Sympathetic nervous system signaling favors bone resorption, acting through the osteoblast cell.  
Increasing the sympathetic tone increases the expression of Receptor Activator of NF-Kappaβ Ligand 
(RANK-L) in osteoblast progenitor cells.  RANK-L is a well-established promoter of osteoclast 
differentiation.  This explains why transgenic mice that are deficient in leptin (ob/ob mice) have higher 
bone mass: leptin’s normal osteoclast stimulatory function is eliminated.   
A second, peripheral mediator of leptin action on bone is Cocaine and Amphetamine Regulated 
Transcript (CART).  This amino acid protein is produced in the hypothalamus, the pituitary gland and 
pancreatic islets; then directly binds and interacts with the osteoblast cell.  CART inhibits bone resorption 
by decreasing RANK-L expression in osteoblasts, thereby decreasing osteocladogenesis (Elefteriou et al. 
2005).  In the absence of CART signaling, mice have relatively lower bone mass though their appetite and 
body weight remain unaffected.  The ability of the brain to regulate bone mass via the central and 
peripheral actions of leptin has now been confirmed and independently verified by studies conducted in 
multiple labs (Cornish et al. 2002; Karsenty 2006; Reid 2008). 
See Figure 2.1 for the Leptin Pathway. 
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Figure 2.1. Leptin signaling pathway and its effect on bone cells 
 
 
Adiponectin 
Adiponectin is a hormone protein exclusively produced by adipocytes.  Identified in 1995, it was 
originally termed adipocyte complement-related protein of 30kDa.   Adiponectin is also referred to as 
adipose most abundant gene transcript 1, due to its abundance in adipocytes (Guerre-Millo 2008).  
Adiponectin circulates as several different multimeric species.  The high-molecular weight form seems to 
be the most physiologically and clinically relevant.  Two adiponectin receptors have been identified:  
AdipoR1 and AdipoR2.  The majority of adiponectin receptors reside in skeletal muscle and liver cells, 
but a relatively smaller number exists on osteoblast cells.  Immunoblot assays revealed that only AdipoR1 
receptor is detected in primary osteoblasts (Luo et al. 2005).  Because adiponectin is solely produced by 
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fat cells, it is paradoxical that circulating adiponectin levels diminish with increased adiposity.  
Adiponectin levels subsequently rise in response to weight-loss (Arita et al. 1999).    
In 1999, Arita et al. identified adiponectin’s positive anti-atherosclerotic action.  These 
researchers showed that adiponectin infusions inhibits monocyte adhesion on arterial walls and suppresses 
macrophage-to-foam cell transformation.  Moreover, detrimental vascular anomalies were observed in 
transgenic adiponectin-deficient mice (Arita et al. 1999).  
Significantly, this adipokine has also been associated with insulin sensitivity.  Adiponectin levels 
are low in states of insulin resistance and increase with improved insulin sensitivity, usually resulting 
from weight-reduction or use of diabetes-mediating drugs (Otabe et al. 2007).  Several studies have 
independently confirmed this observation (Hotta et al. 2001; Lenchik et al. 2003; Spranger et al. 2003a).   
Using mouse-models, Yamauchi et al. found that when insulin-resistant mice were given supplementary 
adiponectin in their diet, their lipid catabolism was enhanced,  leading to reduced tissue triglyceride 
content and eventually correcting their insulin sensitivity (Yamauchi et al. 2001).  Conducting a 
longitudinal study of non-human primates with dietary-induced obesity, Hotta et al. found that 
adiponectin levels progressively decreased parallel to increased body mass and insulin resistance in these 
animals (Hotta et al. 2001).  In a sample of obesity-prone Pima, a Native Americans group residing in the 
southwest US, individuals with low circulating adiponectin concentrations were more likely to develop 
diabetes than those with high concentrations (Lindsay et al. 2002; Spranger et al. 2003a).  Other well-
established metabolic effects of adiponectin include lower hepatic glucose production (Combs et al. 
2001). 
Reactive-oxygen species (ROS) and pro-inflammatory cytokines are potent inhibitors of 
adiponectin gene expression in cultured adipocytes.  As diabetics and obese individuals show markedly 
higher concentrations of cytokines, this pro-inflammatory microenvironment could contribute to the low 
adiponectin levels observed in these individuals (Bruun et al. 2003).  Adiponectin itself can exert anti-
inflammatory effects on endothelial cells and macrophages (Arita et al. 1999).  Thus, decreased 
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adiponectin can exacerbate inflammation, which leads to even lower circulating adiponectin, and so forth 
in a downward spiral (Ouchi et al. 2001). 
Adiponectin also appears to have a relationship with bone cells.  However, this relationship is 
complex and often contradictory.  Research has shown disparate effects on bone cells depending on the 
cell-line, species investigated, the model employed, and in vitro versus in vivo methodology.  Several 
studies have shown a positive effect of adiponectin on bone properties.  Luo et al. (2005) showed that 
adiponectin acts in a dose-dependent manner on primary mice osteoblasts developed in the lab.  
Adiponectin increased osteoblast proliferation and differentiation, type I collagen secretion, and mineral 
matrix nodule formation.  Oshima et al (2005) applied a dual in vitro/ in vivo approach.  This group 
developed an adiponectin-producing adenovirus, which they subsequently injected into mice samples.  
This resulted in increased trabecular bone mass at the tibial growth plate.  They also treated mice bone 
marrow stromal cells with adiponectin, which resulted in RANK-L suppression and lower osteoclast 
differentiation.  When adiponectin was applied directly to osteoblast cells in the lab, this treatment 
increased mRNA expression of alkaline phosphatase (ALP), a common marker of mineralization.  
Williams et al (2009) used a similar dual approach, demonstrating in vitro that adiponectin was dose-
dependently mitogenic to primary rat and human osteoblasts, even at low concentrations (10 μg/ml).  
Using a group of adiponectin knock-out mice, they determined that these mice had an identifiable skeletal 
phenotype: most skeletal parameters were augmented, but not dramatically.  The observed increase varied 
with age and became most apparent at age 14 weeks. 
Alternatively, research on human populations reveals a strong inverse association between 
adiponectin and bone mass.  This has been consistently demonstrated in several independent clinical 
studies (Dimitri et al. 2012; Jurimae et al. 2005; Lenchik et al. 2003; Napoli et al. 2010; Richards et al. 
2007).  Lenchik et al. (2003) studied serum adiponectin level compared against bone mineral densities in 
a group of 80 men and women (86% type 2 diabetics). They found serum adiponectin was inversely 
associated with areal BMD, volumetric BMD, and visceral fat volume.  This association remained 
significant after adjusting for whole body fat mass.  Richards et al. (2007) performed a similar study on 
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1735 non-diabetic women and found that when serum adiponectin levels doubled, BMD decreased by 2–
3.2%.  The relationship remained significant after adjusting for BMI, serum leptin, fat mass, and exercise 
level.   
Low adiponectin levels have even been suggested as a risk factor for incidence of fracture in 
postmenopausal women (Jurimae et al. 2005).  This may be explained by adiponectin’s influence on 
osteoclasts, activated by osteoblasts conducted.  Using a human osteoblast cell-line, Luo et al. (2006) 
found that adiponectin induced RANKL secretion, while simultaneously inhibiting osteoprogerin (OPG) 
expression.  The combined actions promote osteoclastogenesis and increased osteoclast function.  
Pretreating the osteoblasts with MAPK inhibitor (SB203580), abolished adiponectin-regulated RANK-L 
and OPG expression.  Interestingly, adiponectin had a null effect on differentiation when directly applied 
to osteoclast precursor cells.  Thus, osteoblast activation by the AdipoR1 receptor and RANK-L 
expression must be an important part of the pathway (Luo et al. 2006). 
The compilation of conflicting data indicates that adiponectin may play a role in bone 
maintenance function, but the contribution is modest and the relationship may not necessarily be 
causative.  Adiponectin operates in more than one metabolic pathway; this potential interchange may 
clarify the discrepancy between laboratory results and clinical observation. 
 
 
The Effect of Bone on Energy Metabolism 
The above section explains one aspect of the potential metabolic feedback pathway.   To 
complete the loop, bone must have a complementary mechanism to affect change in energy metabolism 
and insulin regulation.  Bone-derived molecules must exist that can act upon other glucose-handling 
organs.  The search for instrumental osteological compounds was simplified by the fact that few 
osteoblast-specific genes exist. 
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Esp Gene 
Esp was the first gene identified as a potential candidate.  Esp is an osteoblast-specific gene that 
codes for secretory molecules (Confavreux et al. 2009).  Esp-/- osteoblast-specific knock-out mice display 
a positive metabolic phenotype including improved glucose handling, higher insulin secretion and 
peripheral sensitivity, bigger islets, and increased β-cell mass (Lee et al. 2007).  Therefore it appears that 
osteoblast expression of Esp is related to insulin secretion, β-cell proliferation, and its product, insulin.  
Adiponectin expression is also increased 2-3-fold in Esp-deficient mice.  Mice with Esp deleted are also 
lean, even with age, and the reduction in fat mass is restricted to visceral fat.  When provided a high fat 
diet, Esp knock-outs were still leaner than wild-type counterparts.  Furthermore, markers of inflammation 
(like TNf–α and IL-6) were low or insignificant in the fat mass of Esp knock-outs.  Thus, proper Esp 
function is probably necessary to develop obesity (Lee et al. 2007). 
Transgenic mutant mice that over-express the Esp gene (Esp +/+) display a contrasting (negative) 
metabolic phenotype (Guerre-Millo 2008; Lee and Karsenty 2008; Lee et al. 2007).  These mice 
developed all the features of type 2 diabetes: decreased β-cell proliferation, impaired insulin secretion, 
hypoinsulinemia, and lower circulating adiponectin. 
OST-PTP (Osteotesticular protein tyrosine phosphatase) is the gene product of Esp in mice; 
PTP1B is the homolog product in humans.  OST-PTP is a trans-membrane, unable to affect distant tissues 
like adipocytes, pancreatic or liver cells. Therefore, OST-PTP must regulate the synthesis, processing, 
and/or secretion of an intermediary osteoblast-derived molecule. 
 
Osteocalcin 
Osteocalcin (OCN) is a good candidate for this target molecule.  The OCN gene is potentially the 
most osteoblast-specific gene; it has not been located on any other cell type (Hauschka et al. 1989).  OCN 
is synthesized by osteoblasts in a premolecular form, bearing three glutamic acid residues (hence the 
alternate name, “bone Gla protein”) (Price 1989).  The majority of OCN molecules go through the 
processing stage where the Gla-residue is gamma-carboxylated.  This allows OCN to bind with high 
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affinity to calcium ions of hydroxyapatite and exist as a non-functional component of the bone 
extracellular matrix (Motyl et al. 2010; Murshed et al. 2004).  However, a relatively small portion of 
OCN molecules do not undergo processing; instead they remain uncarboxylated and are released into the 
bloodstream.  This is considered the bioactive form of OCN, functioning as a hormone.  
Increased levels of circulating bioactive OCN appears to be associated with metabolic benefits: β-
cell proliferation and augmented size, increased insulin secretion, and improved glucose handling (Ferron 
et al. 2012; Lee et al. 2007; Yoshikawa et al. 2011).  Bioactive OCN directly interacts directly with 
adipocytes to stimulate adiponectin expression, which further improves insulin sensitivity in target tissues 
(Otabe et al. 2007; Yamauchi et al. 2001).  Many studies have implicated serum OCN as a marker of 
glucose tolerance (Fulzele et al. 2010; Kanazawa et al. 2009a; Kindblom et al. 2009; Lee et al. 2007; 
Saleem et al. 2010).  Most, but not all studies have shown that diabetics have lower circulating total OCN 
(Ferron et al. 2012; Pittas et al. 2009).  Longitudinal data demonstrated that improved fasting glucose and 
insulin level are associated with increased OCN.   
It is problematic to differentiate under- versus fully-carboxylated osteocalcin in human samples; 
two methods exist employing either hydroxyapatite binding or a (private owned and controlled) direct 
ELISA.  While uncarboxylated (UnOCN) is the form of interest, clinical studies have encountering 
challenges isolating this component. Furthermore, an OCN receptor has not yet been discovered in the 
pancreas.  Thus it is unclear if OCN has a direct consequence on the pancreas or works primarily through 
its positive effect on adiponectin production.  
 
See Figure 2.2 for the relationship of Osteocalcin with energy metabolism. 
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Figure 2.2 Osteocalcin and its effect on energy metabolism 
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The Esp gene is causally linked with OCN carboxylation (Lee and Karsenty 2008; Lee et al. 
2007).  Approximately 90% of total OCN is bound with hydroxyapatite in the serum of in WT mice, with 
the remaining 10% in the circulating uncarboxylated form.  Conversely, in the Esp knock-out mice only 
74% of the OCN was bound in the extra-cellular matrix.  This means that when Esp is inactivated, more 
bioactive OCN is available conferring metabolic benefits (Lee et al. 2007).  The contradictory effects of 
Esp-/- versus Osteocalcin-/-, suggests that these two genes are opposite sides of the same pathway.  This 
hypothesis was proven by a simple test: removing a single OCN allele from the Esp knock-out group 
returned their metabolic phenotype to normal.   Esp-/- mice are a model of Osteocalcin gain-of-
bioactivity.  But how precisely are the genes related; how does Esp control OCN bioactivity? 
 
 
Completing the Metabolic Pathway 
These questions were answered in a seminal study by Ferron et al. (2010).  The authors pursued 
in vitro and in vivo approaches to conclude that insulin signaling is the critical link between bone and 
energy metabolism, utilizing OCN as the vehicle for glucose homeostasis. 
The first step was to understand the relationship between the Esp gene (mice), the insulin 
receptor, and OCN.  Esp produces a protein tyrosine phosphatase (OST-PTP); in humans the synonymous 
protein is PTP1B.  The insulin receptor is a substrate of OST-PTP; giving this protein the ability to 
dephosphorylate (turn-off) the IR.  When Esp is knocked-out, no OST-PTP is produced and the insulin 
receptor is continually active and signaling.  Given increased insulin signaling, the calculated ratio of 
uncarboxylated (active GLU) to carboxylated (inactive GLA) in mice osteoblasts was increased, along 
with the expected improved metabolism.  Importantly, when the insulin receptor was de-activated only in 
the osteoblast, the opposite negative phenotype resulted: decreased number and size pancreatic islets, 
beta-cell mass, beta cell proliferation, and total insulin content.  This signifies that insulin signaling from 
bone cells is an important part of the puzzle. 
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Ferron et al. (2010) simultaneously made another important discovery: insulin signaling in 
osteoblast favors bone resorption.  Bone remodeling parameters (such as CTx) were severely decreased in 
IR-knockout mice.  Moreover, insulin signaling did not affect the number of osteoclasts present; rather, 
their action as evidenced by larger area covered by the resorption pit.  Researchers identified Fox01 
(“chief of staff” in energy metabolism) as the downstream target of insulin signaling in osteoblasts.  This 
pathway ultimately leads to down-regulation of osteoprogerin (Opg) and increased expression of 
RANKL, a known promoter for osteoclast action. 
Ferron et al. (2010) found that osteoclast’s acidification of the bone extra cellular matrix (ECM) 
during resorption is both a sufficient and a necessary condition to decarboxylate OCN.  Bone resorption 
occurs at pH of 4.5; when incubated at this exact pH, the ratio of under to fully-carboxylated OCN 
significantly increased.   
See Figure 2.3 for the OCN – insulin signaling pathway 
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Figure 2.3. The Esp gene – osteoblast – osteocalcin pathway 
 
 
 
Similar to investigations on leptin and adiponectin, the results are not entirely conclusive for 
osteocalcin.  Irwin et al. (2006) reported normal bone mass for a group of insulin receptor-deficient mice 
aged six months.  Fulzele et al. (2010)  performed a comparable test, finding diminished bone mass in IR-
knockout mice but only at an age of three weeks.  The clinical effects on bone may still be inconclusive, 
but Ferron et al. (2010) made a significant contribution in completing our understanding of bone as an 
endocrine organ: establishing that insulin signaling in osteoblasts favors glucose homeostasis by 
promoting bone resorption and osteocalcin bioactivation. 
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Pharmaceutical and Clinical Applications 
Different aspects of the energetic feed-back loop have been validated through clinical 
observations.  Considering the leptin–sympathetic nervous system pathway, β-blocker supplements have 
been tested to treat osteoporosis in postmenopausal women.  This family of medication acts upon the β-
adrenergic receptors in osteoblasts and inhibits activations of RANKL.  β–blockers have demonstrated 
clinical success, with a significant decreased risk of fracture in the postmenopausal female trial group 
(Fernandez-Garcia et al. 2008; Pasco et al. 2004; Reid et al. 2005; Schlienger et al. 2004).  However, 
Ferron and others have warned that many drugs administered to reduce bone resorption and fractures put 
patients at risk for negative metabolism.  By halting the resorption process decreases osteocalcin 
bioactivity and could lead to deleterious glucose handling. 
Coumarin is an anti-coagulant used to treat hypertension, inflammation, and osteoporosis, among 
other conditions.  Coumarin impedes normal osteocalcin carboxylation, leaving more bioactive 
osteocalcin available.  Patients on coumarin treatment demonstrate lower blood glucose and decreased 
hyperglycemia (Egan et al. 1990).  The medication warfarin has a similar function, classified as an 
anticoagulant that inhibits Vitamin K-dependent carboxylation of osteocalcin (Barone et al. 1994; Motyl 
et al. 2010).  Nevertheless, results from warfarin trials are inconclusive.  Warfarin also interacts with 
mRNA expression of uncarboxylated osteocalcin, making its effects on glucose metabolism ambiguous. 
Systemic infusions with low doses of purified uncarboxylated OCN (0.3–3.0 ng/h) appear to have 
promising anti-diabetic results in mice (Ferron et al. 2008; Motyl et al. 2010).  Direct OCN administration 
reduces blood glucose, improves glucose tolerance, increases serum insulin, and produced more 
circulating adiponectin; even in test groups provided a high fat diet.  Importantly, it also had a positive 
effect on insulin target tissues: pancreas, liver, and muscle.  However, comparable unOCN treatment has 
not yet been developed for humans.   
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Summary 
The following points summarize the current understanding of the relationship between bone and 
energy metabolism: 
 The past decade of research suggests that bone and energy metabolism is intimately linked in a 
partnership that likely developed early in the evolution of bone maintenance.  
 A feed-back loop exists in which molecules secreted by adipose tissue, such as leptin and 
adiponectin, affect bone remodeling; correspondingly, bone cells secrete proteins, primarily in the 
form of bioactive osteocalcin, which affect energy metabolism. 
 Both of these pathways impact whole-body energy regulation. 
 The skeleton can no longer be conceived as an inert structural tissue. 
 Bone pays a role in the development and progression of diabetes, as well as mitigates the 
complicating factors such as inflammation. 
 
How does metabolic disease, specifically type 2 diabetes, manifest itself clinically in bone tissue 
and organs?  The next chapter will elucidate the clinical manifestations of bone/energy/glucose 
malfunction. 
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CHAPTER 3. DIABETES AND THE BODY 
This chapter broadens the examination of diabetes, moving from molecular causal pathways, to 
the observable consequences on human tissue.  First, hyperglycemia will be defined and the significance 
of this condition will be clarified.  Second, hyperglycemia’s negative effect on soft tissues is described.  
Finally, the effect of diabetic hyperglycemia on osteological structures that may be identified postmortem 
is illustrated. 
 
Background 
Diabetes is the seventh leading cause of death in the United States based on death certificates 
issued in 2007, and was a contributing factor in another 160,000 deaths (CDC 2011).  Diabetes carries 
with it a number of long-term complications that significantly increase morbidity and mortality.  This 
affords diabetics a life expectancy that is only two-thirds that of the general population (Ahmed 2005).  
Furthermore, treating diabetes elicits tremendous healthcare costs.  The total (direct and indirect) medical 
cost related to diabetes in the US in a single year (2007) is estimated at $174 million (CDC 2011).  This 
chapter will examine the detrimental effects that diabetes extracts on the human body, both soft tissue and 
osteological structures. 
 
The Effect of Hyperglycemia  
Hyperglycemia is a defining feature of both type 1 and type 2 diabetes, primarily due to absolute 
or relative insulin deficiency.  Hyperglycemia also plays an important role in the pathogenesis of diabetic 
complications.  Two benchmark studies, the United Kingdom Prospective Diabetes Study (UKPDS), and 
the Diabetes Control and Complications Trial (DCCT) each independently identified hyperglycemia as 
the principle source of many comorbidities of diabetes.  The syndromes considered in these studies were 
cardiovascular disease and myocardial infarction, neuropathy, peripheral vascular disease, nephropathy 
and end-stage renal disease, retinopathy, ulceration and amputation.  The UK study recognized that the 
long-term risk of developing diabetic complications was strongly associated with baseline levels of 
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hyperglycemia. Any subsequent reduction in HbA1c was likely to significantly reduce the risk of 
complications.  The group with the lowest risk were non-diabetics whose HbA1c values fell within the 
normal range (< 6.0%) (Stratton et al. 2000). 
Chronic hyperglycemia increases protein glycation, the non-enzymatic covalent bonding between 
protein and glucose molecules.  This occurs in many tissues, even those organs lacking receptors for 
glucose, thus damaging a diverse array of cellular structures and affecting systemic metabolic change.  
These primary biochemical changes cause secondary tissue-specific alterations, namely modification of 
neuronal and vascular cell structure and function (Sheetz and King 2002).  Some of these changes 
include: hemodynamic alterations, activation of inflammatory signaling molecules, and endothelial 
dysfunction.   
Several theories have been proposed to explain the precise mechanism of hyperglycemia’s 
negative impact.  These theories fall into two major camps: those highlighting the toxic effects of 
hyperglycemia, like Oxidative Stress Theory and the Aldose Reductase Theory, and those focusing on the 
altered cell signaling pathways,  like the Advanced Gycation Activation (AGE) Theory and the Protein 
Kinase C (PKC) Theory (Ahmed 2005; Sheetz and King 2002).  Oxidative Stress is created when 
hyperglycemia increases mitochondrial oxidative phosphorylation and glucose autoxidation.  The by-
products of these oxidative processes are free radicals that can damage vascular proteins. The Aldose 
Reductase Theory focuses on its namesake enzyme which converts glucose into sorbitol.  Excessive 
sorbitol may cause negative osmotic vascular changes. The AGE theory pinpoints covalent modification 
and cross-linking of proteins and glucose as a form of cellular aging that may cause many diabetic 
complications.  And finally, PKC is a critical intracellular signaling molecule regulating vascular 
permeability, vasodilator release, and endothelial action.  Diabetes can chronically activate PKC.  
Additional details on these complex and heavily-debated theories are beyond the scope of this work.  
Pharmaceutical companies are currently developing compounds that target and attempt to neutralize the 
common pathways in which both glucose and glucotoxins exert their adverse effects.  Coupled with strict 
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control over glucose levels, prescription therapies may offer relief to diabetics in the future (Sheetz and 
King 2002). 
 
Angiopathy 
Angiopathy, a term for the malfunction of the blood vessels, is caused by hyperglycemia, high 
levels of glucose circulating in blood plasma, and by dyslipidemia, disordered lipid metabolism 
manifested as elevated total cholesterol and/or low density lipoproteins (LDL or “bad” cholesterol).  In 
diabetes mellitus, two anigiopathic processes develop simultaneously: arteriosclerosis, calcification of the 
arterial walls rendering them less pliable; and atherosclerosis, plugging of the lumen with plaque 
(concentrated lipoproteins) (Kahn et al. 2005). 
Macroangiopathy describes clogging of major vessels which may cause stroke and ischemic heart 
disease.  This vascular condition inherently prevents blood flow from reaching smaller vessels.  Occurring 
primarily in the walls of minor vessels, microagiopathy causes them to become progressively thickened 
while simultaneously weak to stress.  Angiopathy is particularly significant in diabetics because it can be 
observed in a diverse group of tissues at grossly different levels.  Consequently, crucial blood cells and 
proteins leak into surrounding tissues; oxygen transfer and CO
2
 absorbance is ineffective.  This is 
severely detrimental to tissues sensitive to blood flow and oxygen supply (NIDDK 2008).  Disruption of 
blood vessel mediated physiology is a trademark of prolonged diabetes.   
 
Soft Tissue Pathologies 
Hyperglycemia is the common thread relating most diabetic complications, but it has extensive 
and variable effects.  This distinguishes diabetes as both very difficult to treat clinically and to control 
progressive symptoms.  Soft tissue pathologies derive from malfunction in vital organs.  The complex 
units require extensive vascularization and neural networks, both of which are compromised by 
hyperglycemia.  Soft tissue failure greatly increases morbidity and may contribute to hard tissue 
complications.   
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Nephropathy  
Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) in the kidneys.   
Twenty-five percent of patients entering renal dialysis programs and 35-40% of all kidney transplant 
recipients cite diabetic nephropathy as the source of their ESRD (Ojo 2002).  Incidence of diabetic 
nephropathy is disparate in its distribution, being more prevalent among African Americans, Native 
American and Asians groups (CDC 2011).  
Nephropathy is a disorder of the kidney, an organ whose purpose is to filter blood of waste 
products – nitrogenous waste, surplus potassium, proteins, and excess water.  Glomeruli are the structures 
within the kidneys responsible for filtration.  Each nephron unit possesses one glomerulus for filtration.  
Properly operating glomeruli are vital for normal metabolic function.  Kidney functional ability may be 
tested with a BUN (blood urea nitrogen) test, which measures the amount of nitrogen in blood serum that 
comes from urea (waste product).  Normal BUN levels fall at or below 2.3 (Kagan 2010).  If BUN is 
abnormally high, this indicates the kidneys are not filtering properly and waste remains in the blood 
stream.  Kidney function can also be evaluated with a proteinuria test, which measures the amount of 
albumin in urine.  Albumin is an important protein found in blood.  When albumin is detected in urine, 
this indicates that the glomeruli did not function appropriately and critical proteins are lost into urine 
(Kahn et al. 2005).   
Diabetic nephropathy is often divided into two stages based on values of urinary albumin 
excretion.  Microalbuminuria (a.k.a. initial or incipient nephropathy), may commence within two to four 
weeks of glucose intolerance.  Microalbuminuria is characterized by a small amount of albumin present in 
urine, thickening of the glomerular basement membrane, and increase in the glomerular filtration rate 
GFR (Valk et al. 2011).  Hyperfiltration is brought about by a dilation of the afferent glomerular arteriole, 
without corresponding dilation in the efferent arteriole.  Essentially, this forces the glomerulus to work 
overtime.  Macroalbuminuria (also termed overt or clinical nephropathy) is identified by significant 
amounts of albumin in urine (≥0.5g / 24h), and Kimmelstiel-Wilson lesions on the glomeruli. The 
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overburdened filtration system reaches its functional limit and GFR rapidly declines (Valk et al. 2011).  If 
detected late or poorly controlled, macroalbuminuria progresses to ESRD.   
ESRD is typified by a filtration rate of <20cc fluid/minute (Ojo 2002).  It takes approximately 15-
25 years from the onset of glucose intolerance to develop full ESRD, though progression rate is highly 
variable and patient-dependent.  End-stage renal disease ensues when kidneys can no longer filter toxins 
independently; an alternative, external filtration system may be utilized to maintain correct levels.   
Approximately 500,000 people are dialysis-dependent in the US (Kagan 2010).  Two major 
methods of dialysis exist: hemodialysis and peritoneal dialysis.  Hemodialysis is by far the most common 
form.  Hemodialysis is a process wherein the patient is connected to a blood filtration machine using 
(typically) the radial artery and cephalic vein of the non-dominant arm.  Rudimentary dialysis was first 
successfully performed in the Netherlands in 1945 using a semi-permeable membrane (prototype of 
cellophane) as the blood filter.  Current models utilize complex synthetic polymers to maximize the 
dialyzing surfaces (Kagan 2010).  Diabetics with end-stage renal disease cannot miss a single dialysis 
treatment; their kidney damage is permanent and life-threatening.  Twenty percent of dialysis patients in 
the US die each year.  A number of issues can be lethal: missed treatments, non-compliance with dietary 
restrictions (dialysis-dependent diabetics require low potassium and low-protein diets), unmonitored 
blood pressure, infections at the dialysis puncture sites, and inappropriate care (NIDDK 2008).  ESRD 
diabetics have a higher mortality rate than their cohort. 
 
Retinopathy 
In the US, type 2 diabetes is the leading cause of blindness for individuals between the ages of 20 
and 74 years (CDC 2011).  In a national study of diabetics diagnosed for 15 or more years, 80% 
demonstrated some degree of diabetic retinopathy (Clarke et al. 2006).  As described above, 
hyperglycemia targets vascular structures, including the delicate vessels of the eye.  
Diabetic retinopathy encompasses a number of complications that progressively impairs vision 
and may cause blindness.  Chronic hyperglycemia is responsible for many of the early functional changes 
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in vascular structures of the eye.  This includes leukocyte and monocyte adhesions to microvessels, 
reduced retinal blood flow, and capillary closure (Sheetz and King 2002).  Destruction of pericytes is one 
of the earliest and most specific changes in the retina produced by hyperglycemia.  Pericytes are 
specialized contractile cells lining the delicate retinal vessels.  The death of pericytes predisposes the 
vessels to endothelial proliferation and developing microaneurysms, leaking blood/fluid into the vitreous 
(Kagan 2010).  
There are two major forms of diabetic retinopathy: proliferative diabetic retinopathy (PDR) and 
degenerative macular edema (DME).  With PDR the retinal blood vessels clot, reducing oxygen supply, 
resulting in hypoxia.  In an attempt to provide the necessary oxygen, neovascularization occurs.  
Neovascularization is a process where new blood vessels are formed in novel areas.  New vascular growth 
is not well-organized: the new vessels are weak, and their paths haphazard, often crossing structures or 
blocking light from reaching the retina.  The supplementary vessels are prone to clotting, rupturing and 
scarring.  Throughout healing the scars contract and may dislodge the retina, leading to partial or total 
loss of vision (Johnson and Kurtz 2002).   In DME microaneurysms occur in or near the macula, a critical 
portion on the retina that contains the fovea and cone cells responsible for color vision.  Significant 
swelling and edema in the macula causes permanent destruction to the sensitive tissue, resulting in 
permanent vision loss (Johnson and Kurtz 2002). 
Development of retinopathy is directly related to the length of time one has suffered from 
diabetes.  Insulin-dependent diabetics have a 50% risk of developing retinopathy over a four-year period 
(Klein et al. 1984).  In addition to retinopathy, diabetics are also more likely to develop visual co-
morbidities, like glaucoma and cataracts.  Sudden changes in blood sugar alter the osmolarity of the 
vitreous fluid, causing the lens to swell and may result in near-sightedness (Aiello 2003).  Early detection 
of retinopathy with regular eye exams, glycemic control, and blood pressure monitoring can reduce the 
risks and the symptoms of retinopathy (Aiello 2003).   
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Neuropathy  
Sixty to seventy percent of diabetics experience some form of neuropathy.  Chronic 
hyperglycemia evokes changes in myelinated and non-myelinated nerves; neuropathy ensues shortly 
thereafter.  The prevalence of neuropathy increases with known length of the diabetic disease (Simmons 
and Feldman 2002).  This may affect any aspect of the nervous system: Autonomic, Motor, or Sensory 
nervous systems. 
Autonomic neuropathy is much more common in type 1 diabetes, but advanced type 2 diabetes 
also shows symptoms.  Cardiovascular Autonomic Neuropathy (CAN) is the most widely-researched 
expression of autonomic neuropathy.  CAN is defined as impaired regulation of blood pumping  through 
the cardiovascular system (Tesfaye et al. 2010).  Type 1 and 2 diabetics suffering from CAN are disposed 
to developing tachycardia, silent myocardial ischemia, coronary artery disease, and stroke; all of which 
are highly associated with morbidity and mortality (Tesfaye et al. 2010).  Additional forms of autonomic 
neuropathy include gastrointestinal autonomic/motor neuropathy, erectile dysfunction, and uncontrolled 
bladder (Kagan 2010).  The form of autonomic neuropathy specific to type 2 diabetics involves loss of 
functional sweat glands in the extremities, known as sudomotor dysfunction.  Sudomotor dysfunction 
particularly affects the extremities (hands and feet).  Feet become dry and cracked; especially the thick 
dermal layers cover the calcaneus (heel).  Fissures in skin, coupled with poor circulation and loss of 
sensation together elevate the propensity for infections. 
Motor neuropathy is loss of muscle control due the nerve damage.  Unused, the muscle atrophies, 
leaving the area disfigured and vulnerable to secondary trauma.  In type 2 diabetics, this is often 
manifested as “foot drop.”  Foot drop is caused by peroneal nerve damage; the individual cannot lift the 
foot upward during normal ambulation.  The diabetic’s toes drag against the ground with each step 
(Kagan 2010).  Similarly, “wrist drop” results from loss of radial nerve control, whereby the patient is 
unable to lift the hand into a stop position.  Asymptomatic carpal tunnel syndrome has also been observed 
in 6–11% of diabetics.  This is caused by degradation of the median nerve by hyperglycemic factors 
(Simmons and Feldman 2002) 
44 
 
Sensory neuropathy, also termed diabetic peripheral neuropathy (or polyneuropathy) is the most 
common form of neuropathy, affecting 45% of type 2 diabetics upon diagnosis (Simmons and Feldman 
2002).  Polyneuropathy is experienced as either positive creation of sensation, or negative loss of feeling.  
Positive phenomena include a burning feeling, aching pain, allodynia (heightened sensitivity), and pins-
and-needles sensation.  Negative neuropathy is the gradual loss of feeling, typically beginning as 
localized numbness and ending in complete loss of sensation.  This is the more prevalent form of diabetic 
neuropathy.  Polyneuropathy is characterized by thickening of the axons, decrease in microfilaments, and 
the narrowing of capillaries involving myelinated and nonmyelinated fibers (Sheetz and King 2002).  
These changes directly result from hyperglycemia-induced damage to nerve axons and indirectly caused 
by glycaemia-provoked decreases in neurovascular flow the extremities.  The hands, ankles, and feet 
including toes are the most frequently impaired areas (Sheetz and King 2002).  The earliest symptoms 
involve the distal toes and progress in a predictable direction toward the ankle and calf.  Sensory 
neuropathy is the major cause of diabetic foot ulceration (Kagan 2010). 
Multiple forms of neuropathy combine in a phenomenon known as “diabetic foot” (Simmons and 
Feldman 2002).  Motor-neuropathy-induced atrophy of intrinsic foot muscles produces unusual foot shape 
(“foot drop”, mentioned above).  This leads to unnatural distribution of body weight during mobility, 
increasing plantar pressure.  Constant heightened pressure in an unequipped area breaks down fragile 
dermal tissue and development of ulcers under the first metatarsal head.  Sensory polyneuropathy 
eliminates protective sensation in the feet, ensuring that any minor trauma or ulceration is painless and 
may go undetected (Reiber and Ledoux 2002).  Furthermore, loss of moisture due to sudomotor 
dysfunction causes skin to dry and crack and cause additional arteriovenous clotting.  This can cause skin 
and bone perfusion, which may lead to change in normal bony architecture and permanent foot 
deformities (Singh et al. 2005).  Charcot foot is a specific form of diabetic foot involving microvascular 
changes, microfractures, and permanent foot deformity.  (Figure 3.1)  Characterized by arch collapse the 
foot takes on a convex shape, making it very difficult to walk (American College of Foot and Ankle 
Surgery 2006).   
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Figure 3.1 Charcot foot, normal and x-ray view of bony malformation 
 
 
 
As diabetic foot infections prolong, the bacteria proliferates inward, toward bony structures.  
Incidences of neuropathic infection preceding osteomyelitis are discussed in the osteological pathologies 
section. 
 
Osteological Pathologies 
Many of the osteological pathologies associated with diabetes originate with soft tissue 
complications.  Decreased vascular function, tissue hypoxia, and retarded healing can exacerbate 
symptoms.  If allowed to fester, minor concerns can lead to significant medical problems affecting and 
debilitating the skeletal system. 
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Bone Mineral Density 
Diabetes does not evoke a universal effect on bone quality.  In general the diabetic influence 
appears to be type-specific and contradictory between type 1 and type 2 diabetes.  The diverse results may 
be related to the demographics and specific pathophysiology unique to each type. 
 
Bone mineral density: Type 1 Diabetes 
The majority of data relating diabetes and bone density are primarily derived from treatment-
based clinical literature.  Type 1 diabetics demonstrate universally reduced bone density and greater bone 
fragility (de Liefde et al. 2005; Tuominen et al. 1999; Vandaele et al. 1995).  The effects of type 1 
diabetes are unambiguous and more severe, presumably because type 1 arises at an earlier age during 
crucial periods of skeletal development and peak bone acquisition.  Bone mineral density (BMD) is 
reduced in virtually all studies on type 1 patients (Tuominen et al. 1999; Vandaele et al. 1995).  The 
World Health Organization determined that more than 50% of type 1 diabetic juveniles and adolescents 
experience low BMD and/or trabecular and cortical bone loss (WHO 2004).    
Evidence from both experimental and clinical data now shows that the major skeletal alteration in 
type 1 diabetes is reduced bone formation, rather than increased bone resorption (McCabe 2007).  
Specifically, onset of type 1 diabetes appears to cause de-differentiation of osteoblasts as well as 
suppression of osteoblast maturation and even apoptosis (Rosen and Bouxsein 2006).  Decline in insulin 
production typical of type 1 diabetes is also a contributor to bone fragility.  Experimental data have shown 
that insulin has anabolic effects on osteoblasts.  The inulin-deficient skeletal system has fewer osteoblasts 
available to keep up with normal osteoclastic resorption (McCabe 2007), or to progress on to mature 
osteocytes. This indicates that the skeleton is rapidly affected by impaired glucose and insulin control. 
 
Bone Mineral Density: Type 2 Diabetes 
The relationship between type 2 diabetes and bone mineral density is more controversial.  In 
sharp contrast to type 1, type 2 diabetic patients typically demonstrate higher BMD values at multiple 
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skeletal sites.  Several studies relating bone and diabetes have shown a significant increase in BMD–
scores at the hip, spine, and limbs (Barrett-Connor and Holbrook 1992; Merlotti et al. 2010; Schwartz et 
al. 2005; Strotmeyer et al. 2004) .  Due to the high correlation between diabetes and obesity, increased 
mechanical loading is the hypothesis commonly invoked to explain the thicker, more robust bones 
observed in this group.  Wolff’s Law is used to explain the relationship between bone structural 
morphology and environmental factors.   Wolff’s Law has been more recently referred to as bone 
functional adaptation: bone morphology adapts to the imposed mechanical environment, while accounting 
for specific genetic, developmental, hormonal, and environmental variation (Ruff et al. 2006). 
The type 2 phenotype of higher bone mineral density appears to result from increased bone 
formation, suppressed osteocladogenesis, and osteoclast action.  Though some of these functions could be 
attributed to mechanical forces, increased load-bearing cannot be the singular positive stimulus.  Several 
clinical comparative studies shown than even when controlling for age (Burghardt et al. 2010b), for sex, 
(Barrett-Connor and Holbrook 1992), and menopausal state (Nicodemus and Folsom 2001), type 2 
diabetic patients still had higher BMD values (Burghardt et al. 2010a).  Furthermore, even after adjusting 
for body size the discrepancy between diabetic and non-diabetic BMD values persists.  Strotmeyer and 
colleagues (2004) found type 2 diabetes was associated with 4–5% higher total hip BMD, independent of 
body composition in both white and black males and females. 
Increased adiposity inevitably has an effect on bone formation, although it may not be solely 
related to mechanical loading.  Adipokines and other hormone protein molecules produced by fat cells 
may be influencing osteoblast function (Melton et al. 2008).  Early in diabetic research, insulin was 
examined as a possible instigator due to the overwhelming incidence of type 1 diabetics with 
osteoporosis.  In osteoblast cultures insulin has been shown to stimulate glucose uptake, regulate the 
Na
+
/K
+
 pump, and to simulate type I collagen synthesis (Thomas et al. 1997).  Additionally, insulin has 
definite mitogenic effect on osteoblast cells in vitro (Thomas et al. 2001).  Hyperinsulinaemia also shows 
a strong association with diffuse idiopathic hyperostosis and hyperostosis frontalis externa, both 
conditions which display excess bone formation in mechanically insignificant areas.  Using data from the 
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Rancho Bernardo Heart and Chronic Disease Study, researchers found a significant fasting insulin–BMD 
association after adjusting for covariates (Barrett-Connor and Kritz-Silverstein 1996).  In women, higher 
BMD may be explained by increased androgen due to lower circulating globulin (Schwartz et al. 2002).  
As described in chapter 3, the adipocyte-produced protein leptin has also been identified as a mediator of 
the positive effect of fat mass on the skeleton.  Thomas et al. (2001) found sexual dimorphism in leptin’s 
influence.  Adjusting for leptin levels eliminated the strong association between mass and BMD in the 
female (but not male) test group; thus protein hormones may be more influential for bone density in 
females than males.     
Interestingly, a few studies have demonstrated the polar opposite of decreased BMD in the 
presence of type 2 diabetes.  Wakasugi and colleagues (1993) found decreased BMD at the lumbar spine 
and femora in diabetics compared with control subjects.  Levin (1976) found reduced BMD values type 2 
diabetics at forearm measurements, compared with data from the controls and type one diabetics.   
Incidence of fractures may be a better indicator of bone quality for type 2 diabetics.  Bone density 
indices may not capture true bone strength.  Moreover, estimates of deposition do not necessarily suggest 
enhanced loading capacity.  Bone mineral density has a complicated relationship with type 2 diabetes, the 
nature of which depends heavily upon sex, age, and stage of the disease; these covariates contribute to the 
heterogeneous survey. 
 
Fractures 
Bone mineral density is generally considered a strong predictor of fracture.  However, both type 1 
and 2 diabetics have an increased risk of fracture when compared to healthy controls.  Type 2 diabetics, 
with their heavier body mass and generally increased bone mineral density, demonstrate a paradoxically 
higher incidence of fracture (Merlotti et al. 2010).  Areas typically subjected to fracture include proximal 
humerus, foot, and ankle (Forsen et al. 1999; Keegan et al. 2002; Nicodemus and Folsom 2001; Sagray et 
al. 2013; Schwartz 2003). 
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Type 2 diabetics likely experience more fractures for dual reasons: higher propensity to fall, and 
poor bone quality that may not be captured in measurements of bone mineral density (Schwartz et al. 
2002).  Several risk factors predispose diabetics to fall, and increase the likelihood that their injury will be 
severe.  These factors include neuropathic loss of sensation, unsteady gait, poor balance, retinopathic 
decrease in sight and impaired stereoscopic vision, as well as stroke (Schwartz 2003).  History of falls is 
also notable when considering risk factors; re-injuring an area weakened by prior trauma will have greater 
consequences with longer healing time than damage to a virgin territory (Retzepi and Donos 2010).   
The Study of Osteoporotic Fracture was a prospective study on older women in the US, that 
demonstrated a relationship between type 2 diabetics and fracture that could not be entirely explained 
when risk factors and history of prior falls were accounted for (Schwartz et al. 2001).  The risk factors 
that were accounted for in the study included: peripheral neuropathy, history of stroke, walking speed, 
poor vision, and benzodiazepine use.  This indicates that inherent bone strength is likely contributing to 
fractures, allowing bone to break more easily. Verhaeghe and colleagues (1994) conducted a study on 
bone strength in streptozotocin-induced type 2 diabetic rats.  The rat femora performed poorly under 
stress, displaying lower torsional strength, and energy absorption.  The rodent subjects had normal to 
slightly lower BMD (though not significantly decreased).  So what is causing poor quality in diabetic 
bone? 
Research has shown that low endogenous insulin levels may inhibit normal bone deposition 
(Thomas et al. 2001).  As diabetes advances the pancreas exhausts its capacity to produce the hormone.  
Insulin has an anabolic effect on bone.  Absence of insulin has the potential to decrease bone turnover 
without significantly altering BMD.  Hyperglycemia, the scourge of diabetes, appears to have negative 
impacts on bone that is not captured in density measurements.  Experimental studies have shown that 
glucose can increase osteoclast activity by providing excess nutrition (Williams et al. 1997).  Both acute 
and chronic hyperglycemia may suppress the expression of genes associated with osteoblast maturation 
(McCabe 2007).  Additionally, hyperglycemia increases lactic acid synthesis, which may reduce gene 
expression and mineralization of pH-sensitive osteoblasts (McCabe 2007). 
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A plethora of research has identified advanced glycogen end-products (AGEs) as significant 
factor in diabetic bone quality.  AGEs form as a secondary consequence of chronic hyperglycemia and 
they have a similar detrimental impact on soft tissues and their functions (Ahmed 2005).  AGEs accrue in 
collagen within the bone matrix and may increase fragility.  It is not fully understood how AGE affect 
fragility; it has been suggested that AGEs alter bone collagen properties, AGEs may suppress osteoblast 
expression, and that AGE’s induce production of cytokines like interleukin-6 (Schwartz 2003).  Wang 
(2002) found that AGEs were associated with reduced strength and work to fracture in human bone, 
specifically observed in bone collagen network.  Therefore, other molecules may be modified by 
hyperglycemia which decreases bone strength but are not being captured in measures of bone mineral 
density. 
Longitudinal studies have revealed an important nuance related to the timing of diabetic fractures.  
Using data from the Rotterdam study, researchers showed increased fracture risk of the hip for established 
type 2 diabetics who were receiving treatment; much lower risk was noted for newly diagnosed and non-
diabetic subjects (de Liefde et al. 2005).  Similarly, a Canadian study demonstrated that diabetics 
diagnosed for more than five years had increased fracture risk at multiple sites, while newly diagnosed 
diabetics had reduced risk (Leslie et al. 2007).  Together these data indicate that pre-diabetes and early 
stages of the disease may lend protective benefits to bone.  But prolonged diabetes, with accumulated 
comorbidity factors and extended metabolic disturbance, combine to increase overall fracture risks.  
 
Periostitis, Osteomyelitis, and Amputation  
Periostitis is an inflammation of the sheer lining of connective tissue surrounding bone, the 
periosteum. Given the right environment, periostitis can proceed to osteomyelitis, though not in all cases.  
Osteomyelitis is defined as an infection of skeletal tissue.  Both conditions can be caused by infection 
traveling through the bloodstream, but the initial event for diabetics is typically an injury involving the 
soft-tissue (Kagan 2010). 
51 
 
Trauma may be unbeknownst to the diabetic given the enabling effects of retinopathy and 
neuropathy.  Periosteal infections often begin with a superficial injury to the site.  For example, a “shin 
strike” is described as a blow to the anterior tibia breaking the skin with damage to underlying tissue.  
Diabetic patients experience delayed or impaired wound-healing due to compromised vascular function, 
which may advance infections inward (Vogt et al. 1997).  Moreover, depressed sensation may downplay 
the severity of the injury. 
Osteomyelitis commonly presents in areas prone to ulcers, such as the metatarsal head, digit 
terminus, and the calcaneus (Malone et al. 2013).  Ulcers precede 71–84% of non-traumatic amputations 
performed each year (Reiber and Ledoux 2002).  The risk factors for developing foot ulcers and 
osteomyelitis reads like a playbook for diabetic complications, including: neuropathy and peripheral 
vascular disease, retinopathy, increased plantar pressure, foot deformity, poor glycemic control, and 
prolonged hyperglycemia (Reiber and Ledoux 2002).  Incidence of foot ulcers and osteomyelitis was 
shown to be proportional to number of risk factors in a case-control study of Pima Indians.  Test subjects 
diagnosed with one risk factor were 2.1 times more likely to develop ulcers. Subjects suffering from two 
risk factors were 4.5 more likely than controls; and those with four or more risk factors increased their 
likelihood to 9.7 times more than control subjects (Mayfield et al. 1996).  
“Diabetic foot” and charcot foot have been previously described in this chapter.  Both cause 
disfigurement of the foot leading to misplaced weight distribution (increased plantar pressure) and uneven 
gait. Progressive break-down of the fragile epidermis during mobility causes ulceration, typically over the 
first metatarsal head.  The diabetic often cannot feel pain or discomfort due to neuropathy and may not 
realize how serious the condition has become.  Approximately 50% of patients with limb-threatening 
infections do not display systemic signs or symptoms (Lipsky 2004).  Tissue freshly exposed to an 
anaerobic, moist environment, with reduced capacity for immune response is the perfect storm for 
diabetic foot infections.  The greater the insensitivity to touch, the higher the chance of developing foot 
ulcers (Boyko et al. 1999) and more severe complications. 
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The gold standard for diagnosing osteomyelitis is bone biopsy conducted under fluoroscope; but 
this technique tends to be underutilized due to expense and lack of experience performing the test.  In 
absence of bone biopsies, Malone and colleagues (2013) recommend deep wound culture, whereby the 
ulcerated area is probed and the exposed bone surface is swabbed.  This technique allows clinicians to 
determine the amount of tissue affected and to isolate and culture the bacterium responsible for causing 
the bone infection.  The predominate pathogens involved in diabetic foot osteomyelitis are gram-positive 
Staphylococcus aureus (Lipsky 2004). 
Once the infection has reached bone, there is a real concern that bacteria have entered the 
bloodstream and that sepsis will ensue.  A number of diabetic patients die from septic shock, secondary to 
their diabetes and prior to amputation (Kagan 2010). 
Amputation is the clinical removal of a terminal, nonviable portion of a limb.  The goal of 
diabetic amputations is to maximize the amount of salvageable bone and soft tissue, while ensuring 
adequate vascularization for proper healing.  Any portion of the bone which has experienced 
osteonecrosis or tissue that has become gangrenous must be removed.   
Six major types of amputation exist (Kagan 2010): (1) Partial toe amputation – dissection through 
any of the foot phalanges; (2) Complete toe (Raye) amputation – removing phalanges and metatarsal head 
of the isolated toe; (3) Transmetatarsal amputation – involves removing all phalanges and metatarsal 
heads of all five digits, essentially eliminating the forefoot; (4) Complete foot (Syme) amputation – 
removing the entire foot by dissecting through the ankle joint. This amputation is no longer performed, 
though it may be observed in older diabetic patients. The stump experiences poor healing because the skin 
covering the cartilaginous ends of residual tibia and fibula are exposed to excessive pressure, even when 
using prosthesis; (5) Below the knee amputation – currently the most common diabetic amputation.  The 
limb is dissected at the distal third of the tibia/fibula; (6) Above the knee amputation – this amputation is 
necessary for patients with infection or significant arteriosclerosis extending above the knee and is 
performed by cutting through. 
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Surgeons do not amputate through a joint (between bones). Cartilage-lined joints provide poor 
blood supply insufficient for adequate healing. Rather, long bones and phalanges are bisected, allowing 
enough residual skin and tissue to comfortably cover the stump.  More than 68% of the non-traumatic 
amputations completed each year are performed on type 2 diabetics (CDC 2011). 
 
Periodontitis 
Periodontal disease (PD) has been recognized since the 1960s as a significant complication of 
type 2 diabetes.  Periodontitis was suggested as the sixth major complication by Loe in (1993).  Diabetics 
have a threefold higher incidence of periodontitis than the normal population (Preshaw et al. 2012).  Risk 
of cardiorenal mortality (ischemic heart disease and diabetic nephropathy combined) is also three times 
higher in diabetic patients with severe periodontitis than in diabetics without periodontal disease (Preshaw 
et al. 2012).  Examining the (NHANES) III data, adults with an HbA1c level greater than 9% (diagnosing 
them as type 2 diabetics) had significantly higher prevalence of severe periodontitis than those without 
diabetes, after controlling for age, ethnicity, education, sex and smoking (Tsai et al. 2002).   
Lalla et al. (2007) examined a group of pair-matched children (ages 6-18 years) with and without 
diabetes for signs of PD: loss of ligament attachment, gingival bleed, and combined symptoms. They 
observed a high prevalence of PD in the diabetic group.  This is significant because it identifies PD as the 
first clinical complication of diabetes to manifest in juveniles. Other comorbidities (retinopathy, 
neuropathy, etc.) do not present prior to maturity. 
Periodontal disease and diabetes are locked in a self-perpetuating cycle.  Chronic high blood sugar 
promotes periodontitis; while the body’s inflammatory response to dental infection further exacerbates 
insulin resistance and hyperglycemia (Lalla and Papapanou 2011).  Periodontal disease begins as bacterial 
biofilm (plaque) accumulates at and below the gum line (just above the cement-enamel junction).  Early 
and mild forms of periodontal disease are termed gingivitis. Without treatment or intervention the gums 
become chronically inflamed by the foreign bacteria.  The shallow crevasses around the teeth (periodontal 
pocket) become deeper as the infected ligament pulls away from the alveolar line.  This augmented 
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anaerobic environment allows diverse bacteria to flourish and leads to polymicrobial break down of the 
bone and connective tissue that hold teeth in place (Lalla and Papapanou 2011).   
Periodontal disease initiates an immune response in the body.  White blood cells and 
inflammatory cytokines are released to fight the infection.  Diabetics already demonstrate a 
hyperinflammatory phenotype; they exist in a chronic state of inflammation and are ill-equipped to fight 
acute stresses.  As the inflammatory response continues with no resolution, on-going persistent 
periodontal disease is termed periodontitis (Taylor and Borgnakke 2008).  The inflammatory cytokines 
released at the infected ligament enter circulation via periodontal microcirculation. These proteins can 
travel through the body to affect other organs like the pancreas, intensifying the inflammatory response 
and aggravating insulin resistance (Taylor and Borgnakke 2008). 
If not properly treated, the bones, gums, and connective tissue supporting the teeth degrade. 
Dentition may eventually become loose, fallout, or must be removed.  Research indicates that diabetes 
prevents collagen synthesis in periodontal tissues through an AGE (advanced glycation end product) 
mediated pathway (Ren et al. 2009). 
Conversely, studies have shown that treating periodontal infections significantly improves 
glycemic control of diabetic patients (Lalla et al. 2011; Taylor and Borgnakke 2008).  Given the strong 
association between the two diseases, it has been proposed that dental professionals may be able to 
identify undiagnosed or intermediate diabetics in their dental practice; allowing earlier detection and 
better management of diabetes (Lalla et al. 2011; Lamster et al. 2008) 
 
The current research seeks to examine those pathologies related to diabetes which leave lasting 
impression on bone postmortem.  This includes osteoporosis (as evidenced by bone mineral density), 
fractures, presence of periostitis and osteomyelitis, and periodontitis. 
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CHAPTER 4. MATERIALS  
 
The data for this dissertation was sourced from the William M. Bass Donated Skeletal Collection, 
housed in the Department of Anthropology at the University of Tennessee, Knoxville.  The William M. 
Bass Collection was initiated in 1981 and has increased exponentially over the past thirty years.  At the 
time data were collected for this study, the racial composition of the 1,255 total skeletons was 99% 
European American, 0.06 % African American, 0.02% Hispanic, and 0.02 % Other, including Native 
America and Asian.   
Remains may be self-donated and are accompanies with documents completed by the individual 
prior to their death.  Samples are also donated by the next-of-kin, and a small percentage is sourced from 
Medical Examiner’s offices.  A wealth of information is documented for each individual, including basic 
information such as birth year, race, stature, and weight, demographic information such as city and state 
of residence and occupation, medical data such as chronic conditions and comorbidities, and finally cause 
of death.  Information is self-reported for self-donors, but data are also provided by family to the best of 
their knowledge.  The donor documents have been modified over the years.  Each subsequent version has 
requested additional information as new research questions are being developed.  Consequently donations 
from early years 1980s have less associated information than more recent donations. 
The donation program is a multi-step process, beginning with body retrieval, donation placement 
and sampling at the Anthropology Research Facility, followed by natural decomposition in an outdoor 
environment.  Remains are then processed using water heated to less than 100 ºC and physical removal of 
any residual soft-tissue.  After air-drying remains are accessioned into the Collection and housed in the 
Anthropology Department (FAC. Forensic Anthropology Center 2012). 
The number of diagnosed diabetic individuals in the Bass Collection has increased over the years. 
(Figure 4.1)  This may be explained for two reasons.  As the number of diabetics in the general 
population, particularly in the southeastern US increases, these individuals will be represented in greater 
numbers in skeletal collections and forensic cases.  Also, as popular interest in forensic sciences and 
anthropological donation programs rises, the number of donation received each year increases.  The 
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William M. Bass Skeletal Collection currently receives an average of 111 donations per year, an 
exponential increase from only three donations in the inaugural year 1981.  
For the purposes of this investigation, a sample was constructed of eighty individuals using a 
pair-matched research design.  Pair-matching is optimal for this investigation as difference in sex, age, 
and weight can all influence hormones and metabolism; these factors can in turn affect some of the 
variables under investigation.  Forty diabetics were identified using self-reported antemortem 
information.  Diabetes or type 2 diabetes was listed as a medical complication and/or cause of death.  
Diabetic type was assumed to be type 2, unless otherwise specified, due to its high prevalence in the US.  
Duration of the disease, calculated from date of diagnosis to date of death, is additionally recorded known 
for a few of the later samples.  Forty non-diabetics were also selected, whose null diabetic status was 
inferred through the absence of diabetes listed in the medical history.  Diabetic and non-diabetic samples 
were pair-matched based on sex, age-at-death, and weight-at-death.  While sex and age were relatively 
unproblematic factors to match between samples, body mass proved to be more difficult.  Nonetheless, 
subjects were successfully matched within 75 pounds of one another. 
 
 
 
Figure 4.1. Number diabetic individuals in the William M. Bass Donated Collection, past 20 years 
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Table 4.1 Demographics of the Total Research Sample (n = 80) 
 
Sample group Males 
(n) 
Females 
(n) 
Total 
(n) 
Avg. Age at Death 
(years) 
Avg. Weight at Death 
(lbs) 
Diabetic group 22 18 40 62 205.2 
Non-diabetic group 22 18 40 66 170.4. 
Sample average 22 18 80 64 187.6 
 
 
 
 
Blood Samples 
Blood samples collected from human donations were used to investigate cytokines postmortem.  
The FAC, in collaboration with the Molecular Anthropology Laboratory (MAL) at the University of 
Tennessee, initiated blood sample collection was in 2008.  Currently, upon placement at the 
Anthropological Research Facility, samples including blood, hair, and fingernails are collected from each 
donation.  Those donations lacking viable fluids cannot be sampled for blood.  Protocol dictates that 
aortic blood, approximately 9cc, should be drawn using a sterile syringe at the jugular notch.  Liquid 
blood samples are absorbed onto Fitzco Classic Collection Cards (FP709); three cards are collected for 
each donation (FAC. Forensic Anthropology Center 2012).  The Fitzco paper was initially developed to 
preserve DNA integrity in samples without cold storage.  They are made with a filter paper that is ot 
FTA-coated.  One of the initial research questions specifically addresses whether and how well blood 
molecules other than DNA, such as cytokines, are preserved on the Fitzco cards.   
For blood protein analysis, a sample set was culled from the previously-described 80 paired-
matched samples.  Only donations those with available blood samples, i.e. those donated after 2008, 
could be used in this portion of the analysis.  This decreased the available sample size considerably.  
Some potential samples were eliminated from blood analysis due to an extended postmortem interval, 
determined as the number of days between date of death and date of sample collection.  This was a 
significant preemptive strategy, to increase the probability that samples contain viable molecules.  Little 
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data are available concerning sustainability of proteins after death.  The designated sample size included 
twenty pair-matched samples: ten diabetics, and ten non-diabetics. 
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CHAPTER 5. BLOOD PROTEIN CYTOKINE ANALYSIS 
 The following chapter encompasses the investigation of diabetes in postmortem human blood 
samples.  Diabetes is an inflammatory disease, instigated by metabolic stress.  The primary characteristic 
of diabetes that may be observed in blood plasma is hyperglycemia.  However, the immune response to 
stress also prompts the release of pro-inflammatory cytokines (proteins) that may be quantified in blood.  
The research question addressed in this chapter is whether diabetics and non-diabetics differ in their 
levels of circulating cytokines.  Important background to cytokines and methods for quantifying their 
concentration in blood samples will be covered.  The techniques utilized in this study on the William M. 
Bass samples, as well as the results and discussion all will be contained within this chapter. 
 
Background 
The conceptualization of diabetes as an inflammatory disease has been transformative, altering 
the understood pathophysiology of the disease and identifying new targets for therapeutic treatment.  This 
perspective has revealed a new source of information, cytokines, which are significant biomarkers of the 
inflammatory process (Donath and Shoelson 2011).  In 2006 The World Health Organization (WHO) 
established new standards and criteria for diagnoses and treatment of type 2 diabetes diagnoses and 
management.  The WHO recommends a diverse approach that applies multiple diverse and confirmatory 
tests.  This underscores the highly variable nature of the disease and the importance of early diagnosis 
(World Health Organization [WHO] 2006). 
One of the more novel approaches for examining inflammation is investigating cytokines 
circulating in the body.  Multiple studies indicate that high concentrations of cytokines and other 
inflammatory markers are highly predictive of type 2 diabetes (Pradhan et al. 2001; Spranger et al. 
2003b).  Cytokines are a broad family of low molecular-weight proteins which regulate the nature, 
intensity, and duration of the immune response.  The name is derived from the Greek words “cyto”, 
meaning cell, and “kinos” meaning movement.  Cytokines play an integral role in the inflammatory phase 
of the immune process by detecting the first sign of infection, insult, or trauma.   They subsequently 
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signal the nature of the affliction throughout the cell network and initiate the appropriate immune 
response (McInnes 2013). 
Cytokines differ from other hormone proteins in that they are produced by multiple cellular 
sources in broad ranges, increasing by one thousand-fold concentration in response to injury.   Cytokines 
are pleiotropic; a single cell induces multiple effects in a variety of cells, affecting local and systemic 
change.  They are also redundant, overlapping in their influence, and may synergize with one other 
(Dinarello 2007).  As presented in Chapter Two, many cytokines like and leptin and adiponectin are also 
intimately involved in energy regulation and contribute to bone metabolism.  
Cytokines were originally classified by their specific role in the immune response, functionally 
pro- or anti-inflammatory, and by cellular source from which they are secreted.  Broad categories include 
the interleukins, interpherons, mesenchymal growth factors, the chemokine family, and the adipokine 
family (McInnes 2013).  The tumor necrosis factor (TNF) family, for example, causes apoptosis of 
injurious cells; granulocyte colony stimulating factor (GCSF) stimulates bone marrow to produce and 
release white blood cells into circulation.   
More recent classification systems designate cytokines into superfamilies.  Superfamilies of 
cytokines exhibit structural homology, share sequence similarity, and reciprocal receptor systems 
(McInnes 2013). They are numerically ordered according to discovery date. 
As discussed in earlier chapters, the paradigm of diabetes as inflammatory disease has 
transformed the perception of cytokines from passive by-products to integral mediators of chronic illness.  
Inflammation is a series of go (pro-inflammatory) and stop (anti-inflammatory) signals.  In standard acute 
inflammation, mediators detect the insult, initiate an effective response, and healing commences in a 
seamless cycle (Esposito et al. 2003).  If inflammation progresses, but the next step in the cascade is 
hindered, then the process may detour into a holding pattern.  Prolonged and perpetuating inflammation is 
classified as chronic, and become detrimental to the exposed tissues (Lago et al. 2007; Pickup and Crook 
1998).  When the immune system perpetuates under a constant green light, it becomes overtaxed, 
exhausted, and degraded.  Tissues may become infiltrated with excess leukocytes (white blood cells) and 
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macrophages, and become distorted with collagen bundles (fibrosis) (Nathan 2002).  Chronic 
inflammation effectually hijacks normal immune function.  Classic examples of inflammatory diseases 
include arteriosclerosis, rheumatoid arthritis, and osteoporosis (Ferrucci and Guralnik 2003).  Diabetes 
has been recently added to the list. 
The diabetic inflammatory theory proposes that chronic inflammation causes toxic stress on the 
pancreatic beta-cells, leading to pancreatitis.  Pancreatitis culminates with the destruction of the beta-cells 
and type 2 diabetes (Donath and Shoelson 2011).  A number of inflammatory cytokines have been linked 
to the development of diabetes.  For this study, I selected a group of extensively researched cytokines that 
exhibit a significant relationship with diabetes.  These include leptin, one of the first and most-heavily 
researched cytokines; chemokines, a superfamily responsible for cell-signaling migration; and 
adiponectin, an adipocyte-derived protein with a negative relationship with diabetes.  The role that both of 
these cytokines play in the energy–bone feedback loop was also presented in Chapter Two. 
The ability to measure circulating proteins was achieved in the 1970s with the development of the 
first enzyme-linked immunosorbant assay (ELISA) (Engvall and Perlmann 1971; VanWeemem and 
Schuurs 1971).  Since this time, ELISA has become an essential tool in toxicology and biomedical 
research.  The assay tests a sample (blood or tissue) for the presence of a biomarker of unknown amount 
and quantifies the concentration.  The most commonly utilized technique is a double antibody sandwich 
ELISA.  A capture antibody is embedded at the bottom of a well, serving as anchor.  When the sample is 
added, the antigen (cytokine) is immobilized onto the antibody forming a ligand.  A detection antibody is 
then added to the well, binding specifically to the ligand.  The ELISA is developed by adding a final 
enzymatic substrate (such as streptavidin), that when run under a laser will produce a fluorescent signal.  
Results for each biomarker are quantified based on the strength of this signal (Lequin 2005).  
See Figure 5.1. 
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Figure 5.1. Sandwich ELISA 
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First generation ELISAs were limited by the capacity to test only one cytokine in a given sample 
aliquot.  The number of inflammatory markers being discovered and warranting testing vastly outpaced 
researcher’s testing efficacy.  Development of the multiplex array resolved many of these issues. 
Multiplexed ELISA allows several cytokines to be investigated simultaneously, as well as testing multiple 
subjects, all within the same well-plate.  This is beneficial as some proteins are good indicators of 
disorder, while some inform about severity or progression of an illness (Leng et al. 2008).  Compared to 
the former ELISA methods, multiplex assays have a number of advantages including: high throughput 
capabilities, expend lower sample volume, are more cost effective and less labor intensive, and the ability 
to reliably detect different proteins across a broad range of concentrations (Leng et al. 2008). The ELISA 
process is time-consuming, usually requiring six to eight hours for incubation and washing steps; merging 
tests into a single process greatly increases lab efficiency. Current cytokine research is providing 
important information about the pathophysiology, diagnostic options, and potential therapeutic tools for 
diabetes.  To date, cytokines have not been investigated in postmortem human material. 
The specific goals of this portion of the research are: 1) to determine if cytokines are preserved in 
the blood sample collected on Fitzco Cards from  William M. Bass donations; 2) to successfully extract 
these proteins at concentrations sufficient for further testing; 3) to discern which inflammatory cytokines 
are present and quantifiable in postmortem samples using ELISA multiplex technology; 4) to determine if 
significant differences exists between the diabetic and non-diabetic sample groups in the concentration of 
inflammatory biomarkers, and if results are consistent with biomedical research; and 5) to establish a 
point in the postmortem interval that cytokines are no longer viable in sample aliquots.  
 
Preliminary Methods and Preliminary Results 
Preliminary research for this project was initiated in 2011, requiring a number of pilot trials to 
establish project feasibility.  The University of Tennessee Obesity Research Center (ORC) in the Animal 
Sciences Department provided invaluable assistance, resources, and lab time in order to complete 
preliminary work.  The University of Tennessee FAC was an integral resource through all stages of the 
64 
 
research.  To test the Fitzco paper’s capability to preserve blood proteins, a set of cards was embedded 
with fresh blood samples and with a solution containing adiponectin.  A blank card served as negative 
control.  Ina sterile environment including latex gloves, a sample circle was removed from each card and 
reduced into small pieces using a sterile scalpel.  This extract was placed in a beaker along with 25 ml of 
buffer, and agitated for 25 minutes.  The ensuing solution was filtered into a sterile tube.  Coomassie 
brilliant blue reagent was applied to solution.  Results revealed that proteins from fresh blood samples are 
preserved on the Fitzco paper and they can be successfully extracted into solution.   
 Blood samples collected from Bass donation are obtained postmortem, once the process of 
decomposition has already begun, inevitably degrading the molecules within.  Thus, the next step was to 
repeat the process using postmortem blood.   If postmortem proteins could not be extracted, this portion 
of the research would not possible.  Results demonstrated that blood samples collected after death 
contained preserved proteins that could be extracted at testable levels.  Two buffer solutions were tested 
in the extraction process – phosphate buffer saline (PBS) and radioimmnoprecipitation assay (RIPA) 
buffer.  Buffers were tested to determine which one rendered higher concentrations of potentially fragile 
proteins.  The solution created with the RIPA buffer yielded a higher concentration of total protein, and 
thus RIPA buffer was used for subsequent tests on postmortem material. 
 The utility of mouse-model ELISA versus human-based ELISA technology also warranted 
testing.  The antibodies included in manufactured kits are generally genus-specific for maximum binding 
affinity, though some murine kits may be applied to human samples in research contexts.  Mouse ELISA 
kits were readily available through the UT ORC and are less expensive, and therefore would be desirable 
for this study.  A murine multiplex ELISA was selected that tests for four well-established inflammatory 
cytokines: TNF-α, IL-6, MCP-1, and Leptin.  The ELISA multiplex was conducted on the previously 
extracted postmortem sample.  Results showed positive but low concentrations for all four markers, 
concentrations ranging from 0.0 (undetectable) to 1.5 pg/ml.  This indicates that inflammatory biomarkers 
are indeed present, but a human-based model is necessary for further testing.  The assumption is that 
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proteins begin to degrade over the postmortem interval and maximum specificity is needed to detect 
potentially low concentrations. 
 Four additional postmortem bloodcard samples were collected for the purpose of completing 
preliminary research.  Two samples were taken from donations with diagnosed diabetes, and two from 
donors with no documented diabetic history (Figure 5.2).  These samples were extracted and submitted to 
a human-based multiplex ELISA to choose from the litany of inflammatory markers which should be 
targeted in dissertation research.   
This multiplex included antibodies for 26 inflammatory cytokines.  The multiplex produced 
sufficient protein concentrations for two cytokines: Interleukin 8 (IL-8) and Monocyte chemoattractant 
protein 1 (MCP-1), which is also known as C-chemokine ligand-2 (CCL-2).  Il-8 has a strong relationship 
with diabetes (Bruun et al. 2000), obesity (Sharabiani et al. 2011), and some cancers (Hsu et al. 2010).  
MCP-1/CCL-2 demonstrates a strong correlation with diabetes (Zhang et al. 2011) and arteriosclerosis 
(Charo and Taubman 2004).  Both cytokines are associated with bone function and metabolism (Ferrucci 
and Guralnik 2003; Kim et al. 2005).  Results from the multiplex were compared between the groups, 
diabetics vs. non-diabetics.  Sample size was far too small to reach conclusions (n = 4); however, the 
diabetic subjects possessed a higher average concentrations of both inflammatory markers (See Table 
5.1). 
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Figure. 5.2 Samples used in preliminary ELISA multiplex, prior to extraction 
 
 
 
 
 
 
 
Table 5.1 Results from Multiplex ELISA, Diabetic vs. Non-diabetic Samples (n=4) 
Sample Diabetic status Average IL-8 (μg/ml) Average  MCP-1 (μg/ml) 
63-08D Diabetic 11.7978 13.9263 
57-08D Diabetic 10.1304 15.4178 
31-08D Non-Diabetic 0.91109 4.05986 
21-08D Non-Diabetic 4.2711 13.125 
 
 
 
Both IL-8 and MCP-1/CCL-2 showed promising results for future research.  Leptin and adiponectin are 
two of the best-documented and thoroughly studied cytokines in relation to diabetes and inflammation in 
human populations.  Therefore, these four cytokines were selected to complete data collection for this 
project. 
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Dissertation Methods 
The sample for this research was culled from the 80 pair-matched individuals previously selected 
from the William M. Bass Skeletal Collection.  Permission was granted by the Forensic Anthropology 
Center to use blood samples preserved on Fitzco cards collected from ten diabetic and ten non-diabetic 
pair-matched individuals.  Molecular analysis was conducted in collaboration with the University of 
Tennessee Nutrition Department.  Funding was provided by the Williams M. Bass Endowment for 
forensic research to purchase four singleplex ELISA kits.  Singleplex ELISA is routinely used in cytokine 
research to confirm results from multiplex ELISAs and provide detailed information. 
To meet criteria set for this project, subjects must have been donated after January 2008 to ensure 
available bloods samples, and have completed the decomposition process so that osteological analysis 
could be conducted (discussed in Chapter 8).   
A single circle was removed from each subject’s card using sterile scissors and the paper matrix 
reduced into small pieces (1-2mm) using a sterile scalpel.  Pieces were combined with RIPA buffer in a 
beaker, agitated for 20 minutes, and filtered into a test tube.  Agitation and filtration steps were repeated.  
The remaining aliquot liquid containing preserved proteins were preserved at -80º C prior to and after 
testing. 
A Bradford Quantification Assay (BQA) was run to determine if sufficient protein existed in the 
sample to justify subsequent testing.  A standard curve is created using a control, a protein of known and 
increasing concentrations.  Bovine serum albumin (BSA) is most commonly used.  Control concentration 
data is plotted on a graph and a regression equation is generated from the line of best fit.  Optimally, R
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values should equal as close to 1.0 as possible.  Samples are compared against the control line and their 
unknown protein concentrations are calculated from regression equation.  The samples are always run in 
duplicate or triplicate to minimize human /operational error and to identify outlying values.  Samples in 
this study were run in duplicate; an average of the two values was taken and used for analysis.  Results for 
the BQA will be provided in the next section. 
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ELISA singleplex kits were purchased from the RayBiotech Company.  Each kit contains most 
materials for the assay, including a pre-coated 96-well plate, reagents, and ELISA protocol.  Some of the 
reagents required dilution and/or reconstitution into solution prior to testing.  The protocol for the four 
singleplex ELISAs are generally similar, though each kit is antibody-specific with slight variations in 
amount/concentration of certain reagents.  Similar to the BQA, a standard control protein of known 
concentrations is run alongside the samples to generate a standard curve.  The linear equation produced is 
used to calculate the concentration of the cytokine of interest.  Concentration results were compared 
between diabetic and non-diabetics groups.  A paired T-test was used to test significant differences 
between the groups.  In addition, Pearson Correlation and Spearman rho were used to assess the 
relationship between postmortem interval (days) and total protein concentration in each sample (diabetic 
and non-diabetic, n=20). 
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Figure 5.3. Singleplex ELISA: 
A) RayBiotech sigleplex ELISA kit 
B) ELISA reagents 
C) 96-well plate, just prior to fluorescence  
A 
B 
C 
Column 1: standard control, 
decreasing protein concentration 
from top (Row A) to bottom 
(Row G) 
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Results 
Bradford Quantification Assay  
Each of the twenty samples demonstrated a sufficient positive protein value (See Table 5.2).  
Results indicated that enough protein was present in the postmortem extracted samples that they might be 
successfully subjected to singleplex ELISA. 
 
 
 
 
 
Table 5.2. Results from Bradford Quantification Assay, average protein concentrations (ng/ml) 
 
Diabetic Sample Non-diabetic Sample 
Sample number Avg. concentration 
(ng/ml) 
Sample number Avg. concentration 
(ng/ml) 
09-08D 3.85806506 46-08D 3.110878313 
14-08D 2.256913253 26-08D 1.277324096 
28-08D 0.609272289 12-08D 3.339972289 
53-08D 1.619507229 29-08D 1.271087952 
56-08D 2.327321687 13-08D 1.766012 
57-08D 2.01492 21-08D 1.049689 
63-08D 1.94731 31-08D 1.85314 
72-08D 1.466760241 54-08D 1.21501 
73-08D 1.434724096 16-08D 0.383106024 
108-08D 1.856661446 11-08D 0.685424096 
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Leptin ELISA 
Results from the Leptin kit were not very encouraging.  Even run in duplicates, some of the leptin 
samples produced null values.  Inconclusive and partial data may be due in part to operational/researcher 
error.  Consequently, the number of data points for the subsamples (diabetic vs. non-diabetic) is not equal. 
The diabetic group demonstrated a much higher average leptin concentration, though this was 
primarily due to a high value from a single subject.  This data point was not eliminated due to the very 
small sample size, but should be interpreted with caution.  Paired sample T-test revealed that diabetics 
and non-diabetics were not significantly different in leptin concentration.  See Table 5.3 and Figure 5.4. 
 
 
 
  Table 5.3. Results from Paired T-test of Leptin Concentrations (pg/ml) 
 
 n Mean Median Standard 
Deviation 
Standard Mean 
Error 
Significance 
Diabetics 10 114.84 8.12 274.74 86.88 
0.294 
Non-diabetics 10 25.55 19.51 27.33 8.64 
Total 
20 
89.29 
(mean 
difference) 
9.49 253.8 80.06 
 
 
 
 
 
 
 
Figure 5.4 Results from leptin ELISA, Diabetic vs. Non-diabetic sample 
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Adiponectin ELISA 
  The adiponectin ELISA required the largest dilution of all four kits, stemming from the 
adipokine’s high proportion in blood and tissue.  The alternate name for adiponectin is “adipose most 
abundant gene transcript 1” (apM1).  Results were much higher for the adiponectin, and are thus reported 
at a higher order of magnitude from pico- to nanograms, to make results more manageable.   
Paired sample T-test showed that the diabetic and non-diabetic groups show significant difference 
in adiponectin concentrations.  The diabetic subsample in this study produced a lower average 
adiponectin concentration that the non-diabetic sample (3.75ng/ml and 26.78ng/ml respectively).  
Adiponectin has a well-documented inverse relationship with diabetes.  See Table 5.4 and Figure 5.5 
 
Table 5.4. Results from Paired T-test of adiponectin concentrations (ng/ml) 
 n Mean Median 
 
Standard 
Deviation 
Standard Error 
Mean 
Significance 
Diabetics 10 3.76 2.31 3.62 1.14 
0.0001 
Non-diabetics 10 26.78 24.66 11.54 3.64 
Total 
20 
23.02 
(mean 
difference) 
10.10 12.75 4.03 
 
 
 
 
Figure 5.5 Results from adiponectin ELISA, Diabetic vs. Non-diabetic sample 
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IL-8 ELISA 
The IL-8 ELISA produced no missing or null values.  The diabetic group displayed a slightly 
higher average IL-8 concentration than the non-diabetic group (74.5pg/ml versus 68.9 pg/ml, 
respectively).  This is consistent with clinical research, showing a strong relationship between diabetes 
and increased levels of IL-8, independent of metabolic syndrome risk factors like body mass or with age 
(Herder 2005).  Paired sample T-test found no difference between groups.  See Table 5.5 and Figure 5.6.   
 
 
 
 
 
Table 5.5. Results from Paired T-test of IL-8 concentrations (pg/ml) 
 
 n Mean Median Standard 
Deviation 
Standard Error 
Mean 
Significance 
Diabetics 10 74.51 87.19 51.10 16.16 
0.470 
Non-diabetics 10 65.14 57.03 42.88 13.56 
Total 
20 
9.36 
(mean 
difference) 
72.75 39.24 12.41 
 
 
 
 
 
Figure 5.6 Results from IL-8 ELISA, Diabetic vs. Non-diabetic sample 
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MCP-1/CCL-2 ELISA 
The MCP-1/CCL-2 ELISA produced only one sample with values below the detection threshold.  
Similar to leptin and IL-8, this cytokine had higher average concentrations in the diabetics, but no 
significance difference was found between the groups. 
See Table 5.6 and Figure 5.7. 
   
 
 
Table 5.6. Results from Paired T-test of MCP-1/CCL-2 concentrations (pg/ml) 
 
 n Mean Median Standard 
Deviation 
Standard Error 
Mean 
Significance 
Diabetics 10 9.52 4.34 12.01 3.79 
0.130 
Non-diabetics 10 3.27 3.25 2.52 0.799 
Total 
20 
6.25 
(mean 
difference) 
3.91 11.86 3.75 
 
 
 
 
Figure 5.7 Results from MCP-1/CCL-2 ELISA, Diabetic vs. Non-diabetic sample 
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 Results for all four proteins are summarized in Figures 5.8.  An additional figure displaying 
median protein values is found in the appendix. 
 
 
 
 
 
 
  
Figure 5.8. Results from the four singleplex ELISAs, mean protein concentration 
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Postmortem Interval 
Death initiates a process of biochemical breakdown and deterioration of tissues and structures in 
the human body.  Decomposition is the first phase in a regimented succession, followed by putrefaction 
and skeletonization.  At the earliest stages of decomposition, tissues and fluids may be sampled, 
preserved, and tested for their constituent parts.  This is the impetus for removing samples for DNA 
testing and toxicological examinations.  This project demonstrated that circulating proteins may also be 
sampled and investigated multiple days after death.  The nature of decomposition suggests that at some 
point during the post-mortem interval, proteins and other circulating molecules will cease their viability.   
The interval between date-of-death and date-of-sampling is recorded for each subject in the 
Williams M. Bass Collection, recorded as number of days between the two dates.  The interval (numbered 
days) was compared against the total protein concentration detected for each sample in this study (n=20).  
Correlation tests showed non-significant, low correlation between postmortem interval and total protein 
concentration (Pearson r = -0.333, Spearman ρ = -0.093).  See Figure 5.9. 
 
 
 
Figure 5.9. Total protein concentration vs. interval between death and blood sampling (in days) 
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Discussion 
Data from this study indicate strong potential for protein research using postmortem samples.  
This project has answered several questions, while posing many more.  Several additional inflammatory 
markers can and should be investigated for their relationship with diabetes.  Elevated levels of pro-
inflammatory cytokines are present during the early stages of diabetes and throughout.  Testing cytokines 
in postmortem blood samples provides the opportunity to investigate diabetes in recently diagnosed 
individuals, who do not yet exhibit more advanced symptoms of the disease. 
I began my investigation with a human-based multiplex ELISA including 26 cytokines, but this is 
not a fully exhaustive search.  Many more cytokines potentially exist in the samples which may be tested 
using different combinations of kits.  Furthermore, the protein milieu itself may complicate detection.  
Leng (2008) noted that some common inflammatory markers have been shown to bind to carriers proteins 
such as α2-macroglobulin.  Levels of proteins like α2-macroglobulin change with inflammation state, 
aging, disease or frailty, as well as specific assay conditions. Thus, all these factors can influence the 
ability of multiplex assays to detect these specific cytokines by potentially altering the amount of free 
cytokine available for detection. 
Certain data from both the multi and singleplex ELISAs produced negative or null values.  It is 
possible that proteins are present but at very low values due to the deterioration in postmortem samples.  
Very limited research has been published on the rate of degradation for various proteins after death.  
Some unstable proteins may be exhausted within a few hours of the postmortem interval, making their 
preservation, extraction, and detection problematic.  A comprehensive search for viable proteins and a 
comparison of their sustainability would be beneficial. 
Additional dilutions of the ELISA standards and reagents might extend the standard curve to the 
lower end of the spectrum so that protein concentration below the minimum threshold can be read.  Very 
low concentrations are not validated for all kits (Lequin 2005), but may be necessary for research utilizing 
postmortem samples. 
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Blood samples inherently heterogeneous, containing eythrocytes leukocytes, plasma, proteins, 
and other constituents; the samples used in this study were no exception.  Additional filtration and/or 
purification steps should be investigated to eliminate additional molecules from competing with 
antibodies and/or interfering with fluorescence.  Although many of these factors may be eliminated 
during the postmortem interval, they constitute an unnecessary liability which could obscure results.  
Other operational concerns include validation of the reported results.  Each of the four singleplex ELISAs 
would benefit from confirmatory tests, and a statistically significant sample size.  This is particularly true 
for the leptin ELISA. Though the diabetic group showed higher average concentration of this cytokine, 
too many data points were unavailable to draw conclusions. 
Sample size caveats aside, each of the four cytokines demonstrated the expected relationship with 
diabetes.  Results from the leptin ELISA provided the fewest datapoints, but adhered to the known 
positive relationship with diabetes.  Leptin is released or withheld in response to energy availability 
(Auwerx and Staels 1998).  Leptin also assists in glucose regulation and synthesis of glucocorticoids.  In a 
state of high energy storage and hyperglycemia, leptin is continually produced and released, but leptin 
receptors have become impaired or unresponsive.  This may be due to a leptin-induced increase in the 
suppressor of cytokine signaling-3 (SOCS3) gene which blocks intercellular transmission of the leptin 
signal (Bjorbaek et al. 1999).  Consequently, many diabetics display unusually high circulating leptin 
values.  
There is growing evidence that high levels of circulating leptin promote inflammation (Spranger 
et al. 2003b).  Leptin contributes to the production of T-lymphocytes, induces several pro-inflammatory 
cytokines in macrophages and monocyte, and influences the differentiation, activity and cytotoxicity of 
natural killer (NK) cells (Otero et al. 2006; Raso et al. 2002; Tian et al. 2002).  Furthermore, ob/ob mice, 
which lack genetic production of leptin, are immunodeficient and suffer from high mortality.  Therefore, 
leptin logically plays a role in immunity and inflammation (Lago et al. 2007). 
Adiponectin has a paradoxical relationship with diabetes, showing very low values for those 
diagnosed with impaired insulin and glucose handling and obesity (Arita et al. 1999).  Adiponectin is 
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closely related to insulin sensitivity.  High levels of adiponectin confer improved glucose handling.  
However, the exact pathway of adiponectin’s action has not been elucidated.  Notably, average 
adiponectin concentration was lower in the diabetic group in this study, suggesting impaired insulin 
action.  High circulating levels of adiponectin have also been described as a potent anti-atherogenic factor 
that protects vascular endothelium against inflammation (Lago et al. 2007).  This is likely due to 
adiponectin’s ability to promote phagocytosis of apoptotic cells, removing cellular debris from plasma 
and tissues that would otherwise become inflamed.  Moreover, its production is inhibited by pro-
inflammatory cytokines like IL-6, TNF-α, two additional cytokines which show elevated levels in 
diabetics (Bruun et al. 2003; Fasshauer et al. 2003).  The observation that diabetics in this study have 
lower average adiponectin concentrations is consistent with clinical research. 
IL-8 and MCP-1/CCL-2 are part of the chemokine superfamily of very low molecular-weight 
inflammatory markers.  Chemokines have multiple functions in the immune process, ranging from 
hematopoiesis, angiogenesis, arteriosclerosis, as well as allergic and autoimmune reactions.  They also 
play a role in regulation of leukocyte migrations along concentration gradients (Herder 2005).  It has been 
proposed that chemokines are partially responsible for macrophage infiltration in adipose tissue and into 
the pancreatic islets, promoting pancreatitis.  Clinical research shows increased levels of chemokines in 
type 2 diabetic patients (Esposito et al. 2003; Herder et al. 2005; Zozulinska et al. 1999).  Results in this 
study are consistent with this observation.  It would be beneficial to conduct other ELISA multiplexes to 
identify additional chemokines that may be equally or more indicative of diabetes in postmortem samples.  
Though results may be inconclusive given small sample size, it appears that protein concentration 
considerably decreases at four days after death.  Samples collected more than four days (96 hours) after 
death may no longer be viable.  At this juncture, more friable proteins may have degraded past their 
detection and testability.  After four days the blood sample may not be representative of the inflammatory 
status antemortem.  There is potential to include recommendations for protein sampling in future Forensic 
Anthropology Center Standard Operating Procedures (SOPs). 
80 
 
Results from the single and multiplex ELISA would benefit from confirmatory testing and a 
significantly large samples size.  This would allow testing between subsets of the total sample.  Certain 
adipokines are highly influenced by sex hormones.  For example leptin production is promoted by 
estrogen.  Given an appropriately large sample size, it would be important to examine if the relationship 
between cytokine concentration and diabetes status if different between the sexes.  Sample context should 
also be recorded including: medical examiner cases versus natural deaths, environmental temperature and 
humidity, and other influential variables. 
If inflammatory cytokines are detected in a blood sample from human remains, this will not 
single-handedly conclude diabetic or inflammatory status.  Hyperglycemia and increased pro-
inflammatory cytokine concentrations represent changes that occur early in the diabetic disease process. 
Coupled with additional skeletal information, such as bone density and the presence of osteological 
pathologies, these data may suggest diabetic status.   
 
The next chapter will focus on the influence that hyperglycemia and chronic inflammation have 
upon bone quality.  Bone mineral density examination was conducted to discern how diabetes affects 
bone in intermediary stages of the disease. 
  
81 
 
CHAPTER 6. BONE MINERAL DENSITY ANALYSIS 
 Bone mineral density (BMD) is often employed as a measure of bone quality.  In this 
chapter, attention is turned to how altered metabolic regulation typical of diabetes affects bone quality.  
Bone mineral density is used most often in clinical settings to diagnose osteoporosis and risk factors like 
osteopenia.  The major objective in this section of the study is to identify differences in bone density that 
may be attributed to the influence of diabetic dysregulation.  This chapter is organized as follows: 
background, the methods employed in this study for testing bone mineral density, results and discussion 
 
Background 
There are four methods to clinically measure bone density: Quantitative Computed Tomography 
(QCT), Peripheral Quantitative Computed Tomography (pQCT), Dual Energy X-ray Absorptiometry 
(DEXA) and Quantitative Ultrasound (QUS), each possessing benefits and disadvantages.  DEXA 
examines integral bone mass and aerial density, using relatively low levels of radiation and thus is safe for 
living patients and non-destructive to the bone.  DEXA is sensitive to subtle changes in density, rendering 
it optimal to monitor response over time to therapeutic treatments.  Additional advantages include a short 
scan time, relatively low operational cost, and consensus in data interpretation using World Health 
Organization T-scores (Blake and Fogelman 2007).  Shortcomings of DEXA include the inability to 
differentiate between cortical and trabecular bone, and failure to measure volumetric density.  Rather, the 
DEXA scanner captures a programmed region of interest, calculating the density of the bone contained 
within that area.  Nonetheless, DEXA is ubiquitous in clinical practice and has become the gold standard 
for assessing bone mineral density and osteoporosis. 
 Bone mineral density is a product of intrinsic and external factors including age, sex, activity 
level, nutrition, and body mass.  These factors individually influence, compound, and contradict one 
another’s effect on bone density.  A considerable amount of research has been dedicated to understanding 
and treating the effects of age and menopause on bone density in females.  Reduced hormone levels take a 
negative toll on regular bone maintenance; the result is lower bone density and increased risk of fracture.  
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On the other hand increased body mass offers protection against bone loss.  Overweight women have 
denser bones when compared against normal weight and slender females of similar age and menopausal 
status (Reid 2008).  The relationship with weight is similar but weaker for males and has been confirmed 
for subjects from diverse ethnic backgrounds (Reid 2002).  Consequently, a strong relationship persists 
between body mass and bone density regardless of sex or ethnicity (Rosen and Bouxsein 2006). 
The challenge in the current project is to tease out the contribution of diabetes and energy 
metabolism from other factors.  As discussed in Chapter Three, the relationship between bone density and 
diabetes depends of the type and availability of insulin.  Research has shown that insulin has an anabolic 
effect on bone (Cornish et al. 1996).  This is clearly shown in the low BMD and osteopenia characteristic 
of type 1 diabetes, particularly apparent in periods of longitudinal growth (Levin et al. 1976; McCabe 
2007).  Furthermore, type 2 diabetics consistently show higher than average bone density, possibly due in 
part to hyperinsulinaemia (Barrett-Connor and Kritz-Silverstein 1996; Merlotti et al. 2010; Strotmeyer et 
al. 2004).  Increased visceral adiposity, common in diabetes and contributing to its pathophysiology, 
provides an important source of other anabolic hormones like estrogen.  In addition, adipocytes play a 
significant role in bone maintenance by releasing influential cytokines such as leptin (Cornish et al. 2002; 
Karsenty 2006), adiponectin (Kanazawa et al. 2009b), and osteocalcin (Ferron et al. 2008).   
Diabetes and obesity are essentially two sides of the same coin that contributes to bone density. 
Although diabetics characteristically carry more body mass, they paradoxically demonstrate a high 
incidence of fracture (Melton et al. 2008).  This suggests that increased mechanical loading concordant 
with obesity is not necessarily mechanically advantageous.  Furthermore, those suffering from advanced 
diabetes and excessive body mass may have ceased normal loading patterns due to limited mobility and 
edema.  This removes mechanical forces from the equation, but does not alter the metabolism-bone 
interaction.  As discussed in Chapter 2, bone and energy metabolism are intricately locked in a positive 
feedback loop (Confavreux et al. 2009).  Diabetes is a systemic disease and the consequences should not 
be limited to those skeletal areas under mechanical pressure. 
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For this reason, I intentionally examined areas that are consistently loaded such as the femur, as 
well as skeletal sites experiencing reduced loading like the forearm.  The tibia was also included in this 
study, as diabetics face exceptionally high incidence of fracture in this bone (Kagan 2010; Keegan et al. 
2002).  The femoral neck and vertebrae are renowned hotspots for osteoporotic fractures, but diabetics 
have a higher rate of fracture in the lower limb and ankle.  Tibiae experience a distinctive loading pattern.  
Distal elements, like the tibia, are energetically more costly and consequently are morphologically smaller 
and more slender than proximal bones such as the femur (Alexander 1998; Dellanini et al. 2003).  
Lieberman and Crompton (1998) suggest that limbs respond to strain in a proximal-distal gradient from 
the axis, with distal elements experiencing more micro-damage.  Other researchers have failed to confirm 
this hypothesis, finding an equivalent rate of Haversian remodeling in the femur and tibia (Drapeau and 
Streeter 2006).  Nonetheless, diabetics have a uniquely high incidence of fracture in the distal limb, due in 
no small part to the effects of neuropathy (decreased sensation) and retinopathy (impaired sight).   
This project marks the first time data have been collected from the tibia using a GE Lunar iDXA 
scanner, using a protocol created by myself and Dr. Dixie Lee.  This research not only provides 
comparison across limb compartments, but also provides a new source of data for future research.  
 The forearm, distal radius and ulna, was also scanned in this the study to examine skeletal 
elements that are not involved in ambulatory loading.  If diabetic metabolism is a whole-body 
phenomenon, then its effects on bone density should be observed throughout the skeleton.  The forearm 
was also important as a source of comparison in females of advanced age.  Considered a risk factor for 
fracture, low BMD measurements in the radius and ulna are expected in non-diabetic females of normal 
weight. It should be noted that in individuals demonstrating extreme obesity, who probably suffer from a 
diabetic comorbidity, often utilize the upper limbs to assist in walking.  The pressure of bearing undue 
weight requires these individuals to rely on their arms to reach a standing position.  They may also use 
their arms for assistance with walking device (four-prong walker, cane, etc.) using all four limbs to 
distribute weight.  This trend in obese mobility was noted in the William M. Bass Skeletal Collection 
(Moore 2008).  Morbidly obese individuals in the collection were excluded from the present study, to 
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eliminate the extreme cases and focus on moderate changes in metabolism, most common in the modern 
population. 
 The goals of this portion of the project are: 1) to compare bone density data from the William M. 
Bass Skeletal Collection against clinical research and population-based study data conducted on type 2 
diabetics; 2) to determine if significant differences in bone density exist between individuals in the 
diabetic versus non-diabetic sample groups, and if so, at what skeletal sites is the disparity observed; and 
3) to discern how potentially influential factors like age, sex, and body mass affect the relationship 
between bone density and diabetic status. 
 
Methods  
 This section of the research focuses on bone mineral density examined in three skeletal areas: the 
proximal femur, the distal tibia, and distal forearm (radius and ulna).  The sample is derived from the 
William M. Bass Skeletal Collection, containing 80 pair-matched individuals of known age, sex, and 
body mass.  This includes 40 individuals with diagnosed diabetes, 22 males and 18 females, with and 
average age of 62 years.  The corresponding non-diabetic sub-sample also includes 40 total individuals, 
with 22 males, 18 females, with an average age of 66 years. 
 To scan the skeletal elements, I followed the basic methodology created by Moore (2008), who 
also used the William M. Bass Skeletal collection in her research.  A General Electric (GE) Lunar iDXA 
scanner was employed for this study, which boasts higher scanning sensitivity, improved accuracy and 
data reproducibility than the previous generation of DEXA technology (General Electric 2008).   
(See Figure 6.1) The iDXA scanner is owned and operated by the University of Tennessee Kinesiology 
and Recreation Sciences Department, housed in the Applied Physiology Laboratory.  The interface 
software is designed to analyze and catalogue data from each subject.  Prior to scanning, demographic 
data – sex, birthdate, race, and weight – was entered for each sample; the Bass Collection number was 
used in lieu of name.  All samples in this study were of European American ancestry.   
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Figure 6.1. GE Lunar iDXA scanner and desktop computer with user interface software. 
 
 
The individual’s age at death was subtracted from the date of scan, to calculate a birthdate that 
would reflect their actual age.  A uniform weight of 90 lbs was used for every sample to account for the 
minimal soft tissue detected by the scanner and standardize the amount of radiation emitted.  This is 
consistent with about 12cm of soft tissue, as recommended by General Electric manufacturers.  The 
iDXA scanner must accommodate different tissue thickness, including obese and emaciated individuals.  
Using a standard weight ensures that the scanner will anticipate minimal tissue over the bone, will 
maintain a constant level of radiation, and will produce accurate results.    
The iDXA software also uses this information to generate two indices: a Z-score and a T-score.   
The Z-score compares the individual’s density to age and sex-matched individuals from a master 
database.  The T-score compare’s the subject to the optimal bone density of a young healthy individual of 
the same sex.  T-scores are used clinically to diagnose osteoporosis and osteopenia.  Z- and T-scores have 
no bearing on the current study. 
To conduct the scans, dry bones were placed in a plastic container measuring 65cm long, 14 cm 
tall and 11 cm wide. The container is designed as a planter box, but easily accommodates all bones used 
in the study.  This is the very same box utilized by Moore (2008) that was retained by the Kinesiology 
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Department for future anthropological work.  White rice served as the soft-tissue density equivalent.  The 
GE Lunar scanner is programmed to detect soft tissue before initiating the scan.  Without sensing tissue, 
the iDXA will abort the scan to prevent unnecessary exposure to radiation.  A thin layer of rice (10cm) 
was placed at the bottom of the box so that the bones would be completely encapsulated.   
When scanning the femur, condyles were placed directly on the rice with the posterior side down, 
anterior side up.  Femora were rotated medially in rice to assume anatomical position, and then covered in 
rice up to 20cm below the container rim. (See figure 6.2)  The box was placed on the scanner table, in the 
approximate position of a human’s lower limb.  The arm of the machine began in a position just superior 
to the midshaft.  The regions of interest (ROI) are pre-determined for the femur and include: total neck, 
upper neck, lower neck, Ward’s triangle, shaft, and total femur average.  This final variable (total femur 
average) is an independent measurement taken by iDXA, rather than derived from other measurements. 
 
 
 
Figure 6.2. Arrangement of femur in rice for scanning 
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To obtain forearm scans, radius and ulna were articulated together in anatomical position, as the 
machine is programmed to detect a live human arm.  Great care was taken to keep the elements 
connected, lest they shift while covering bones with rice or while placing container on the table.  For this 
scan the machine arm was placed more superiorly, beginning the scan at the proximal end of the elements 
(near the elbow) and scanning distally.  Areas of data collection for the forearm includes radius ultra-
distal, ulna ultra-distal, both (radius and ulna) ultra-distal, radius distal ⅓, ulna distal ⅓, radius total, ulna 
total, both total.  As with the femoral variables, radius/ulna “totals” do not suggest a calculated average, 
but independently collected values. 
Tibiae are not part of the standard set of elements under investigation and no protocol exists for 
image capture or analysis.  The GE research and development team recommended the scans be conducted 
in femur mode, being the closest bone in size and morphology to the tibia.  Tibiae were placed in the 
container similar to femora and covered with rice.  Because femur mode was being utilized, tibiae were 
scanned with the distal end facing the top (head) of the machine, so that the iDXA believed it was 
scanning the proximal femur.  Regions of interest were created using the “free capture” function, 
including the distal third of the tibia, along the metaphyseal line of metaphysis, and the medial malleolus.  
The distal 1/3 was individually measured on each bone, given inter-personal variation in bone size.  A 
small metal marker was placed in the rice matrix to indicate where the ROI should be placed.  The marker 
is actually designed as a fishing line sinker, but several preliminary trials confirmed that the metal alloy 
could be imaged by the scanner without altering the image or creating background interference.  The ROI 
is the designated area in which the scanner detects bone mineral content (BMC).  Bone density is derived 
from the amount of BMC within each region of interest.   
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Figure 6.3. Regions of interest scanned on tibiae 
 
 
 
In all cases the left element was used for study, unless absent or otherwise in too poor quality due to 
taphonomic processes.  For data collection purposes, each sample was scanned twice, with the average of 
the two values used in statistical analysis.  All statistical analyses were conducted in SPSS Statistics 
version 21. 
Preliminary testing began by assessing the reliability of measurements.  Researcher intra-observer 
error was tested using a subsample of ten femora, ten tibiae, and ten radius/ulna pairs, selected at random.   
Skeletal BMD measurements were gathered by the researcher using the iDXA scanner, and then re-taken 
after an interim period of a week (seven days).   Repeatability was tested with a paired t-test of 
significance, as well as a correlation between the two trials.  No significant difference exists between the 
two trials for the nineteen total measured areas.  The two trials are also highly correlated (correlation 
values ranging from 0.91 to 0.99). 
Percentage error on bone mineral content (BMC) and on region of interest (ROI) were calculated 
for each variable using another fifteen samples, values fell within the range of acceptability, <6% and 
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<5% respectively.  Data were also screened for normality and extreme outlying values in each of the 
nineteen total variables. 
 The first objective in the analysis was to determine if demographic variables age, sex, and body 
mass have potential influence on the results.  Each of these factors has an independent relationship with 
bone density, shown in clinical research.  If samples were not matched closely enough, these variables 
could obscure the analysis on the effects of diabetes.  First, a paired-sample T-test was run on the 
demographics factors (age, sex and body mass) for the two groups.  .   
Obesity has a close association with diabetes and the contribution of each condition to bone 
density is difficult to separate.  For this reason, the relationship between weight and bone density data 
warranted further investigation.  Next, the correlation between each of the continuous demographic 
variables and BMD was investigated.  Pearson Correlation test was used.  Three separate correlations 
were run, one for each skeletal element under investigation. 
Then, Multivariate analysis of variance (MANOVA) was used to determine if significant 
difference exists in bone mineral density between the two groups.  Pilai’s trace multivariate methods were 
selected to evaluate a large number of variables within each skeletal area simultaneously, thus decreasing 
the probability of type 1 error. The MANOVAs were run on femur, forearm, and tibia data separately. In 
the MANOVA model, bone density variables were included as continuous dependent variables.  Sample 
(diabetic versus non-diabetic), sex, and the sample-sex interaction were used as fixed categorical factors.  
The interaction between sample and sex is important because diabetic status may affect males and 
females differently.  MANOVA results will be reported separately for the femur, forearm, and tibia.   
Finally, Analysis of variance (ANOVA) was also performed on each of the BMD variables.  This 
was done to examine the interaction between sex and diabetic status.  This relationship may vary for each 
BMD variable, and ANOVA allows analysis on variable by variable basis.  As with the previous 
MANOVA tests, sample group, sex, and the interaction between sample and sex were designated as fixed 
categorical factors.   
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Results were subjected to discriminant function analysis (DFA) to confirm differences found 
between groups and identify the most discriminatory BMD variables.  All statistical analyses were 
conducted in SPSS Statistics version 21. 
 
 
 
Results 
Paired T-test Results 
No significant difference was found between the diabetic and non-diabetic groups based on 
demographic factors of age, sex, and body mass.  Demographics may influence bone density, but the 
effect should be comparable between the groups and should not confound the analysis. 
 
Correlation Results 
Three Pearson’s Correlation tests were run to evaluate the correlation between demographic 
variables (age, weight, BMI) and BMD variables of the femur, forearm, and tibia variables.  Results for 
the Pearson Correlation demonstrated that body mass was significantly correlated with five of the femoral 
variable at the p ≤ 0.05 level (2-tailed).  Alternatively, results showed that weight was not significantly 
correlated with any of the forearm variables or the tibia variables.  Correlation R-values were low, even 
those indicated as statistically significant.  Weight was not included as a covariate in any subsequent 
analyses. Results from the Pearson Correlations are displayed in Tables 6.1–6.3.   
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Table 6.1. Results from Pearson Correlation of Demographic versus Femur Variables 
 
 Age Weight BMI 
Age 1.0 -0.116 -0.081 
Weight (lb) -0.116 1.0 0.936 
BMI -0.081 0.956* 1.0 
Neck -0.252* 0.305* 0.144 
Upper Neck -0.270 0.314* 0.146 
Lower Neck -0.183 0.302* 0.170 
Ward’s Triangle -0.270* 0.222 0.057 
Trochanter -0.171 0.217* 0.056 
Shaft -0.153 0.288* 0.138 
Femur Total -0.206 0.268* 0.116 
*Correlation with weight which are significant at the 0.05 level (2-tailed). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.2. Results from Pearson Correlation of Demographic versus Forearm Variables 
 
Age Weight BMI 
Age 1.0 -0.116 -0.066 
Weight -0.116 1.0 0.931 
BMI -0.066 -0.931* 1.0 
Radius ultra-distal -0.170 0.099 0.046 
Ulna ultra-distal -0.141 0.044 0.064 
Both ultra-distal -0.130 0.105 0.028 
Radius distal 33% -0.254 0.143 -0.015 
Ulna distal 33% -0.283* 0.182 0.041 
Both distal 33% -0.278* 0.154 -0.005 
Radius total -0.236 0.123 0.021 
Ulna total -0.269* 0.142 -.0110 
Both total -0.290* 0.156 0.009 
*Correlation with weight which are significant at the 0.05 level (2-tailed). 
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Table 6.3. Results from Pearson Correlation of Demographic versus Tibia Variables 
 
 Age Weight BMI 
Age 
1.0 -0.116 -0.066 
Weight -0.116 1.0 0.931 
BMI -0.066 -0.931* 1.0 
Distal 1/3 Shaft -0.208 0.213 0.079 
Metaphysis -0.098 0.146 0.016 
Medial Malleolus -0.274 0.230 0.112 
*Correlation with weight which are significant at the 0.05 level (2-tailed). 
 
 
 
MANOVA Results 
MANOVA was conducted to evaluate the difference between the diabetic and non-diabetic 
groups, incorporating all BMD variables within a skeletal element.  This involves seven femoral 
variables, nine forearm variables, and three tibia variables.  The interaction between sample and sex was 
also included into the models.  Results are reported separately for the three skeletal areas. 
 
Femur MANOVA 
 With all variables in the model, Sample group membership (diabetic versus non-diabetic) had a 
significant effect (p = 0.008), as did Sex (p < 0.0).  Notably, there is a significant interaction between 
sample and sex. (p = 0.028).  MANOVA results confirm the significant effects on each of the seven 
femoral variables.  See Table 6.4, also continued on the following page. 
 
 
Forearm MANOVA 
With all nine forearm variables included in the model, no significant difference was found 
between the sample groups.   However, individual BMD variables show significant difference between 
sample groups in eight of the nine variables (p <0.05). Sex proved a significant factor in the total model.  
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This is consistent with clinical data for differences between males/females in wrist bone density.  The 
relationship between the diabetics and non-diabetics is not dependent on sex, rather it is the same 
(replicated) in males and females.  See Table 6.5. 
 
 
 
 
Table 6.4. Femur MANOVA Results 
 
Effect Test Value F 
 
Hypothesis 
df 
Error 
df 
Significance 
Sample Pillai’s Trace .231 2.998 7.000 70.000 .008 
Sex Pillai’s Trace .443 7.954 7.000 70.000 .000 
Sample*Sex Pillai’s Trace .195 2.421 7.000 70.000 .028 
 
 
Table 6.4 continued. Femur MANOVA Results, Effect of Demographic Factors on BMD Variables 
 
Factor Dependent 
Variable 
Type III Sum 
of Squares 
DF Mean Square F Significance 
Sample 
Group 
Neck .222 1 .222 7.960 0.006 
Upper neck .133 1 .133 4.861 0.031 
Lower neck .244 1 .244 7.312 0.008 
Wards .151 1 .151 4.346 0.040 
Trochanter .290 1 .290 15.507 0.000 
Shaft .451 1 .451 10.315 0.002 
Total Femur .351 1 .351 12.975 0.001 
Sex 
Neck .943 1 .943 33.735 0.000 
Upper neck .880 1 .880 32.248 0.000 
Lower neck .790 1 .790 23.648 0.000 
Wards 1.281 1 1.281 36.747 0.000 
Trochanter 1.020 1 1.020 54.609 0.000 
Shaft 1.403 1 1.403 32.116 0.000 
Total Femur 1.104 1 1.104 40.819 0.000 
Sex *Sample 
Neck .299 1 .299 10.703 0.002 
Upper neck .198 1 .198 7.242 0.009 
Lower neck .502 1 .502 15.029 0.000 
Wards .349 1 .349 9.998 0.002 
Trochanter .221 1 .221 11.845 0.001 
Shaft .592 1 .592 13.563 0.000 
Total Femur .384 1 .384 14.208 0.000 
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Table 6.5. Forearm MANOVA Results 
 
Effect Test Value F 
 
Hypothesis 
df 
Error 
df 
Significance 
Sample Pillai’s Trace .181 1.672 9.000 68.000 0.113 
Sex Pillai’s Trace .572 10.104 9.000 68.000 0.001 
Sample*Sex Pillai’s Trace .145 1.286 9.000 68.000 0.261 
 
 
Table 6.5 continued. Forearm MANOVA Results, Effect of Demographic Factors on BMD Variables 
 
Factor Dependent 
Variable 
Type III Sum 
of Squares 
DF Mean Square F Significance 
Sample 
Group 
Radius UD .045 1 .045 6.853 0.011 
Ulna UD .008 1 .008 .719 0.399 
Radius 33% .166 1 .166 10.804 0.002 
Ulna 33% .120 1 .120 8.345 0.005 
Both UD .043 1 .043 6.905 0.010 
Both 33% .153 1 .153 11.995 0.001 
Radius Total .085 1 .085 8.836 0.004 
Ulna Total .103 1 .103 10.433 0.002 
Both Total .067 1 .067 7.425 0.008 
Sex 
Radius UD .357 1 .357 53.889 0.000 
Ulna UD .151 1 .151 13.522 0.000  
Radius 33% .954 1 .954 62.014 0.000 
Ulna 33% .694 1 .694 48.375 0.000 
Both UD .303 1 .303 48.991 0.000 
Both 33% .868 1 .868 67.839 0.000 
Radius Total .552 1 .552 57.659 0.000 
Ulna Total .419 1 .419 42.277 0.000 
Both Total .530 1 .530 58.724 0.000 
Sex*Sample 
Radius UD .003 1 .003 .399 0.530 
Ulna UD .003 1 .003 .249 0.619 
Radius 33% .038 1 .038 2.448 0.122 
Ulna 33% .066 1 .066 4.583 0.036 
Both UD .010 1 .010 1.566 0.215 
Both 33% .047 1 .047 3.646 0.050 
Radius Total .013 1 .013 1.349 0.249 
Ulna Total .047 1 .047 4.794 0.032 
Both Total .018 1 .018 1.976 0.164 
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Tibia MANOVA Results 
With all variables in the model, both sample group and sex again had significant effects (p = 
0.036, and p < 0.00, respectively).  The interaction between sex and sample was also significant for tibia 
BMD (p = 0.05).  When individual variables model were investigated in the MANOVA, sex was a 
significant factor for all variables, sex-sample interaction was significant for the distal 1/3 shaft and the 
medial malleolus, but not at the metaphysis.  See Table 6.6. 
 
 
 
Table 6.6. Tibia MANOVA Results 
 
Effect Test Value F 
 
Hypothesis 
df 
Error 
df 
Significance 
Sample Pillai’s Trace .108 2.988 3.000 74.000 0.036 
Sex Pillai’s Trace .338 12.615 3.000 74.000 0.000 
Sample*Sex Pillai’s Trace .100 2.736 3.000 74.000 0.050 
 
Table 6.6 continued. Tibia MANOVA Results, Effect of Demographic Factors on BMD Variables 
 
Factor Dependent 
Variable 
Type III Sum 
of Squares 
DF Mean Square F Significance 
Sample 
 
Distal 1/3 shaft .250 1 .250 2.570 0.113 
 
Metaphysis .287 1 .287 4.532 0.036 
Medial 
Malleolus .291 1 .291 9.066 0.004 
Sex 
 
Distal 1/3 shaft 2.865 1 2.865 29.454 0.000 
 
Metaphysis 1.738 1 1.738 27.498 0.000 
Medial 
Malleolus .932 1 .932 29.066 0.000 
Sex*Sample 
 
Distal 1/3 shaft .370 1 .370 3.804 0.050 
 
Metaphysis .048 1 .048 .755 0.388 
Medial 
Malleolus .129 1 .129 4.015 0.049 
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ANOVA Results 
 Analysis of variance (ANOVA) was performed to investigate the relationship between diabetic 
status and sex.  Sample group membership (diabetic status) appears to have a significant effect on bone 
density, but this effect may not be consistent between males and females.  Furthermore, this relationship 
may vary depending on the skeletal element and variable examined.  Only those variables which 
displayed a significant sample-sex interaction were subjects to ANOVA. Results are separated by skeletal 
element: femur, forearm, and tibia. 
Femur ANOVA 
 ANOVA was run on seven femoral variables.  Within the female subsample, the diabetic group 
BMD is significantly different from non-diabetic BMD.  Additionally, female diabetics have significantly 
heavier bone density values than non-diabetics.  This relationship does not hold true for the male 
subsample.  Males do not show such an exaggerated discrepancy, and the diabetics actually show 
decreased BMD values in six of the seven variables.  Results for one of the femoral variables: Neck, are 
shown in Table 6.7 and Figure 6.4.  Additional femur ANOVA results may be found in the Appendix. 
 
 
Table 6.7. ANOVA Results: Femur Neck 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.9325 0.1677 
0.0001 
Non 18 0.7036 0.1501 
Male 
Diabetic 22 1.0278 0.1759 
0.748 
Non 22 1.0447 0.1707 
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Figure 6.4. Means for Neck BMD, separated by sex. 
 
 
Forearm ANOVA 
 ANOVA was run on the nine forearm variables.  Results for the first of the forearm variables, 
Radius Ultra-distal are shown in Table 6.8 and Figure 6.5.  Additional forearm ANOVA results may be 
found in the Appendix.  Forearm ANOVA demonstrates that significant difference exists between 
diabetic and non-diabetics in eight variables.  This difference is observed in both sexes; diabetics show 
denser forearm bone in both the females and the males.   
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Table 6.8. ANOVA Results: Radius Ultra-distal  
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.4150 0.0841 
0.040 
Non 18 0.3555 0.0825 
Male 
Diabetic 22 0.5377 0.0739 
0.138 
Non 22 0.5014 0.0851 
 
 
 
 
 
Figure 6.5. Means for Radius Ultra-distal BMD, separated by sex. 
 
 
Tibia ANOVA 
 ANOVA was performed on the three tibia variables.  Similar to the femur ANOVA, the female 
subsample showed greater diversity.  Female diabetics have significantly higher BMD values than the 
non-diabetics.  The male subsample did not show a significant disparity between groups.  Results for one 
of this tibia variables: Distal ⅓ shaft, are shown in Table 6.9 and Figure 6.6., and the remaining tibia 
ANOVA results may be found in the Appendix.  
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Table 6.9. ANOVA Results: Tibia Distal ⅓ shaft 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 1.5452 0.3745 
0.045 
Non 18 1.2961 0.3437 
Male 
Diabetic 22 1.7888 0.2631 
0.764 
Non 22 1.8132 0.2711 
 
 
 
 
 
 
Figure 6.5. Means for Tibia distal ⅓ shaft BMD, separated by sex. 
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Discriminant Function Analysis Results 
 Discriminant function analysis (DFA) was used to confirm differences found between groups.   
Tests were run at each skeletal area to compare diabetic and non-diabetic groups, separated by sex.  DFA 
substantiated the significant differences between diabetic and non-diabetic females in femur, forearm, and 
tibia bone density (Wilks’ Lambda significance: p = 0.000 – 0.002).  Step-wise variable selection 
identified Trochanter BMD, Ulna total BMD, and Malleolus BMD as the most differentiating variables in 
each skeletal region.  DFA showed no significant difference between diabetic and non-diabetic males 
(Wilks’ Lambda significance values: p = 0.531 – 0.680).  No single variable or set of variables could be 
identified as being highly differentiating in the male subgroup.  See results from DFA in the Appendix. 
 
  
Discussion 
Results showed that the significant difference may be found in the bone mineral density of 
diabetics versus non-diabetics.  However, sex status has a substantial influence on this relationship.  In 
variables of the forearm (radius and ulna), diabetics generally produced heavier BMD values, regardless 
of sex.  But in the lower limb, the relationship between groups is different for males and females.    
In the analysis of femur and tibia data, female diabetics displayed dense bones than their 
counterparts.  This is consistent with previous research, finding greater relative modification in BMD in 
the female samples, versus male subsamples (Barrett-Connor and Holbrook 1992).  Findings are also 
consistent with obesity research, where a higher correlation was found between body weight and BMD 
for female than for males (Moore 2008).  Diabetic females also dominate in forearm BMD values, but the 
difference between the groups is less prominent and is not always significant (in three of nine variables). 
 Results are likely connected to the relationship between elderly females and osteoporosis.  With 
an average age of 64.25 years, the majority of females in the total sample are probably postmenopausal.  
The non-diabetic female group displayed the expected postmenopausal bone loss characteristic of this 
demographic.  Alternatively, the diabetic group has additional factors affecting the regulation of bone 
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cells.  While body mass is comparable in the two group, the diabetics inevitably possess more fat cell, 
specifically more visceral fat.  Adipocytes provide a supplemental source of estrogen in females.  Also, 
diabetics likely had high amounts of adipocyte-released cytokines like leptin.  Leptin is known to have a 
direct positive effect on osteoblasts (through the CART pathway), even in the absence of extreme obesity.  
This trend is not necessarily dependent upon sex, but seems most apparent only in females for the current 
sample.  Hyperinsulinaemia may have a similar positive effect.  Additionally, diabetics have lower levels 
of circulating osteocalcin (un-OCN).  These insulin-sensitizing molecules become bioactive as a result of 
low pH created by osteoclast activity.  The end result of this process is an elevated high proportion of 
inactive OCN bound up in the bone matrix and decreased osteoclast action.  Future research should focus 
on premenopausal females to further investigate the relationship between diabetes, innate estrogen 
production, and bone density. 
The male sample showed conflicting results.  In variables of the lower limb, the non-diabetic 
group demonstrated higher bone density. However, in the forearm, male (and female) diabetics produced 
higher BMD.   The male subsample did not show as much variability and the females, and disparity 
between diabetic and non-diabetic males was rarely statistically significant. 
  Research has shown that aging has a less profound effect on male bone density.  While older 
males experience lower testosterone and estrogen levels, it does not extract such a high cost on their bone 
health.  While diabetes may be acting in the same way on males bone as female bone, the absence of 
osteoporosis in males may make the discrepancy indiscernible.  Furthermore, clinical data shows that 
diabetic males typically suffer from more severe comorbidities.  The combined effects of retinopathy, 
neuropathy, and nephropathy may debilitate diabetic males more so than females.  Diabetic men may be 
loading their bones less than normal healthy males.  Thus, the benefit of mechanical loading outweighs 
the effect of altered energy metabolism.  Additional research should be conducted on a sample with 
known diabetic complications and activity levels, as this may be the more significant factors for males. 
This part of the research addressed the skeletal biological questions pertaining to how diabetes 
affects bone quality, and at which skeletal areas.  Results suggest that the relationship between energy and 
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bone metabolism plays a small but intrinsic role in total bone density.  Along with other factors like sex, 
age, and mechanical loading, energy metabolism constitutes an important influence on bone density.  
Nutrition denotes another essential factor contributing to bone density.  A number of dietary components 
have been identified as contributing to bone health including vitamins D, C, A, magnesium, zinc, copper, 
iron, fluoride, and protein.  Significant among these nutrients are calcium and phosphorous, comprising 
roughly 80-90% of the mineral component of the bone matrix.  Variations in calcium consumption early 
in life can account for approximately five to ten percent difference in peak adult bone mass.  This 
relatively slight difference can translate into a 50% decrease in adult hip-fracture rates (Ilich and 
Kerstetter 2000; Matkovic et al. 1979). 
 
Additionally, effects of diabetes are additive and may require time before detection.  Type 2 
diabetics generally experience changes in bone mineral density and increased incidence of fracture five to 
ten years after initial diagnosis.  This trend is more evident in one sex (females) and more easily 
recognized when other hormones like estrogen are eliminated from the equation.  Therefore, altered 
energy metabolism, commonly manifested as diabetes, represents more modest contribution than that of 
sex hormones and mechanical loading. 
In the broader application of this research, bone density offers another source of data for the 
forensic anthropologist.  Because the relationship is more obvious in females, analysis of bone density 
may be more applicable in this group.  A female skeleton aged at approximately 60 years or older, having 
abnormally high bone density in femoral and forearm measurements, may indicate metabolic 
dysregulation.  This information coupled with pathological conditions which will be discussed in the next 
chapter, lends credence to a suspected diagnosis of diabetes. 
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CHAPTER 7. EXAMINATION OF OSTEOLOGICAL PATHOLOGIES 
 
Chapter Seven represents the final analytical chapter, covering the macroscopic examination of 
skeletal pathologies associated with diabetes.  Prolonged hyperglycemia and poor glucose control are the 
primary causes of diabetic complications such as neuropathy, retinopathy, and nephropathy.  As these 
conditions progress they begin to negatively affect bone by reducing vascular oxygen supply, 
desensitizing to fractures and ulcers, and providing a conduit for infectious pathogens.  The appearance of 
osteological diabetic complications signifies a later stage in the disease process, requiring a longer 
infirmary period to develop.  The effects of hyperglycemia and the pathway to bone will be reviewed, 
followed by a description of the methods used to record osteological pathologies, and concluding with the 
results from this investigation. 
 
Background 
Diabetes is a complex disease with the ability to affect nearly every system and tissue in the body.   
This is primarily related to hyperglycemia and the negative impact of excess blood glucose.  Chronic 
hyperglycemia is the major source of micro- and macrovascular diabetic complications like nephropathy, 
retinopathy, and neuropathy (Sheetz and King 2002).  Glucose is an important component in multiple 
metabolic and chemical processes, thus a glucose imbalance can affect many pathways.  Several theories 
have been waged to explain the relationship between hyperglycemia and vascular derangements. 
One of the more well-established theories explaining the relationship between hyperglycemia and 
vascular derangements involves advanced glycation end-products (AGEs).  Glycation is a chemical 
process where excess glucose (a defining feature of hyperglycemia) bonds with proteins, creating 
insoluble molecules, called AGEs (Ahmed 2005).  AGEs are deposited in the small blood vessels and 
vascular basement membranes.  Deposits in the glomeruli of the kidneys retard and over-burden the 
filtration process (nephropathy), lead to functional exhaustion, and eventually end stage renal failure.  In 
the delicate vessels of the eye, AGE deposits impede blood flow which may cause vascular penetration 
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and rupture.  Intraocular hemorrhage can results in permanent damage and blindness (retinopathy).  When 
deposited in particularly sensitive locations, such as the macula or on the lens, AGEs may induce macular 
edema, or form opaque cataracts.  AGE deposits in the terminal microvessels of the limbs produce one of 
the hallmark complications of diabetes, peripheral vascular disease (PVD), or peripheral neuropathy. 
Nerve deterioration in the hands and feet causes selective anesthesia (loss of feeling).  Decreased 
sensation, coupled with compromised sight leads to a greater number of injuries to the hands, feet, and 
distal legs of diabetics.  Reduced blood flow also increases healing time (Ahmed 2005).   
Diabetic complications do not terminate in soft tissue or vascular structures.  Soft tissue 
pathologies, like ulcers provide an entry point for infectious pathogens.  Unattended infection progresses 
inward, further debilitating blood supply, affecting muscle, and eventually contacting bone.  
Osteomyelitis is an infectious disease, caused by a foreign microorganism, characterized by progressive 
inflammatory destruction of bone (Lew and Waldvogel 1997).  The major pathogen observed in diabetic 
osteomyelitis is Staphylococcus aureus, which has the ability to adhere to the bone surface by expressing 
receptors (adhesins) for components of the bone matrix: collagen, fibronectin, and lamanin.  Once affixed 
to bone, S. aureus expresses phenotypic resistance to antimicrobial treatment (Sia and Berbari 2006).  
Cytokines and other pro-inflammatory molecules which are common in diabetes promote the progression 
of osteomyelitis infection.  Leukocytes respond to the infected area, attempt to engulf the infectious 
microorganisms, and release enzymes that lyse the bone.  Necrotic boney abscess, isolated segments of 
necrotic bone (sequestra), and an aperture in tissue (fistula, or cloaca) providing drainage for pus, and the 
irregular formation of new bone are identifying features of osteomyelitis (Lew and Waldvogel 2004). 
Diabetics experience a high incidence of fracture, regardless of their bone density measurements  
This may also be due to vascular complications brought about by hyperglycemia.  AGE deposits create 
collagen cross-linked formations in the bone matrix rendering the bone structure weaker and more 
susceptible to stress and strain (Wang et al. 2002).  Animal studies have shown that rabbits with high 
AGE content in bone have impaired mechanical properties, despite normal BMD (Saito et al. 2010).  
Human studies show serum levels of AGEs are increased in diabetics, and positively associate with 
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increased prevalence of fractures in this group (Kanazawa et al. 2008).  Additional features which may 
contribute to bone fragility in diabetics include more rapid bone loss with retarded apposition, differences 
in bone geometry, higher propensity to fall and accumulation of micro damage at low bone turnover sites.  
Net depreciation in bone quality potentially leads to porosity and fractures in skeletal areas unique to 
diabetics.  Longitudinal data suggest that early stages of type 2 diabetes may provide protective benefits 
to bone strength.  However, detrimental factors predominate over the course of diabetic disease and have 
a negative impact on bone integrity in the long run (Schwartz et al. 2005). 
Diabetes has been identified as a major causal force in the development of periodontitis (Preshaw 
et al. 2012).  Diabetics have a threefold higher risk of developing periodontal disease than the health non-
diabetic population (Emrich et al. 1991).  Periodontitis is inflammation that begins in the gingiva, 
extending into the periodontal ligament, and results in deterioration of alveolar bone.  The initial stages of 
disease are often asymptomatic and painless.  But as periodontitis progresses, fibers of the periodontal 
ligament are destroyed (attachment loss) and alveolar bone is resorbed simultaneously.  This creates slack 
in the anchoring structures of teeth and a gap in the alveolar pocket, leading to tooth loss (Lalla et al. 
2011).  Diabetic patients may be unaware of their periodontitis until destruction has proceeded to the 
point of tooth mobility. 
There has been recent focus on a two-way relationship between periodontitis and diabetes.  
Diabetes is not only a significant risk factor for periodontitis, but periodontal disease in turn has a 
negative impact on glycemic control.  The major culprits connecting the two diseases are inflammation 
and hyperglycemia.  Hyperglycemia (excess sugar) creates dental biofilm (plaque) along the gum line.  
This foreign element irritates the soft tissue and instigates an immune response.  In diabetic patients, 
baseline inflammation is already elevated, and plaque intensifies the effect.  The inflammatory response 
stimulates cytokines, which promote insulin resistance and diabetes.  Thus, periodontitis and diabetes are 
locked in a feed-forward cycle (Lalla and Papapanou 2011).  
Clinical studies demonstrate that many diabetic complications affect bone in the later stages of 
the disease.  There is potential to recognize diabetic comorbidities in postmortem human material by 
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examining osteological pathologies present in the skeleton.  Medical research indicates that the following 
pathologies may present on the diabetic skeletons: fractures and increased porosity in the distal lower 
limbs, proximal humerus, and distal forearm (radius and ulna); osteomyelitis in distal lower limbs and the 
feet; development of osteophytes and exostoses in the distal leg, tarsals, and metatarsals; and periodontitis 
with associated dental deterioration (Barrett-Connor and Holbrook 1992; Buchbinder 2004; Kagan 2010; 
Lew and Waldvogel 2004; Ortner 2008; Taylor and Borgnakke 2008). 
A confounding factor in this research is that the pathologies observed are not mutually exclusive 
in their source.  Many of the above-described pathologies may present on skeletal remain for reasons 
other than diabetes.  However, the pattern and location of pathologies within a set of remain potentiates 
the distinction of diabetes.  Fractures, for example, show dramatically higher incidence in elderly 
individuals of both sexes, regardless of diabetic status.  Osteoporotic fractures and fractures due to age-
related changes in bone quality are observed most often in the hip (femoral head and acetabulum joint 
complex), and in the wrist, often as a result of breaking a fall.  Alternatively, diabetics show a higher 
number of macro- and micro-fractures in the lower limb (distal tibia and fibula) and the ankle (Keegan et 
al. 2002).  Therefore, fractures and porosity may be present in skeletal areas significant for diabetics, but 
not typically associated with osteoporosis. 
Similar discrepancy in pattern is noted with regards to osteomyelitis.  Within the general clinical 
population osteomyelitis occurs with greatest frequency in post-operative patients, particularly those 
receiving joint prostheses and implanted devices (Sia and Berbari 2006).  Osteomyelitis secondary to 
surgery can occur in any bone, though rarely in the cranium.  The second most commonly encountered 
type is diabetic osteomyelitis, a chronic bone infection caused by diabetic foot ulcers and vascular 
insufficiency.  Diabetic osteomyelitis may be observed in the absence of major surgery or prostheses, and 
is found almost exclusively in the distal leg, tarsals, metatarsals, and foot phalanges.  “Diabetic foot” is a 
well-known complication in radiological studies and medical research, but has yet to be documented in 
postmortem osteological samples. 
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Another confounding factor is physical activity pattern.  Degenerative changes in bone can result 
from minor trauma and repetitive activities.  This type of degeneration commonly occurs with vocations 
pastimes that require a high level of physical activity place increased stress on the legs and feet.  “Heel 
spurs” are exostoses known to develop in highly mobile individuals (Buchbinder 2004), and are also 
associated with type 2 diabetes.  But most diabetics who suffer multiple comorbidities have limited 
mobility.  Rather than intense activity, the etiology of diabetic heel spurs is related to bearing excessive 
body mass while simultaneously overproducing anabolic hormones like leptin and insulin.  Heel spurs 
form from calcification deposits on the medial process on the inferior calcaneus, at the origin the plantar 
fascia (Riddle et al. 2003).  Exposure to strain may tear the fascia and calcification occurs in response.  
Infrequent mobility and disproportionate body weight, coupled with overactive anabolic hormones 
promotes the development of heel spurs in diabetics.  Diabetic may express heel spurs but do not 
demonstrate the well-developed muscle attachment sites observed in active individuals.   
  
The hypothesis for this part of the research is that the presence and pattern of osteological 
pathologies will be distinct in diabetics, and will differ from non-diabetics who may still present some of 
the described conditions.   The goals for this portion of the research include: 1) to determine if 
pathological complications of diabetes described in clinical literature are observable in bone, 2) to 
determine if diabetics and non-diabetics significantly differ in the presence/extent of the osteological 
pathologies, 3) to determine the best set of characteristics that differentiate diabetics from non-diabetics. 
 
Methods 
Diabetes is a disease primarily characterized by altered glucose metabolism, a phenomenon 
which cannot be examined postmortem.  However, gross osteological features may serve as markers of 
the disease presence.  The previously described pair-matched sample used in bone mineral density 
scanning was also used for analysis of skeletal pathologies.  This includes a skeletal sample of 39 
diabetics and 40 non-diabetics, matched on demographic factors sex, age, and weight.  One set of remains 
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from the original pair-matched sample (described in Chapter 4) was returned to next of kin after bone 
density scanning but prior to osteological analysis.  Thus, the total number of samples in each subgroup is 
not equal.  Each skeleton was examined and scored in its entirety for pathologies.  This was done blindly 
with regards to diabetic status.  Data for this portion of the research are binary and ordinal in nature. 
Seventeen total variables were investigated, concerning five major diabetic indicators: fractures, 
macroscopic porosity, osteomyelitis, osteophyte/exostosis formation, and periostitis with associated 
dental conditions.   
Fractures were scored as the total number observed in each specified area: distal humerus, distal 
forearm (radius and ulna), distal lower limb (tibia and fibula), and feet (metatarsals and foot phalanges).  
A major fracture exhibiting any radiating fractures would be counted as a single failure event, in order to 
quantify the number of incidents rather than severity of breakage.  Left and right elements were scored 
additively, so that one fracture in the left distal tibia and another fracture in the right distal tibia would be 
given a total score of “2”.  No perimortem fractures were observed in the current sample 
Areas examined for macroscopic porosity include: humeral head, distal forearm (radius and ulna, 
including both styloid processes), carpal bones, distal one-third of the lower limb (tibia and fibula, 
including medial and lateral malleoli), and the tarsal bones.  Porosity was scored according to extent of 
the area affected, as described in Standards for Data Collection from Human Skeletal Remains (Buikstra 
and Ubelaker 1994).  This was done on a quarter scale of increasing involvement from “0” (no porosity 
observed) to “4” (entire area porous).  For example, if one-fourth of the total observed area contains 
viable porosity, a score of “1” was designated.  If one-half of the area was porous, a “2” was recorded.   
Osteophyte and exostosis formation was examined on the distal tibia and fibula (terminal ends, 
including both malleoli), inferior edge of the calcaneus (heel spur), tarsals and foot metatarsals (including 
other joint articular surfaces of the calcaneus).  Osteophytes were scored as present (“1”) or absent (“0”). 
Areas investigated for osteomyelitis include the distal tibia and fibula, tarsals, metatarsal, and foot 
phalanges. Skeletal sites were examined for any of the following characteristics (or combination of 
features): abscess-related bone destruction, a cloaca cavity, sequestra of necrotic bone, and deposition of 
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new bone (involcrum) with uneven or scalloped edges (Ortner 2008).  Osteomyelitis was scored as 
present (“1”) or absent (“0”) in each skeletal location. 
Periodontitis has several corresponding dental conditions, related to inflammation and 
progressive destruction of the periodontal ligament.  Periodontitis was investigated as the loss of alveolar 
bone at the cement-enamel junction (ligament connection point), not caused by antemortem tooth loss. A 
score of “1” indicating loss of alveolar bone and “0” normal alveolar sockets.  Periodontitis often 
promotes plaque development along the gumline, which was also scored on a present/absent scale.  
Diabetic hyperglycemia furthermore stimulates the development of dental caries.  Caries were scored as 
total number observed in a set of dentition. 
Preliminary data screening was performed to test the reliability of scoring methods.  Then, chi-square 
tables were used to examine and eliminate variables with limited or no response.  Extraneous variables 
were removed to prevent confounding the statistical analysis.  Finally, logistic regression was used to 
select the set of variables that best classify samples in the study into either diabetic or non-diabetic 
groups.  This test was employed due to the categorical (binary) and ordinal nature of both outcome and 
predictor variables.  Logistic regression also calculates the percentage of correctly classified samples 
using the model of best fit.  All statistical analyses were conducted in SPSS Statistics version 21. 
 
Results 
Preliminary testing began by assessing the reliability of scoring methods.  Researcher intra-
observer error was tested by selecting five skeletons at random and scoring them in their entirety 
(seventeen total variables).  These same five samples were re-scored after an interim of one week.  Data 
from trial one and trial two were subjected to a paired T-test for significant difference and a Pearson 
Correlation test.  Tests revealed no significant different between the two trials (p<0.0001), with 
correlation coefficient values = 0.958.  Therefore, scoring methods were considered reproducible and 
valid for further evaluation. 
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Of the 79 available skeletons, half (n=40) were edentulous, and thus any observed deterioration 
may be due to antemortem tooth loss.  Dental pathologies like plaque development and carious lesions 
could not be scored for edentulous sample, though they may have been present in life.  Samples with 
available dentition (n=39) were scored for dental pathologies, but these variables not included in the 
logistic regression due to the significant number of missing variables (n=40, unavailable for analysis).   
This reduced the number of total variables from seventeen to fourteen. 
 
Chi-Square Tests 
Data were screened using chi-square tables, comparing the expected and observed observations in 
each predictor variable.  Some of the variables were rarely observed in the entire skeletal sample.  
Variables with no or very few data points are not informative or differentiating in terms of group 
membership.  Limited responses in multiple variables can also limit the statistical analysis.  As an 
example, in the 79 total skeletons examined, not a single fracture was observed in the humeri.  
A chi-square test was run on each of the fourteen variables.  In addition to observed and expected 
counts and percentages, chi-square generates an adjusted residual.  This is a measure of the departure of 
the observed from the expected counts (similar to a z-score).  Predictor variables that are associated with 
group membership will have observed counts much greater or much less than the expected.  Those 
variables with adjusted residuals greater than an absolute value of 1.0 were considered predictors of 
interest.  
Chi-square tests eliminated seven variables (adjusted residual <1.0), reducing the number of 
variables under investigation to seven in total.  See tables 7.1 – 7.7 for chi-square tables of the seven 
variables of interest.  See Table 7.8 for a list of variables retained for logistic regression. 
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Table 7.1. Chi-Square Results: Fractures Tarsals and Metatarsals 
  Fractures Tarsals/Metatarsals 
  0 1 2 
Non-diabetic 
Observed count 37 3 0 
Expected count 34.4 4.6 1.0 
% within group 92.5% 7.5% 0% 
Diabetic 
Observed count 31 6 2 
Expected count 33.6 44 1.0 
% within group 79.5% 15.4% 5.1% 
Total 
% within group 86.1% 11.4% 2.5% 
Adjusted residual 
(absolute value) 1.7 1.1 1.5 
 
 
 
 
Table 7.2. Chi-Square Results: Porosity Carpals 
  Porosity carpals 
  0 1 2 3 
Non-diabetic 
Observed count 15 10 7 8 
Expected count 13.2 10.1 9.1 7.6 
% within group 37.5% 25% 17.5% 20% 
Diabetic 
Observed count 11 10 11 7 
Expected count 12.8 9.9 8.9 7.4 
% within group 28.2% 25.6% 28.2% 17.9% 
Total 
% within group 32.9% 25.3% 22.8% 19% 
Adjusted residual 
(absolute value) 0.9 9.1 1.1 0.2 
 
 
 
 
Table 7.3. Chi-Square Results: Osteomyelitis Distal ⅓ Tibia and Fibula 
  Osteomyelitis Tibia/Fibula 
  0 1 
Non-diabetic 
Observed count 34 6 
Expected count 25.8 14.2 
% within group 85% 15% 
Diabetic 
Observed count 19 20 
Expected count 25.2 13.8 
% within group 48% 52%% 
Total 
% within group 66% 35.4% 
Adjusted residual 
(absolute value) 3.8 3.8 
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Table 7.4. Chi-Square Results: Osteomyelitis Tarsals and Metatarsals 
  Osteomyelitis Tarsals/metatarsals 
  0 1 
Non-diabetic 
Observed count 39 1 
Expected count 30.9 9.1 
% within group 97.5 2.5 
Diabetic 
Observed count 22 17 
Expected count 30.1 8.9 
% within group 56.4% 43.6% 
Total 
% within group 77.2% 22.8% 
Adjusted residual 
(absolute value) 4.4 4.4 
 
 
 
 
Table 7.5. Chi-Square Results: Osteophytes – Distal Tibia and Fibula 
  Osteophytes- Tibia/Fibula 
  0 1 
Non-diabetic 
Observed count 24 16 
Expected count 16.2 23.8 
% within group 60% 40% 
Diabetic 
Observed count 8 31 
Expected count 15.8 23.2 
% within group 20.5% 79.5% 
Total 
% within group 40.5% 59.5% 
Adjusted residual 
(absolute value) 3.6 3.6 
 
 
 
 
Table 7.6. Chi-Square Results: Heel Spurs 
 Heel Spurs 
  0 1 
Non-diabetic 
Observed count 30 10 
Expected count 21.3 18.7 
% within group 75% 25% 
Diabetic 
Observed count 12 27 
Expected count 20.7 18.3 
% within group 30.8% 69.2% 
Total 
% within group 53.2% 46.8% 
Adjusted residual 
(absolute value) 3.9 3.9 
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Table 7.7. Chi-Square Results: Osteophytes Tarsals and Metatarsals 
  Osteophytes Tarsals/Metatarsals 
  0 1 
Non-diabetic 
Observed count 30 10 
Expected count 19.2 20.8 
% within group 75% 25% 
Diabetic 
Observed count 8 31 
Expected count 18.8 20.2 
% within group 20.5% 79.5% 
Total 
% within group 48.1% 51.99% 
Adjusted residual 
(absolute value) 4.8 4.8 
 
 
 
 
 
 
Table 7.8. Pathology Variables used in Logistic Regression 
 
Pathology Type Variable location 
Fractures Tarsals and metatarsals  
Porosity Carpals and metacarpals 
Osteomyelitis 
Distal third leg (tibia and fibula) 
Tarsals and metatarsals 
Osteophyte formation 
Distal third leg (tibia and fibula) 
Heel spur (inferior calcaneus) 
Tarsal and metatarsals joint interfaces 
Dental pathologies Plaque development 
 
 
 
 
 
 
Logistic Regression 
The major goal was to find the set of pathologies that best differentiates diabetic from non-
diabetics.  Binary logistic regression was selected to predict membership in a categorical outcome 
variable (diabetic or non-diabetic) using a combination of binary and ordinal predictor variables 
(pathologies).  Logistic regression uses logarithmic transformations to model a non-linear association in a 
linear way.  
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In the regression, seven pathology variables were entered as predictors, the dependent outcome 
variable was coded as “1” (diabetic) and “0” (non-diabetic).  Backward Wald was the method used to 
enter variables into the model (0.10 level of significance for removal from the model). 
Results produced a model including six variables: Porosity of the carpals, osteomyelitis in tarsals and 
metatarsals, heel spurs, osteophyte development in the distal tibia/fibula and in the tarsals/metatarsals, and 
plaque development.  One variable (carpal porosity) selected by the Backward Wald shows statistical 
non-significance (p=0.097, odds ratio = 0.616).  This suggests that a smaller model, including fewer 
variables may be more effective. 
To test legitimacy of the model, the regression was repeated using Forward Wald methodology.  
This test selected a model of best fit including three variables: osteomyelitis in tarsals and metatarsals, 
heel spurs, and osteophytes in the tarsals/metatarsals.  The model uses fewer variables, and had a slightly 
higher percentage of correctly predicted cases.  This means that more samples were correctly assigned to 
the diabetic or non-diabetic categories.   
The final model selected to best differentiate diabetics from non-diabetics includes the above-
listed three variables.  See Table 7.9. 
Results from the logistic regression show an average classification rate 82.75%.  The variables 
selected as having the most differentiating potential are concentrated in the foot and ankle.   
See Figures 7.1 – 7.3 for observed counts (diabetic versus non-diabetic) in the three predictor variables. 
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Table 7.9. Forward Wald Logistic Regression Results 
 
Model Summary 
Step -2 Likelihood Cox & Snell R-Square Nagelkerke R-Square 
1 84.67 0.270 0.360 
2 75.88 0.347 0.462 
  3* 69.04 0.401 0.534 
*Estimation terminated at iteration number 4 because parameter estimates changed by < 0.001 
 
Classification Table 
  Non-diabetic Diabetic Percentage Correct 
Step 3 Non-diabetic 36 4 90.0 
 Diabetic 10 29 75.5 
 Overall percentage   82.75 
 
Model 
Variables Standard 
error 
Wald 
Statistic 
Degrees of 
Freedom 
p-value Odds ratio 
Osteomyelitis- tarsals/metatarsals 1.146 5.908 1 .015 0.620 
Heel spurs .610 6.598 1 .010 0.209 
Osteophytes- tarsals/metatarsals .612 5.995 1 .014 0.224 
 
 
 
 
 
 
 
Figure 7.1 Osteomyelitis in tarsals and metatarsals, diabetic versus non-diabetics 
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Figure 7.2 Heel spurs, diabetic versus non-diabetics 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 Osteophytes in tarsals and metatarsals, diabetic versus non-diabetics 
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The selected model had better classification of non-diabetic sample than for diabetic samples 
(90% and 75%, respectively).  This is likely due to the heterogeneous nature of the disease and treatment 
regimens.  Not all diabetics will present every complication, and their hyperglycemia is variably 
managed. 
Predictor variables examined separately may not be considered conclusive, but when the selected 
three are expressed in a set of skeletal remains, this indicates a systemic pathological condition that alters 
bone health and metabolism, such as diabetes 
 
 
Discussion 
Results indicate that a specific set of skeletal pathologies may suggest diabetes in a set of skeletal 
remains.  However, a number of limiting issues must be discussed related to methods and the collection 
used. 
The William M. Bass Collection has a large proportion of individuals that are edentulous.  Without 
prior dental records it is difficult to identify the cause of dental decay.  More recently, medical records 
like dental radiographs are provided for donated remains in the collection. It might be useful to examine 
another modern skeletal collection with more complete dentition for the relationship between diabetes and 
periodontitis and tooth loss.  Once a sufficient number of antemortem dental records have been collected 
it may be beneficial to use these documents as the data source to investigate periodontal destruction in 
diabetic remains. 
Few fractures were observed in the research sample.  Type 2 diabetics report a high incidence rate 
of fracture (Merlotti et al. 2010; Vestergaard 2007), though this was unconfirmed in the present study.  
This may be related to form of analysis employed (gross observation) rather than x-ray or computerized 
tomography (CT) imaging which would reveal greater level of detail.  A number of amputations were 
observed in the sample.  Amputations may have been performed subsequent to fractures that become 
infected and necrotic, but antemortem records to not relate this information.  The absence of fractures 
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could be related to mobility patterns, or lack thereof.  Diabetes decreases mobility of many patients 
suffering from PVD, ESRD, and retinopathy.  Reduced mobility decreases the probability of experiencing 
a fracture event.   
Furthermore, the highest rate of fractures in any form among diabetics is in type 1 diabetic pre-
menarchal females. Hyperglycemia appears to have the greatest negative influence on bone quality during 
vulnerable periods of peak bone acquisition.  The subjects in this study were all type 2 diabetic adults, 
who acquired their peak bone mass prior to developing diabetes.  In addition, corticosteroids (commonly 
used to treat asthma and chronic obstructive pulmonary disease, COPD) have a well-documented negative 
effect, increasing risk of fractures (Kanis et al. 2004; van Staa et al. 2002).  The limited fractures observed 
in the sample might have been related to medication regimen rather than diabetes and hyperglycemia.   
Osteomyelitis was a significant pathology detected in the diabetic subset.  This observation 
supported by clinical literature, as “diabetic foot” is one of the most commonly diagnosed complications 
of the disease.  Clinical manifestation of diabetic foot include reduced sensation and blood supply, altered 
weight distribution, accumulation of microfractures, and development of ulcers.  The inward progression 
of infectious pathogens and depression healing capacity leads to soft tissue and bone infections, necrosis, 
and eventual amputations.  Features of diabetic foot were observed in the diabetic skeletal samples from 
the William M. Bass Collection.  Amputation was not included as a predictor a variable for diabetes, as 
the root cause might be related to a non-diabetic injury.  Osteomyelitis is the primary cause of diabetic 
amputations, and represents the culmination of neuropathic complications. 
Diabetes is manifested first as hyperglycemia that progressively affects multiple organ systems, 
including the skeleton.  Diabetic pathologies observed in bone imply that diabetes had a significant 
amount of time to advance.  Longitudinal studies have revealed that the number of diabetic complications 
is directly related to the duration of the disease.  Pre-diabetes and early stages of the disorder may lend 
protective benefits to bone, as evidence by increased BMD.  But prolonged diabetes, with accumulated 
pathologies and chronic hyperglycemia vastly increases morbidity.  For a limited number of remains in 
the collection, date of diagnosis is provided and length of the disease may be calculated.  Given more 
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complete antemortem information, duration of disease could be compared with to the extent of skeletal 
pathologies.  One would expect to find a positive correlation in these two factors.   
Socioeconomic status may be a major factor in this study.  Access to treatment, prescription 
medication, and adequate nutrition could be significant determinants in the presence/absence of diabetic 
skeletal complications.  Given proper glycemic control, diabetic complications decrease in manifestation 
and severity.  Socioeconomic status, including access to medical resources, is unknown for the Bass 
Skeletal Collection.  It may be inferred however through proxy variables like occupation and residence 
(derived from economic status of the city/state in which one resides).  Notably, skeletal donation is a 
relatively cost-effective option for disposition of remains.  Donations in the Bass Skeletal Collection may 
not be representative of the full spectrum of socioeconomic statuses and the consequences.  Although this 
collection provides an opportunity to examine diabetic complications in bone, the osteological 
pathologies may not be represented at the same prevalence in other skeletal assemblages.  
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CHAPTER 8. CONCLUSIONS 
This concluding chapter will discuss the purpose and goals of the research.  Major findings and 
implications will be reviewed.  And finally, future research questions and projects will be proposed to 
continue the discussion about bone and metabolism. 
 
Overview 
This research served dual purposes in skeletal biology and forensic anthropology.  The skeletal 
biology focus was to assess whether type 2 diabetes has affects skeletal health, as evidenced in bone 
density and osteological pathologies.  The forensic goal was to determine if type 2 diabetes could be 
identified in a set of human remains, utilizing postmortem blood samples or by examining a “best set” of 
macroscopic skeletal characteristics.  This work represents an integrative approach, combining medical 
and clinical information with biochemical and radiological methodology, to further anthropological 
understanding about how this disease is affecting the modern US population.  
Nutrition and metabolism undeniably influence skeletal development.  As researchers redefine the 
intrinsic relationship between energy metabolism and bone, diabetes should be included in the list of 
modern conditions affecting humans.  The effect of over-nutrition and excess energy storage (obesity) 
changes human mechanical load-bearing.  Simultaneous changes in the molecular environment, 
promoting the release of cytokines and a pro-inflammatory response hold equal significance.  These 
microscopic changes have the ability to alter bone metabolism in ways we are just now beginning to 
understand. 
Furthermore, this research allowed investigation of the full spectrum of the diabetic disease 
process.  Like most diseases, diabetes goes through a natural progression in the human body.  Diagnosis 
of diabetes signifies the tipping of a precariously balanced scale of risk factors and lifestyle choices.  As 
symptoms and complications accumulate, the diabetic patient becomes increasingly debilitated.  The final 
stages generally terminate with a combination of primary cause (hyperglycemia) and multiple morbidity 
factors.   The research design was selected in order to investigate the beginning, middle, and end of the 
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diabetic disease process.  Postmortem blood analysis represents early changes in the inflammatory 
response to hyperglycemia.  Changes in bone mineral density convey an intermediary stage of the disease, 
foreshadowing more serious symptoms.  Macroscopic skeletal pathologies embody the culmination of 
many diabetic complications developed over the long duration of illness.  The analytical methods in this 
research were undertaken to provide information about different stages and aspects of diabetes. 
 
Summary and Interpretations of Results 
Blood protein analysis showed that cytokines may be successfully investigated using postmortem 
blood samples.  Though cytokines are informative concerning inflammatory state, they remain a proxy 
variable for diabetic status.  Sample size was a significantly limiting factor in this study.  The diabetic 
subsamples produced slightly higher average concentration in pro-inflammatory cytokines IL-8 and 
MCP-1/CCL-2, and higher levels of leptin, a hormone positively correlated with obesity and diabetes.   
Moreover, the diabetic group had significantly lower concentrations of adiponectin, a protein associated 
with insulin sensitivity and glycemic control.  When compared with the non-diabetic group, diabetics 
showed great variability in average protein concentrations.  This is likely due to variation in individual 
immune response and as well as stage of the disease.   Research indicates that therapeutic treatment and 
glycemic control decreases the inflammatory response in diabetics, even if insulin resistance remains a 
symptom. 
It is imperative to note that high levels of circulating cytokines are not exclusively observed in 
type 2 diabetes.  Many cytokines are derived from adipocytes, and as adiposity increases, secretion of 
cytokines follows suit.  Inflammatory proteins play a key role in the transition from pre-diabetes to the 
full-blown disorder.  Once elevated, cytokine concentrations typically remain high.  But obese individuals 
in the pre-diabetes stage may demonstrate a cytokine profile similar to diagnosed diabetics.   
In addition, it is not simply the sheer number of adipocytes, but more importantly, the location.  
As discussed in chapters one and two, visceral adiposity is more harmful because in surrounds and 
interfaces with insulin sensitive organs.  A non-diabetic individual with a greater percentage of visceral 
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adiposity produces more inflammatory proteins, but their glucose metabolism may not be affected yet.   
Results presented in this dissertation should be interpreted with caution and supplemented with additional 
research on postmortem samples with a variety of metabolic phenotypes.  
This study also indirectly demonstrated that diabetes has an impact on bone quality.  Bone 
mineral density was significantly different between the diabetic and non-diabetic group in seven BMD 
measurements of the femur, eight in the forearm, and two variables in the tibia.  More importantly, the 
relationship between diabetics and non-diabetics varied between the sexes.  Female diabetics displayed 
significantly denser bones than non-diabetic females in all measured sites of the lower limb and forearm. 
The male subsample did not reflect significant difference between groups.  Furthermore, non-diabetic 
males had (slightly) higher BMD values leg variables, while the non-diabetics showed higher values in 
the forearm.   
Sex-differences in these results are likely related to menopausal state in the female subsample.  
Excess adipocytes in the diabetic group are a supplemental source of bone-promoting hormones like 
estrogen and leptin, while insulin resistance ensures high circulating levels of this anabolic hormone in 
the early and middle stages of the disease. Non-diabetic females lack these fleeting advantages in bone 
density. Notably, sex-related differences were not noted in forearm BMD measurements.  Both male and 
female diabetics displayed higher BMD in the forearm.  Though the difference was not unanimously 
significant, forearm data confirm a moderate but tangible metabolic contribution to density in the absence 
of significant mechanical forces. 
Macroscopic osteological pathologies represent the advanced stages of diabetes and the 
deleterious effect of hyperglycemia and compromised tissue function.  This project demonstrated that 
clinical characteristics of diabetes are recognized in postmortem skeletal material.  Of the seventeen 
variables investigated, three skeletal pathologies concentrated in the feet had the highest classification 
power.  “Diabetic foot,” caused by the three forms of diabetic neuropathy, is one of the most commonly 
diagnosed and treated diabetic complications.  Data from this research confirm that features of diabetic 
foot can identified in postmortem skeletal samples.   
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Two of the pathologies selected by logistic regression involve development of osteophytes, which 
also occur in conjunction with arthritis.  Osteoarthritis (OA) is typically observed in highly mobile, 
elderly, and obese individuals due to increased or prolonged loading of the skeleton.  There is a 
significant amount of overlap in diabetic and obese complications, as one condition often perpetuates the 
other.  Obese subjects experience OA, but overweight diabetics are also likely to develop chronic ulcers 
that progress into osteomyelitis.  A pattern of osteophyte/exostosis development, coupled with infection 
in the lower limb and feet is more indicative of diabetes than obesity. 
The diabetic profile observed in this research includes slightly elevated inflammatory biomarkers, 
increased bone mineral density (particularly pronounced in females), and osteological pathologies related 
to “diabetic foot”.  Each of these interrelated factors has the potential to interact and promote diabetic 
characteristics downstream in the disease process.  For examples, increased cytokines not only mediate 
inflammation but they may have anabolic influence on bone deposition.  Heightened baseline 
inflammation retards healing and reduces capacity to identify and eradicate infectious pathogens.   
 
As discussed in earlier chapters, lifestyle, nutrition, and socioeconomic status may have a 
significant effect on the manifestation of diabetes, and the results rendered in this study.  It is not simply 
caloric intake, but specific food sources which impact metabolism and bone health.  Studies have 
unequivocally shown that inappropriate diets  that are high in carbohydrates, sugars, and fats, and 
simultaneously low in essential vitamins and nutrients promote diabetes (Drewnowski and Darmon 2005).  
Foods with heavy concentrations of simple sugars, triglycerides, and fatty acid contribute to lipotoxicity 
and endoplasmic reticulum stress, which stimulate the inflammatory response.  Negative food choices, 
even consumed in moderate levels, may produce high cytokine levels. 
Diet also impacts bone density and regular bone maintenance.  Poor nutrition, particularly when 
experienced at key periods of bone acquisition, universally has a negative impact on bone.  As 
endocrinologist Charles Dent stated in a keynote address to the International Symposium on the Clinical 
Aspects of Metabolic Bone Disease: “senile osteoporosis is a pediatric disease”(Dent 1973).  Individuals 
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with greater peak bone mass acquired in youth have a higher baseline and run a lower risk of developing 
osteoporosis and fractures later in life (Ilich and Kerstetter 2000).  Peak antemortem bone mass is 
unknown for this research sample.  But those individuals who experienced poor nutrition in youth or early 
adulthood enter the skeletal maintenance and depreciation phase at a BMD deficit (Ilich and Kerstetter 
2000). 
For postmenopausal women, who constituted the majority of female subjects in this study, 
nutritional status is even more significant, due to loss of gonadal hormones.  Research indicates that bone 
loss observed in mid- to late-postmenopausal women is exacerbated by calcium deficiency (Cumming 
1990; Heaney 2000).  Multiple studies have shown that postmenopausal bone density significantly 
improves with calcium supplementation (Cumming and Nevitt 1997; Devine et al. 1997; Prince et al. 
1995).  Moreover, the combined effects of calcium and estrogen replacement therapy appear to have the 
largest positive influence on female bone density in later stages of life (Haines et al. 1995; Prestwood et 
al. 1999).  As mentioned earlier in this work, dietary regimen and supplementation is unknown for the 
William M. Bass Collection, but potentially has a large impact on both cytokine and BMD results. 
Physical activity is another undoubtedly significant factor in this work.  Mechanical loading 
experienced throughout life strongly influences overall bone strength observed in adult load-bearing 
bones (Frost 2001).  Routine exercise or intense bursts of physical activity help maintain bone density at 
optimal levels (Warburton et al. 2006).  Like nutrition, mechanical loading contributes to peak bone mass 
acquired in the first few decades of life.  Regular exercise also improves or sustains bone density in 
elderly individuals of both sexes (Klibanski et al. 2001).   
The close relationship between load-bearing and bone strength could obscure the moderate effect 
of altered (diabetic) metabolism.  Diabetic males who were moderately to extremely physically active in 
youth may not demonstrate the same patterns of reduced bone density observed in this study, owing to 
their higher baseline BMD.  Likewise, non-diabetic females who maintain high levels of activity 
throughout life may demonstrate high BMD values, on par with those observed in the diabetic female 
125 
 
group in this study.  At present, level of physical activity is not directly measured in the Bass Collection, 
and therefore this important factor cannot be fully controlled between groups. 
Access to adequate nutrition, physical activity, and medical resources collectively contribute to 
socioeconomic status.  Individuals from lower educational and socioeconomic backgrounds are more 
likely to develop obesity and diabetes (Flegal et al. 2002).  Economic analyses show that foods high in 
fats/sugars are lower in cost and provide more calories per unit price (Drewnowski and Darmon 2005).  
Public health agencies contend that low income and minority groups (who suffer higher rates of metabolic 
syndrome) should be better educated about food choices to improve long-term health (ADA 2001).  
However, from an economic and consumer perspective these choices are rational and effective 
(Drewnowski and Darmon 2005).  Furthermore, underprivileged individuals may be less physically active 
because they lack expendable income, available time, and may reside in areas considered unsafe for 
leisure activities.  Socioeconomic status and access to medical resources is another crucial factor that 
could affect any of the diabetic characteristics discussed in this research. 
 
Methodological Limitations 
Some methodological short-comings in this research should be noted.  A larger sample size 
should be used for all the analytical methods, but particularly in the blood protein investigation.  Multiple 
collection cards also should be obtained for each sample, to allow confirmatory trials for both multiplex 
and singleplex ELISAs.  The Fitzco Company manufactures collection cards specifically designed to 
capture and preserve proteins, which may enhance protein viability even after death.  The extraction 
methodology used in the study was sufficient for the original analysis but could be improved upon.  
Extraction protocol should be optimized to eliminate molecules that may compete with proteins for 
antibody-binding in the ELISA.    
To investigate bone quality this study used a GE Lunar iDXA scanner, the most current 
generation in DEXA technology.  The iDXA permits standardization of tissue depth to scan bones devoid 
of tissue, the ubiquitous use of DEXA in clinical practice allows comparison across literature.   However, 
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problems with DEXA are the inability to distinguish between trabecular and cortical bone, failure to 
measure volumetric changes, and the assumption of a common cylinder shape for bones. Peripheral 
quantitative computed tomography (pQCT) allows for more detailed examination and assessment of 
trabecular thickness and density.  Studies conducted on diabetics with pQTC have shown decreased bone 
volume and cross-sectional area (Melton et al. 2008).  In trabecular regions, increased bone density 
compensated for lower area.  No comparable change in cortical density was observed, resulting in 
reduced bending strength and potential fracture (Petit et al. 2010).  More nuanced changes in bone 
quality, and potential difference between diabetic and non-diabetic males may have gone undetected 
because trabecular density could not be determined in the current research. 
This study was unable to confirm the relationship between diabetes and periodontitis.  A sample 
set with a higher percentage of complete and partial dentition is necessary to complete this analysis.  The 
Bass Collection is not currently optimal for such a study, alternate skeletal collections may be more 
suitable.  However, as dental records are provided more often with donations, dental radiographs may 
provide a better picture of antemortem dental health.   
 
Future Research 
Currently, little research has been conducted concerning degradation of blood serum proteins 
over the postmortem interval (Ubelaker et al. 2004).  Protein’s amino acid and collagen triple helix 
structure permits extensive cross-linking and lends a certain level of fortification.  Similar to hair, proteins 
are one of the later elements to yield to decay, though high temperatures (above 50º C) and acidic pH 
promote denaturation of the chemical bonds (Voet and Voet 2004).  Going forward, samples should be 
drawn from postmortem remains at consecutive intervals (0 days, one day, two days, etc. after death).  
Total concentration of available proteins should be quantified to determine a cut-off point after which 
obtaining sufficient number of viable proteins is not possible.  Cytokines are highly variable in their size, 
structure, and function, and they may differ in their sustainability.  Some proteins may have longer viable 
period after death, so those biomarkers should be targeted when working with postmortem material.  This 
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information could be incorporated into standard operating procedures for the Forensic Anthropology 
Center, medical examiner’s offices, or any research entity that has an interest in establishing the 
inflammatory and/or diabetic status in a set of remains.   
The original project design intended to test blood samples for the cytokine Osteocalcin (OCN).  
Recent research has implicated osteocalcin as a major player in the energy and bone feedback loop 
(Confavreux et al. 2009; Ferron et al. 2008; Lee and Karsenty 2008).  It appears that this osteoblast-
specific molecule may be the link between bone maintenance and energy metabolism.  At the time of data 
collection, human-specific ELISAs testing for osteocalcin were not commercially available (though a few 
murine models exist).  However, as pro-inflammatory cytokines become increasingly important in 
diabetes research and diagnosis, this limitation will likely change.  Future studies should repeat the 
cytokine testing protocol, beginning with a multiplex ELISA including osteocalcin, followed by an 
(OCN) singleplex to provide more detailed concentration results.  Once available, uncarboxylated 
(bioactive) osteocalcin should be targeted, which has the ability to mobilize from the bone matrix and 
affect insulin sensitivity. 
 Moreover, there is great potential in combining analyses into a more comprehensive examination 
involving both bone density and osteological pathologies.   The assumption is that individuals 
experiencing low bone quality will potentially demonstrate more pathologies   Low levels of macroscopic 
porosity were recorded and very few fractures were observed in the current research, so the correlation 
between density and associate pathologies was negated.  Given a larger sample size to observe more 
pathologies and bone density collected with pQCT, data could be combined into a single analysis.  
Statistical methods like fuzzy clustering and decision trees may hold potential to combine categorical and 
continuous data to assign an unknown set of remains into diabetic or non-diabetic categories.  
Finally, type 2 diabetes is rapidly increasing in the juvenile population.  The SEARCH for 
Diabetes in Youth study noted that in some minority groups (American Indian, African American, and 
Pacific Islanders) the rate of newly diagnosed cases of type 2 diabetes has surpassed that of type 1 
diabetes (Cavallo 2006).  It is critical to determine when diabetic changes in the skeletal system begin to 
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occur.  Given that diabetic complications are directly related to duration of the disease, will individuals 
diagnosed in youth start demonstrating changes in bone density and the development of skeletal 
pathologies at early ages?  Moreover, what effect will prolonged type 2 diabetes take on their long-term 
adult skeletal health? 
Medical professionals typically diagnose and treat an extensive list of diabetic complications in 
patients 60 years and older, as this age-group has the highest percentage of diabetics.  But as the age at 
diagnosis decreases, the time-line similarly shifts so that younger individuals may suffer from more 
severe comorbidities.  The consequence may be evident in the skeletal material of young and middle-age 
adults.  Data sources like blood samples, radiographs, DEXA scan, and pQCT density data may be most 
informative for these living subjects.  Recognizing early diabetic changes and monitoring the progression 
will be key in future studies.  
 
This research marks an important introduction in the field of anthropology to the 
multidisciplinary investigation of diabetes in human body, and may generate additional research into the 
ongoing public health crisis.  The current century has been termed: “The obesity era” (Berreby 2013).  
From a retrospective view, obesity and comorbidities like type 2 diabetes may characterize the 
populations living during this era.  The biological consequences of diabetes demand documentation, as 
they will inevitably become hallmark features of 21
st
 century peoples in the skeletal records.  As 
anthropologists, we must be able to recognize alterations in the skeleton due to the unique metabolic state 
caused by diabetes, and anticipate identifying this effect in the postmortem materials in which we will 
inevitably encounter. 
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Figure A.1. Results from the four singleplex ELISAs, median protein concentration. 
 
*Leptin, MCP-1/CCL-2, and IL-8 reported in pg/ml. Adiponectin reported in μg/ml 
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Femur ANOVA Results 
 
Table A.1. ANOVA Results: Femur Upper Neck 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.7677 0.1731 
0.001 
Non 18 0.5860 0.1408 
Male 
Diabetic 22 0.8786 0.1862 
0.728 
Non 22 0.8967 0.1541 
 
 
 
 
 
Means for Femur Upper Neck BMD, Separated by Sex. 
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Table A.2. ANOVA Results: Femur Lower Neck 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 1.0630 0.1702 
0.0001 
Non 18 0.7927 0.1622 
Male 
Diabetic 22 1.1035 0.1987 
0.417 
Non 22 1.1516 0.1911 
 
 
 
 
 
Means for Femur Upper Neck BMD, Separated by Sex. 
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Table A.3. ANOVA Results: Femur Ward’s Triangle 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.7585 0.2016 
0.001 
Non 18 0.5384 0.1493 
Male 
Diabetic 22 0.8802 0.1886 
0.444 
Non 22 0.9263 0.1988 
 
 
 
 
 
Means for Ward’s Triangle BMD, Separated by Sex. 
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Table A.4. ANOVA Results: Femur Trochanter 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.7670 0.1474 
0.0001 
Non 18 0.5404 0.9776 
Male 
Diabetic 22 0.8883 0.1358 
0.730 
Non 22 0.8731 0.1544 
 
 
 
 
 
Means for Femur Trochanter BMD, Separated by Sex. 
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Table A.5. ANOVA Results: Femur Shaft 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 1.1621 0.2275 
0.0001 
Non 18 0.8383 0.1757 
Male 
Diabetic 22 1.2554 0.2136 
0.773 
Non 22 1.2775 0.2132 
 
 
 
 
 
Means for Femur Shaft BMD, Separated by Sex. 
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Table A.6. ANOVA Results: Femur Total 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.9824 0.1815 
0.0001 
Non 18 0.7099 0.1314 
Male 
Diabetic 22 1.0792 0.1608 
0.904 
Non 22 1.0854 0.1770 
 
 
 
 
 
Means for Femur Total BMD, Separated by Sex. 
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Forearm ANOVA Results 
 
 
Table A.7. ANOVA Results: Ulna Ultra-Distal 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.3315 0.0764 
0.462 
Non 18 0.2995 0.1656 
Male 
Diabetic 22 0.4069 0.0663 
0.739 
Non 22 0.3986 0.949 
 
 
 
 
 
Means for Ulna Ultra-distal BMD, Separated by Sex. 
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Table A.8. ANOVA Results: Both Ultra-Distal 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.3881 0.0823 
0..010 
Non 18 0.3195 0.0677 
Male 
Diabetic 22 0.4897 0.0694 
0.326 
Non 22 0.4654 0.0914 
 
 
 
 
 
Means for Both Ultra-distal BMD, Separated by Sex. 
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Table A.9. ANOVA Results: Distal 33% Radius 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.7910 0.1409 
0.009 
Non 18 0.6558 0.1515 
Male 
Diabetic 22 0.9669 0.0865 
0.128 
Non 22 0.9189 0.1162 
 
 
 
 
 
Means for Distal 33% Radius BMD, Separated by Sex. 
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Table A.10. ANOVA Results: Distal 33% Ulna 
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.7189 0.1611 
0.006 
Non 18 0.5836 0.1111 
Male 
Diabetic 22 0.8485 01039 
0.517 
Non 22 0.8284 01005 
 
 
 
 
 
Means for Distal 33% Ulna BMD, Separated by Sex. 
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Table A.11. ANOVA Results: Both Distal 33%  
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.7551 01472 
0.006 
Non 18 0.6185 0.1285 
Male 
Diabetic 22 0.9160 0.0776 
0.143 
Non 22 08765 0.1285 
 
 
 
 
 
Means for Both Distal 33% BMD, Separated by Sex. 
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Table A.12. ANOVA Results: Radius Total  
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.6043 0.1111 
0.021 
Non 18 0.5134 0.1137 
Male 
Diabetic 22 0.7458 0.0705 
0.124 
Non 22 0.7060 0.0960 
 
 
 
 
 
Means for Radius Total BMD, Separated by Sex. 
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Table A.13. ANOVA Results: Ulna Total  
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.5709 0.1321 
0.002 
Non 18 0.4497 0.0826 
Male 
Diabetic 22 0.6674 0.0873 
0.396 
Non 22 0.6441 00925 
 
 
 
 
 
Means for Ulna Total BMD, Separated by Sex. 
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Table A.14. ANOVA Results: Both (Radius Ulna) Total  
 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.5736 0.1125 
0.018 
Non 18 0.4854 0.0989 
Male 
Diabetic 22 0.7072 0.0790 
0.278 
Non 22 0.6790 0.0906 
 
 
 
 
 
Means for Both (Radius/Ulna) Total BMD, Separated by Sex 
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Tibia ANOVA Results 
 
Table A.15. ANOVA Results: Tibia Metaphysis 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 1.0457 0.2296 
0.046 
Non 18 0.8763 0.2595 
Male 
Diabetic 22 1.2929 0.2169 
0.362 
Non 22 1.2217 0.2906 
 
 
 
 
 
Means for Tibia Metaphysis BMD, Separated by Sex. 
 
  
159 
 
Table A.16. ANOVA Results: Tibia Medial Malleolus 
Sex Diabetic Status n Mean BMD Standard deviation Significance 
Female 
Diabetic 18 0.7755 0.1278 
0.001 
Non 18 0.5738 0.1840 
Male 
Diabetic 22 0.9118 0.1325 
0.492 
Non 22 0.8713 0.2403 
 
 
 
 
 
Means for Tibia Medial Malleolus BMD, Separated by Sex 
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Table A.17. Step-wise Discriminant Function Analysis Results. Femur – Females 
Wilks’ Lambda Test of Function 
Function # Variables 
Selected 
Variable 
Name 
Wilks’ 
Lambda 
Chi 
Square 
df Exact F 
Statistic 
Significance 
1 1 Trochanter 0.535 20.97 1 29.59 0.000 
Eigenvalues 
Function Eigenvalue Canonical Correlation     
1 0.870 0.682      
Functions at Group Centroid 
Diabetic  0.907       
Non-Diabetic -0.907       
 
Cross-validated Classification Results 
  Predicted Group Membership 
Total 
 Non-Diabetic Diabetic 
Count 
Non-Diabetic 15 3 18 
Diabetic 3 15 18 
Percent 
Non-Diabetic 83.3% 16.7% 100% 
Diabetic 16.7% 83.3% 100% 
*83.3% correctly classified 
 
 
 
Table A.18. Step-wise Discriminant Function Analysis Results. Forearm – Females 
Wilks’ Lambda Test of Function 
Function # Variables 
Selected 
Variable 
Name 
Wilks’ 
Lambda 
Chi 
Square 
df Exact F 
Statistic 
Significance 
1 1 Ulna Total 0.757 9.312 1 10.89 0.002 
Eigenvalues 
Function Eigenvalue Canonical Correlation     
1 0.320 0.493      
Functions at Group Centroid 
Diabetic  0.55       
Non-Diabetic -0.55       
 
Cross-validated Classification Results 
  Predicted Group Membership 
Total 
 Non-Diabetic Diabetic 
Count 
Non-Diabetic 13 5 18 
Diabetic 6 12 18 
Percent 
Non-Diabetic 72.2% 27.8% 100% 
Diabetic 33.3% 66.7% 100% 
*69.5% correctly classified 
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Table A.19. Step-wise Discriminant Function Analysis Results. Tibia – Females 
Wilks’ Lambda Test of Function 
Function # Variables 
Selected 
Variable  
Name 
Wilks’ 
Lambda 
Chi 
Square 
df Exact F 
Statistic 
Significance 
1 1 Malleolus 0.70  1 14.59 0.001 
Eigenvalues 
Function Eigenvalue Canonical Correlation     
1 0.429 0.548      
Functions at Group Centroid 
Diabetic  0.637       
Non-Diabetic -0.637       
 
Cross-validated Classification Results 
  Predicted Group Membership 
Total 
 Non-Diabetic Diabetic 
Count 
Non-Diabetic 14 4 18 
Diabetic 3 15 18 
Percent 
Non-Diabetic 77.8% 22.2% 100% 
Diabetic 16.7% 83.3% 100% 
*80.5% correctly classified 
 
 
 
 
 
Table A.20. Discriminant Function Analysis Results. Femur – Males (All variable included) 
Wilks’ Lambda Test of Function 
Function # Variables 
Included 
Wilks’ 
Lambda 
Chi 
Square 
df Significance Eigenvalue Canonical 
Correlation 
1 7 0.854 6.072 7 0.531 0.171 0.302 
Functions at Group Centroid 
Diabetic  0.404       
Non-Diabetic -0.404       
 
Cross-validated Classification Results 
  Predicted Group Membership 
Total 
 Non-Diabetic Diabetic 
Count 
Non-Diabetic 12 10 18 
Diabetic 10 12 18 
Percent 
Non-Diabetic 54.5% 45.5% 100% 
Diabetic 45.5% 54.5% 100% 
*54.5% correctly classified 
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Table A.21. Discriminant Function Analysis Results. Forearm – Males (All variables included) 
Wilks’ Lambda Test of Function 
Function # Variables 
Included 
Wilks’ 
Lambda 
Chi 
Square 
df Significance Eigenvalue Canonical 
Correlation 
1 7 0.824 7.23 9 0.612 0.213 0.419 
Functions at Group Centroid 
Diabetic  0.451       
Non-Diabetic -0.451       
 
Cross-validated Classification Results 
  Predicted Group Membership 
Total 
 Non-Diabetic Diabetic 
Count 
Non-Diabetic 8 14 18 
Diabetic 10 12 18 
Percent 
Non-Diabetic 36.4% 63.6% 100% 
Diabetic 45.5% 54.5% 100% 
*45.45% correctly classified 
 
 
 
 
 
 
Table A.22. Discriminant Function Analysis Results. Tibia – Males (All variables included) 
Wilks’ Lambda Test of Function 
Function # Variables 
Included 
Wilks’ 
Lambda 
Chi 
Square 
df Significance Eigenvalue Canonical 
Correlation 
1 7 0.963 1.51 3 0.680 0.038 0.191 
Functions at Group Centroid 
Diabetic  -0.190       
Non-Diabetic 0.190       
 
Cross-validated Classification Results 
  Predicted Group Membership 
Total 
 Non-Diabetic Diabetic 
Count 
Non-Diabetic 14 8 18 
Diabetic 11 11 18 
Percent 
Non-Diabetic 63.6% 36.4% 100% 
Diabetic 50% 50% 100% 
*56.8% correctly classified 
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